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s Smooth 
S Spider 
s-cn Smooth-concentric morphotype 
s-g Smooth-glossy morphotype 
s-m Smooth-matte morphotype 
sn-wr-cr Snowball-wrinkled-crepe 
SAB agar Sabouraud agar 
Sap Secreted aspartyl proteinases 
SD Standard deviation 
SDA Sabouraud dextrose agar 
SDS Sodium dodecyl sulfate 
sec. Seconds 
Ser/S Serine 
SIR Silent information regulator 
sn Snowball 
Spp. Species 
SZMC Szeged Microbiology Collection 
t Time 
TAE Tris-acetate-EDTA 




tcc Tracheal crepe colony 
Thr/T Threonine 
TOF Time of flight 
Tris Tris-(hydroxymethyl)-aminoethan 
Tris-HCl Tris hydrochloride 
tsc Tracheal smooth colony 
TRR Tandem repeat region 




v/v Volume per volume 
VVC Vulvovaginitis candidiasis 
WGD Whole genome duplication 
wr Wrinkled 
WT Wild type 
w/v Weight per volume 
YOLT Yeast on-target lysis 




The prevalence of Candida species has increased in the last two decades, becoming the 
third to fourth most common cause of infections in hospitals. In general, Candida spp. are 
opportunistic pathogens found as commensals in the Gastrointestinal Tract (GI), the oral 
cavity, oral mucosa, vagina, or skin, without causing any symptoms or pathology. When the 
immune system is altered (e.g. T-cell deficiencies in immunocompromised patients), a 
preliminary colonization process of the skin or mucosa (superficial candidiasis) may 
progress to life-threatening invasive candidiasis, sepsis, and eventually to death. Invasive 
Candidiasis (IC) has become a serious problem in the last years, affecting young and elderly 
population. Candida albicans is the most frequent cause of invasive candidiasis globally, 
but over the last decades non-Candida albicans Candida (NCAC) species have become more 
medically relevant. Candida spp. are able to exist inside the human host displaying 
different pathogenicity and antifungal drug resistance strategies. Most microbes, including 
NCAC species, usually constitute microbial communities encased in an extracellular 
polymeric substance forming biofilms on abiotic and biotic surfaces. Candida glabrata and 
Candida parapsilosis are the two most common causes of NCAC infections. Their relevance 
have been attributed to the ability to form biofilms on abiotic surfaces and the increased 
multidrug resistance capacity, together leading to different levels of pathogenicity. Both 
species display superficial, mucosal and systemic infections associated with abiotic devices, 
presenting clear morphologic and phenotypic differences between them. C. glabrata and 
C. parapsilosis belong to two different Candida clades, presenting differences at genomic 
and pathogenic level. The fungal cell wall is the outermost layer involved in host-pathogen 
recognition, cell structure, permeability, protection and virulence and the phylogenetic 
distance between both species is reflected by variations in cell wall composition including 
its proteome. 
In this study, we performed phenotypic and morphological analyses of two C. glabrata and 
C. parapsilosis clinical strain collections, to decipher how phenotypic and morphological 
differences will predetermine genome and cell wall proteome as a pathogenic strategy 
during host infection. Based on previous studies (de Groot et al., 2008 and Gabaldón et al. 




C. parapsilosis clinical isolates will provide more information regarding cell wall 
constituents and genomic differences within NCAC clinical isolates. 
A high variability in phenotypic properties between isolates were found. In this study, we 
observed that C. glabrata showed a positive correlation between biofilm formation 
capacity, cell aggregation and cell sedimentation. In case of C. parapsilosis, biofilm 
formation capacity on abiotic surfaces was influenced by the colony morphotype. 
C. glabrata and C. parapsilosis proteome is highly variable and it has been divided in a core 
proteome and a unique variable proteome. Differences in the number of adhesins 
identified in the cell wall positively correlate with adhesion. Here, we observed that 
C. glabrata cell wall adhesins enable the co-interaction with C. albicans hyphae facilitating 
epithelia invasion. Differences in the variable proteome may also elucidate a high 
immunogenic heterogeneity as a possible host-defense mechanism. In C. parapsilosis, an 
increased number of adhesins identified in the cell wall correlates with “rough” and high 
biofilm-forming morphotypes. C. parapsilosis rough morphotypes presented azoles’ and 
caspofungin reduced-susceptibility, nevertheless, EUCAST-based antifungal susceptibility 
testing in the collection was not able to predict these variations. Rough morphologies in 
patient´s culture would be an indicator of biofilm´s presence to start echinocandins 
therapeutic treatment. 
Our studies proposed that phenotypic variations in C. glabrata and C. parapsilosis clinical 
isolates will predetermine differences at genomic and proteomic level. A reduced number 
of adhesins in the wall correlates with low biofilm-forming (LBF) isolates and high virulence 
capacity indicating that these morphologies will easily disseminate trough the bloodstream. 
Genome sequence analyses of selected C. glabrata isolates confirm the presence of 
deletions and duplications of cell wall adhesin-encoding genes as an important adaptive 





1.1 Epidemiology of Candida spp. 
 
The prevalence of Candida species has increased in the last two decades becoming the 
third to fourth most common cause of infection in hospitals (reviewed by Pappas et al., 
2018). In general, Candida spp. are opportunistic pathogens found as commensals in the 
gastrointestinal tract (GI), the oral cavity, oral mucosa, vagina, or skin, without causing any 
symptoms or pathology. Several factors such as abdominal surgeries, malignant neoplasms, 
corticoid steroid use, and chemotherapeutic treatment can lead to higher risks of infection 
(Quindós, 2014). Patients with diabetes mellitus (Lamster et al., 2008), or the use of non-
sterile medical devices together with preceding bacterial infections, are potential 
candidates to suffer from Candida pathologies (Percival et al., 2014). When the immune 
system is altered (e.g. T-cell deficiencies in immunocompromised patients), a preliminary 
colonization process of the skin or mucosa (superficial candidiasis) may progress to life-
threatening invasive candidiasis, sepsis, and eventually to death (reviewed by Nobile and 
Johnson, 2015). Invasive candidiasis (IC) has become a serious problem in the last years 
affecting young population and adults. As an example, Candida albicans is the main species 
involved in Vulvovaginitis Candidiasis (VVC) or Oral-Pharangeal Candidiasis (OPC), affecting 
a high percentage of healthy women (~ 80%) and immunosuppressed or terminally ill 
patients, respectively (reviewed by Kim and Sudbery, 2011). 
Recent epidemiological studies have confirmed a high percentage (~ 50%) of a thirty-day 
mortality (~8-30 days) remarking the importance of the host´s health conditions. 
Nevertheless, fast diagnosis has been crucial to reduce early-phase mortality (0-7 days) in 
IC (Puig-Asensio et al., 2014). Since the last decade, there are several studies on Candida 
infections in hospitals and Intensive Care Units (ICU) that analyse the frequency of patients 
with candidemia and the use of antifungals therapies. Studies conducted in the United 
States on candidemia episodes between 1992 and 2011 have indicated that it is still 
associated with high mortality rates especially in elderly population ≥ 65 years old 
(Cleveland et al., 2012). A complementary study in the U.S has reported an increase of 





incidence of hospitalization was higher in adults (45-85 years old) than in young patients 
(18-44 years old) in the year 2000 (Zilberberg et al., 2008). 
Other studies have outlined C. albicans, C. glabrata, C. parapsilosis, C. tropicalis, and 
C. krusei as the most frequent causes of candidemia in the United States: epidemiological 
data from the 1980s marked a high frequency of IC due to C. albicans. According to several 
antifungal surveillance studies (e.g. the ARTEMIS study) performed between 1997 and 
2007, C. albicans was still the most frequent cause of fungemia (62%) all over the world 
(reviewed by (Pfaller and Diekema, 2007; Pfaller et al., 2006) this proportion has fluctuated 
over time, decreasing in the last decade in favour of non-Candida albicans Candida species 
(NCAC). The percentage of patients infected by C. albicans was clearly reduced in 2011 
(11% reduction) and has been surpassed by C. glabrata (~15% increase in 2011) and 
C. parapsilosis (~5 % increase in 2010) (Lockhart et al., 2012; Lyon et al., 2010; Pfaller et al., 
2010). 
In Europe, the distribution has supported that C. albicans (56%) is the most prevalent cause 
of candidemia followed by C. glabrata, C. parapsilosis, and C. tropicalis. In agreement with 
this, the most prevalent single Candida spp. reported overall was also C. albicans, albeit the 
distribution of NCAC species varies between countries (Tortorano et al., 2004). For 
instance, C. glabrata infections are more frequent in Northern Europe and the U.S. (13.2% 
and 29% respectively), while C. parapsilosis is more prevalent in South America or Spain. 
There are several hypotheses regarding these divergences such as climate differences, 
hospital hygiene, and improper use of antimycotic treatments (reviewed by Guinea, 2014).  
A review by (Ruhnke, 2014) has indicated that approximately around 4 thousand cases of 
Candidemia in Intensive Care Units of German hospitals (ICU) were described in 2008. The 
prevalence was ~ 5 patients per 100 000 inhabitants, this frequency was quite similar to 
the values for invasive candidiasis (IC). Several studies performed along the country in ICU´s 
corroborated that the percentage of C. albicans compared with non-Candida albicans 
Candida species was approximately 30 % higher (Meyer et al., 2013; Tragiannidis et al., 
2012). 
Divergences in Candida spp. patient´s distribution have been remarked; while 
Candida tropicalis, Candida krusei and C. glabrata frequently colonized and infect elderly 
patients, C. parapsilosis is frequently found in children (reviewed by Quindós, 2014; Trofa 





more frequent than in adults (reviewed by Yapar, 2014). C. parapsilosis is considered an 
extended moderately non-pathogenic fungus frequently find as associated nosocomial 
infection due to the use of medical devices (reviewed by Jahagirdar et al., 2018). In 2004, 
Pfaller and Diekema published an epidemiological study along ten years focused on the 
prevalence of Bloodstream Infections (BSI) ranking C. parapsilosis as the third most 
common cause of septicemia appearing, in some situations, as a secondary infection (Patel 
et al., 2000). 
Conversely, C. glabrata is known to be commonly present in elderly and neutropenic 
patients (Bodey et al., 2002; Malani et al., 2011). The incidence of C. glabrata has been 
increased in the last years, becoming the second most prevalent Candida pathogen in 
nosocomial infections affected by the dose of antibiotic administered, the immune system 
of the patient, as well as the period of hospitalization (reviewed by Rodrigues et al., 2014). 
C. glabrata infections frequently increment with the age of the patient (Krcmery and 
Barnes, 2002), and has raised the frequency in the oral cavity due to a remarkable ability to 
adhere to denture-surfaces (Li et al., 2007; Rodrigues et al., 2017). Compared with another 
NCAC species is quite usual to find it coupled with C. albicans in oral candidiasis (reviewed 
by Rodrigues et al., 2017). 
Studies performed by Pappas and McCarty have shown that the antifungals 
administered, the age of the patient and the ability to recover from bloodstream infections 
varies between adults and young population in the different Candida spp. (McCarty and 
Pappas, 2016; Pappas et al., 2003). The uncontrolled administration of antibacterials 
decreases bacterial communities and promoting fungal pathologies. Broad spectrum 
antibiotics have usually altered the gut microbiota disrupting the colonization resistance 
facilitating Candida spp. be part in a long term colonization process (Erb Downward et al., 
2013; Hill et al., 2015). Although resistance to more than one antifungal drug of different 
substance classes is still infrequent, multidrug resistance have increased in the last years 
including some novel species such as Candida auris (Arendrup and Patterson, 2017). The 
lacking development of new antifungal agents in the last decades, the extensive use of 
antibiotics, and increasing long-term hospitalization have constrained the use of antifungal 
drugs, as well as lead to an alteration in the susceptibility rates. Knowing the limitation of 
antifungals therapies, azoles are still the most frequent antimycotic drugs used. The high 





patients makes FLU the most administered antifungal currently. FLU inhibits lanosterol 14-
α-demethylase (ERG11) essential for the Candida membrane biosynthesis (Pfaller et al., 
2010). The level of azole resistance in Candida species have varied depending on the type 
of infection and the species of study (reviewed by Whaley et al., 2016). The clinical 
resilience against FLU has also increased through the appearance of other Candida spp. 
Principally, Candida isolates are still susceptible to liposomal amphotericin B (AMB) and 
mostly to echinocandins (CAS and MICA), although recent data suggest that therapies 
against C. glabrata and C. krusei may require high doses of echinocandins (Kuhn et al., 
2002). In particular, C. glabrata is quite special showing a Minimal Inhibitory Concentration 
(MIC) of 64 µg/ml towards FLU. The decreased susceptibility of C. glabrata to antifungal 
drugs seems to be attributable to the long-period treatments and some specific properties 
as haploidy. The absence of reaction against azoles has promoted the use of novel 
antifungal agents as echinocandins inhibiting the synthesis of β-1, 3-glucan (Cleveland et 
al., 2012; Lockhart et al., 2011; Pfaller et al., 2012). In the last fifteen years has been 
reported C. glabrata susceptibility against the semisynthetic echinocandin ANI (Pfaller et 
al., 2005), as well as, C. glabrata susceptibility against VOR which has risen in certain 
European and Latin American countries (Pfaller et al., 2004).  
In contrast, susceptibility against echinocandins (ANI, MICA and CAS) and azoles (especially 
FLU) has decreased in the last decade in the C. parapsilosis complex, although it is clearly 
strain dependent (reviewed by Neji et al., 2017; Pfaller et al., 2004). This is in particular the 
case for CAS and ANI in C. parapsilosis sensu stricto (van Asbeck et al., 2008). The depletion 
of FLU susceptibility in C. parapsilosis clinical isolates has been related with a point 
mutation in the ERG11 and an upregulation of the MRR1 transcription factor. The 
procedure of reduced azole´s susceptibility in C. parapsilosis is similar to the one described 
for C. albicans (Silva et al., 2011). 
A shift in Candida spp. frequency is also evident, and invasive candidiasis due to C. albicans 
has been surpassed by C. glabrata, C. parapsilosis including the emergence of the recent 
multidrug-resistant C. auris (Lamoth et al., 2018). Therefore, a reliable characterization 
using novel techniques as PCR-RFLP, Sanger-sequencing (Cornet et al., 2011), T2 magnetic 
resonance (Zervou et al., 2017) and MALDI-TOF MS systems for species-determination 
(Bader et al., 2011) are crucial prerequisites for an early and adequate Candida-infection 





capacity, biofilm formation and production of hydrolytic enzymes will facilitate the 
development of antifungal therapies against particular Candida spp. (Schaller et al., 2005). 
 
1.2 Features and phylogeny of the genus Candida 
 
Yeasts of the Candida genus were first described as Oidium albicans by Robin in 1853. 
Originally, they were included in a different group encompassing most Ascomycetes in the 
imperfect stage causing fruit infections (“powdery mold”) far related to the “thrush” or 
pathogenic fungi (Ainsworth and Austwick, 1955). In 1923, they were grouped into the 
genus Candida (Berkhout, 1923) still used today. Former reviews from the end of the 19th 
to the beginning of the 20th century have included the first studies regarding Candida in-
situ isolated from patients (Martin and Jones, 1940). In 1954, Candida spp. were admitted 
as generic name in the classification system (Roger et al., 1953) and incorporated into the 
kingdom Fungi, division Ascomycota, order Saccharomycetales, and family 
Saccharomycetaceae (reviewed by Barnett, 2004). 
Today, the name Candida is known to be quite broad and heterogeneous, comprising more 
than 150 species of which only around 12% have clinical relevance (Odds, 1988; Schauer 
and Hanschke, 1999). The most representative one is C. albicans (Robin (Berkhout), 1923) 
described as the primary opportunistic fungal pathogen causing bloodstream infections in 
population with a permanently weakened immune system. The Candida clade has been 
described as extremely diverse including several species close to the basidiomycetes as 
well as imperfect yeasts able to develop pseudohyphae or only yeast morphologies. They 
are characterized attending to their capability to use carbon sources, the ability to ferment 
(Shepherd et al., 1985), their clinical relevance, reproduction, colony-morphology shape, 
and level of pathogenicity (reviewed by Fitzpatrick et al., 2010; Hull et al., 2000; 
McCullough et al., 1996). 
Fitzpatrick et al. (2006) performed a fungal phylogenetic analysis based on genome 
sequences reorganizing the Saccharomycotina subdivision. In 2012, Kurtzman and 
collaborators studied the characterization of Candida in the subphylum Saccharomycotina 
including Saccharomyces and Arxula. This subphylum was then classified as monophyletic, 






This subphylum is divided into the monophyletic CTG clade and the whole genome 
duplication (WDG) subclade (Figure 1A). The majority of pathogenic Candida species were 
classified in the CTG clade underlying as main characteristic the translation of the CUG 
codon into serine rather than leucine in the standard genetic code. C. parapsilosis is 
phylogenetically more closely related to C. albicans, C. tropicalis, and C. dubliniensis coming 
from the same branch of the CTG clade with no apparent sexual cycle and differing from 
C. guilliermondii, (sexual cycle described), Candida lusitaniae and Debaryomyces hansenii 
on the number of alleles per chromosome (reviewed by Santos et al., 2011). 
Contrary, a unique WGD subclade is constituted by the Nakaseomyces genus (Kurtzman 
and Robnett, 2003) including the glabrata group. Inside the group, it has been 
distinguished the pathogenic C. glabrata as a close relative of Baker´s yeast together with 
Candida bracarensis (Correia et al., 2006), Candida nivariensis (Alcoba-Flórez et al., 2005) 




Figure 1. Candida spp. phylogenetic tree (modified from Butler et al., 2009; Gabaldón and Carreté, 2016). (A) 
Phylogenetic representation of the Candida and Saccharomyces clades into the Saccharomycotina 
subdivision. Red boldfaced squares represent the location and phylogenetic distance of the three species of 
interest in our study (C. albicans, C. glabrata and C. parapsilosis). (B) Diagram of the Saccharomyces clade 
including the WGD subclade that contains the glabrata group. In red are indicated the three Candida species 
with identified Epithelia Adhesin Proteins (EPA). 
 
In this study, we refer to C. glabrata and C. parapsilosis as the main NCAC species of 
interest. Initially, C. glabrata was described as Torulopsis glabrata (Anderson) by Lodder 






C. glabrata (Yarrow and Meyer, 1978). This change in the phylogenetic classification 
pointed at the pathogenicity of C. glabrata rather than the absence of pseudohyphae and 
hyphae formation (reviewed by Rodrigues et al., 2017). The above mentioned WGD clade 
encompassed species with duplication in the genome, placing C. glabrata close to 
Saccharomyces castellii in the basal part of the tree (Fitzpatrick et al., 2006; Butler et al., 
2009). 
Similarly, C. parapsilosis was originally described by Ashford in 1928 as Monilia parapsilosis 
and the type strain (ATCC 22019) was reassigned four years later as C. parapsilosis by 
Langeron and Talice, 1932. In the first descriptions, C. parapsilosis was considered as a 
minor pathogen with no remarkable clinical pathogenicity (reviewed by van Asbeck et al., 
2009). 
Butler et al. (2009) has remarked a high diversity in genome size, GC content 
and levels of ploidy between Candida-clade species. Species from the same subclade have 
no clear variation in the number of protein-encoding genes; and pathogenicity correlates 
with specie-modifications of certain cell-wall protein families and enrichment of virulence-
 encoding genes. 
In contrast, the Saccharomyces clade does not present and elevated number of virulence-
factors, highlighting some specific glycophosphatidiylinositol-linked aspartyl proteases or 
phospholipases implied in C. glabrata pathogenicity (Kaur et al., 2007). 
Nevertheless, Gabaldón and colleagues have reported that C. nivariensis, C. bracarensis 
and C. glabrata are considered pathogenic species which present between 9 to 18 EPA-
encoding genes respectively (reviewed by Gabaldón and Carreté, 2016) and only one EPA 
gene was shown up in the non-pathogenic N. delphensis.  
Therefore, phylogenetic analyses comparing C. albicans, C. glabrata and C. parapsilosis 
have shown diversity between them, pointing that new virulence factors have emerged 
along the evolution process (reviewed by Gabaldón et al., 2016). 
 
1.3 C. albicans infections and host-pathogen interactions 
 
Together with Saccharomyces cerevisiae, C. albicans is the best investigated yeast that has 
been used as a classic study model for pathogenicity over the last decades. It is considered 





cells are incubated at 37 °C. It is commensal yeast without symptomatology becoming 
harmless when the yeast-host balance is affected by different situations triggering a broad 
spectrum of human diseases (Figure 2). 
 
 
Figure 2. Schematic overview of C. albicans tissue invasion. (A) Commensalism and alteration of the host 
immune system. (B, left) Candida colonization and dissemination in the gastrointestinal tract. (B, middle) 
Biofilm formation on epithelia surfaces and indwelling devices with the extracellular polymeric matrix (ECM). 
(B, right) yeast and hyphae penetration through the epithelia leading to bloodstream infections, Invasive 
Candidiasis (IC). (C) Frequent host-sources affected by Candida spp. and their respective diseases (adapted 
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Cell morphogenesis has been described as a crucial step during the colonization and 
invasion process (Whiteway and Bachewich, 2007). As a polymorphic fungus, C. albicans 
can be present as round yeast cells, pseudohyphae form linked to the mother cell, true 
hyphae with real septum and chlamydospores (reviewed by Sudbery et al., 2004; Kim and 
Sudbery, 2011). Originally, C. albicans yeast cells were considered to constitute a non-
invasive stage only involved in commensalism, whereas true hyphae were known as key 
structures during epithelia penetration (invasion). Recently, functional plasticity in 
C. albicans has increased its relevance, attending to a variety of new cell types that reports 
different in vitro and in vivo properties The “white-opaque” switch (Slutsky et al., 1985; 
Slutsky et al., 1987) is triggered by several factors that facilitate the transition between 
morphologies such as change in temperature (30°C to 37°C), pH (pH 4 to 7), or media. 
Other ellipsoid cell types (opaque, grey and GUT), in addition to the standard “white-yeast” 
form, show morphological differences as well as infective variability during yeast-host 
interaction (reviewed by Noble et al., 2017). 
An abundant number of cell wall proteins (Als1, Als3, Hwp1), transcription factors (Efg1), 
secreted enzymes (Sap family) and the only recently discovered cytolytic peptide toxin 
Candidalysin (Moyes et al., 2016) are crucial virulence attributes for C. albicans infection 
(reviewed by Jacobsen and Hube, 2017). Concisely, C. parapsilosis, extracellular lipases 
have been pointed as one of the most determinant factors in the host-infection process 
(reviewed by Toth et al., 2017). 
The expression of essential CWP encoding-genes in case of C. albicans (HWP1, HYR1, ALS3) 
are clearly up-regulated during yeast-hyphae switch. To corroborate the importance of 
morphogenesis in the infection process, mutants of hyphae-induced proteins have shown 
an alteration in hyphae formation which consequently affects the cell wall constituents and 
the pathogenicity (Lo et al., 1997; Zheng et al., 2007). Several genetic and environmental 
factors are involved in morphology-switching affecting hyphae development and in vivo 
biofilm formation (reviewed by Kim and Sudbery, 2011) Candida morphotype has also 
affected the host immune system recognition, for example, yeast cells and hyphae form, 
present different recognition receptors which (IL12 and IL4 respectively) will activate 






1.4 Candida biofilms 
 
Biofilms are microbial communities encased in a matrix of extracellular polymeric 
substances distinguishing themselves from the free floating cells (reviewed by Costerton et 
al., 1999; Harriott and Noverr, 2011). Approximately, 80 % of the microorganisms live as 
biofilms, (reviewed by d’Enfert and Janbon, 2016) mostly in endothelial cells and mucosa 
(e.g. host tissues, tooth surfaces, respiratory tract, urinary tract and eyes) (reviewed by 
(Mukherjee et al., 2005). The ability of Candida cells to adhere to host surfaces (Figure 3A) 
and abiotic medical devices (such as indwelling catheters, pacemakers, dental prosthesis, 
contact lenses, or artificial joints) is defined, among others, by their cell wall composition 
(Hawser and Douglas, 1995; Hawser, 1996a; Hawser, 1996b; Baillie and Douglas, 1999). A 
combination of cell wall proteins and transcriptional factors regulate the attachment of 
Candida cells to different surfaces such as polymethylmethacrylate, elastomers, as well as 
host surfaces (Nobile et al., 2006; Chandra et al., 2008; Finkel et al., 2012). Candida biofilms 
are a combination of different cell stages or morphologies such as round blastospores, 
pseudohyphae, and hyphae depending on the number and species involved. As defined by 
(Baillie and Douglas, 1999; Nobile et al., 2009), biofilm formation on host tissues is 
generally divided into three main stages (Figure 3B), remarking the importance of the cell 
morphology and the composition of the matrix on the establishment of the biofilm. The 
initial phase (early) occurs during the first 11 hours, including the attachment and 
aggregation of spherical cells along the surface. Afterwards, the secondary stage 
(intermediate) during the following 12-30 hours, remark the primary development of the 
Extracellular Matrix (ECM/EPS) containing glycoproteins, carbohydrates, lipids and nucleic 
acids. The largest proportion of polysaccharides is mainly constituted by glucose and 
mannose, this polymeric substance is secreted by Candida and host cells previously 
incorporated into the microbial community. The ECM covers the whole surface of the 
biofilm as a superficial and complex layer embracing the total number of cells conferring a 
defence mechanism (Nett et al., 2015). The final phase (mature) comprises a 
heterogeneous and stratified distribution of microcolony aggregates embedded in the 
matrix where the hyphae of filamentous species create a stable architecture (Chandra et 





this, the non-adherent daughter cells disperse and invade the tissues and bloodstream 
(reviewed by Cavalheiro and Teixeira, 2018). 
In fungal biofilms, usually C. albicans is present as one of the most frequent Candida 
species. Many clinical studies about interactions between C. albicans with other 
microorganisms have been reported in the last years. C. albicans could be easily found in 
dental prosthesis and oral mucosa in combination with different Streptococcus species 
(Nobbs et al., 2010). Moreover, it can be a dual colonizer of epidermis, skin injuries and 
medical devices together with Pseudomonas aeruginosa and Staphylococcus epidermidis 
(Jack et al., 2015; Lindsay et al., 2014). Dual biofilms generally increase (excluding 
Lactobacillus spp.) the capacity to adhere and colonize host surfaces just like the defence 
against antifungals drugs and host immune response (reviewed by Peleg et al., 2010). 
Remarkably, fungal biofilms offer less susceptibility against the four major antifungals 
currently used such as azoles, polyenes, echinocandins or/and nucleosides (Fox et al., 
2015). 
Ramage et al. (2002) reviewed that the consistency of the biofilm microbial community 
(mainly sessile cells) and the polymeric matrix are not the only factors involved in 
antifungal resistance. They underlined that, at least, two transmembrane efflux pumps 
(ABC and MSF transporters) located in the plasma membrane, seem to be involved in the 
process. 
A recent study from Uppuluri et al. (2018) in C. albicans has introduced a new concept 
based on biofilm propagation from independent “free-floating”” cells differing from 
planktonic in their composition and functionality . They are “dispersed” from the outer-










Figure 3. Biofilm formation on biotic and abiotic surfaces in C. albicans (modified from Chandra et al., 
2008). (A) General schematic model of mixed biofilms in human surfaces. Yellow big spheres represented 
C. albicans yeast cells in early and intermediate stages, grey and orange big spheres represented other 
possible Candida spp. cells together with C. albicans. Small green, red and purple spheres indicated different 
bacteria species together with C. albicans (mixed biofilms) included in the EPS/ECM. * cytolytic Candidalysin 
(Moyes et al., 2016). (B) In vitro model of putative biofilm formation process on catheters and prosthesis. 
Biofilms are divided in three main stages: early (11h.) represented by yeast cells (yellow), intermediate (12-30 
h.) represented by yeast and incipient hyphae forms and mature phase (38-72 h.), yeast and developed 
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1.5 The fungal cell wall 
 
The cell wall is the outermost part of Candida spp. that confers stability and rigidity as well 
as protection. It is defined as a fungal exoskeleton and a matrix in contact with host 
surfaces. The constituents of the cell wall are essential during the colonization process and 
invasion. The cell wall plays an important role in terms of pathogenicity and is a therefore 
also a target for the development of antifungals treatments (Klis et al., 2001). Both, the 
external cell surface structures and the components of the inner layers are part of the cell 
wall pathogen-associated molecular patterns (PAMPs) which are recognized by the host 
innate immune system (reviewed by Jouault et al., 2009). 
C. albicans cell wall has been studied for long time together with S. cerevisiae, differing on 
baker yeast´s cell wall in the amount of glucans (20 % higher in yeast form) and the 
reduction of mannoproteins content (10 % less than S. cerevisiae). Approximately, the 90 % 
of the total mass is made up of carbohydrates followed by proteins and lipids. It is generally 
divided in two fractions, the unified inner part in contact with the plasma membrane that 
especially contains chitin and glucans (50-60%), and a thicker heterogeneous layer with 
covalently bound mannoproteins (Figure 4) with direct contact to the host surface 
(reviewed by Klis et al., 2009). 
The internal cell wall layer presents mainly β-1, 3-glucans linked to β-1, 6 glucans and chitin 
(Klis et al., 2001). Approximately a 35-40 % of the total dry mass of yeast cell wall is 
comprised by cell wall proteins (CWPs) which are also classified into two different 
categories based on location and structure. It can be distinguished a first group of GPI-
CWPs connected to the network of polysaccharides in the inner cell wall and a second 




















Figure 4. Schematic Candida spp. cell 
wall model. Top, outer part of the cell 
wall composed by chains of mannans 
linked to the proteins by an 
asparagine residue (Asn). Middle, cell 
wall proteins (GPI-CWP (adhesins), 
Ecm33 and Pir proteins) linked to β-1, 
3-glucans, β-1, 6 glucans and chitin 




1.6 Candida spp. cell wall proteins (CWP)  
 
In the last years the development of bioinformatics programs and the improvement of 
sequencing techniques has promoted that several laboratories design different strategies 
to calculate algorithms which analyse the whole Candida genome to find expected adhesin-
like encoding genes. These implements are essential to predict CWPs including GPI-
anchored CWPs (De Groot et al., 2003; Eisenhaber et al., 2004). As an example, the 
program FungalRV has been used to predict putative adhesins-encoding genes in 
C. albicans (Chaudhuri et al., 2011). 
The cell wall proteins are involved in protein-protein attachment, yeast-microbe linkage 
and host-pathogen interaction. As it has been mentioned before, the proteins are classified 
depending on their structure and location. Within the covalently CWP proteins, two 
different types have been characterized. The glycophosphatidylinositol (GPI)-anchored 
proteins are mainly located in the outer part of the cell wall (Verstrepen and Klis, 2006; 
(Hoyer et al., 2008; Zupancic et al., 2008) linked with the β-1, 3 glucans by β-1, 6 glucans 
(reviewed by Chaffin, 2008). In case of proteins with internal repeats (Pir proteins), it has 
been found covalently attached to the plasma membrane via alkali-sensitive connectors 





colleagues, proteomic analyses of C. albicans cell wall have exhibited new surface proteins 
classified in four different groups including carbohydrate-active enzymes, adhesins, 
putative flocculins (Pga24p) and superoxide dismutases (de Groot et al., 2004). 
In contrast, the Candida cell surface presents several unbound proteins that can be found 
either in the cell wall or in the supernatant (Bgl2p) as well as secreted proteins like the 
Cht3p and Pra1p. Proteins like the Ecm33 and the aspartyl proteases Sap9 and Sap10 that 
has been found as a transit protein which can be present, at the same time, in the 
membrane and the cell wall (reviewed by Chaffin, 2008). 
 
1.7 GPI-anchored Cell Wall proteins (adhesins) 
 
As it has been mentioned before, the GPI-anchored CWP proteins are defined as adhesins 
which are mainly situated in the outer layer of the cell wall. These adhesins are secreted via 
Golgi apparatus and their elementary structure consists on a C-terminal part defined as a 
low complexity domain containing tandem repeat regions (TRRs) rich in serine and 
threonine (Ser/Thr) residues linked to the endoplasmic reticulum (ER) membrane by 
glycophosphatidylinositol linkage (GPI-anchor). The N-terminus part or high complexity 
domain presents a signal peptide involved in the secretion process and confers the 
adhesion-binding specificity to different host surfaces (Figure 5). The glycosylation of the 
proteins increase the molecular mass of them which contains a signal peptide that is going 
to be removed in the mature structure (Nather and Munro, 2008; de Groot et al., 2013). 
 
 
Figure 5. Cell wall GPI-anchored proteins (adhesins) general structure, adapted from ten Cate et al., 2009; 
de Groot et al., 2013. Mature adhesins are divided in two main parts, N-terminal domain (green) and C-
terminal domain (yellow) linked to the cell-wall Candida glucans by a GPI-anchor site containing a large 
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The mature structure of the adhesins is characterized by the absence of the signal peptide 
and the high N- and O-protein glycosylation during the transfer to the cell wall (Figure 6). 
The highly glycosylated mannan-network is located in the outer part of the cell wall direct 
contact with the host-recognition structures (PRRs). Novel techniques have been 
developed to extensively analyse adhesin structures, these new strategies include binding-
domain crystallization, mutagenesis, atomic force microscopy (AFM) and nuclear magnetic 
resonance (NMR) (Ielasi et al., 2012; Beaussart et al., 2012). 
 
 
Figure 6. Adhesin-like cell wall proteins secretion and cell wall attachment process. (A) Structure of adhesin-
protein secreted via endoplasmic reticulum and Golgi apparatus containing GPI anchor (orange). Signal 
peptides removal and protein’s glycosylation take place along the secretory pathway. In the membrane the 
GPI anchor is cleaved from the mature protein. Protein is stabilized with Ca2+ via O-glycosylated chains and 
integrated into the cell wall via glucans (reviewed by Verstrepen and Klis, 2006). (B) Mature adhesin scheme 
constituted by N-terminal binding domain (green), C-terminal anchoring domain (light pink), TRRs (Tandem 
Repeats Regions) in colours, and protein “branches” constituted by N-mannans and O-mannans. Adhesins 

























C. albicans adhesins has been investigated for long time. They have been distributed into 
three families including the deeply analysed Als family, the Hwp family and the Iff/hyr that 
has been described in CTG-clade Candida species, in contrast, these adhesins has not been 
detected in C. glabrata (Jackson et al., 2009; Butler et al., 2009; Boisramé et al., 2011). 
Als family: The agglutinin-like-sequence (Als) CWP family was the earliest CWP described in 
C. albicans divided in three subfamilies attending to the low complexity C-domain (tandem 
repeats domain) and they are implicated in adhesion to host surfaces. Differences between 
the subfamilies depend on the repeat region (reviewed by Hoyer, 2001). The majority of 
the adhesins genes are located in telomeric regions of the chromosomes 3, 6 and R (Hoyer 
et al., 1995; Hoyer et al., 1998a; Hoyer and Hecht, 2001).  
There is a broad variation between ALS genes among isolates and there are influenced by 
media composition (Als1), morphogenesis process (Als3 and Als8) and growth parameters 
(Als4) (Hoyer et al., 1995;Hoyer et al., 1998a; Hoyer et al., 1998b; Hoyer and Hecht, 2000). 
They are homogeneously distributed along the cell wall (Kapteyn et al., 2000) connected 
with the β-1, 6-glucan. The ALS genes are also presented in C. dubliniensis (reviewed by 
Hoyer et al., 2001). Complementary studies have asserted the presence of ALS encoding-
genes in several NCAC species as C. dubliniensis, C. tropicalis and C. parapsilosis. It has been 
detected a strong variability between ALS genes along isolates, for example, the size of the 
adhesins fluctuate between strains, which mean that the divergence in the number of 
repeats is a key point in the attachment to the host (Hoyer and Hecht, 2001). The Als-
adhesins have been also differentiated attending to their functionality in the pathogenic 
process, for example, Als1, Als2, Als3, Als4 and Als9 are involved in the adherence to 
epithelia and endothelial cells as well as laminin, fibronectin, and collagen (Als3). The 
members of Als family take part in the attachment of Candida cells to abiotic devices (glass, 
silicone-elastomers and acrylic methacrylate). In contrast, deletion mutants of Als5, Als6 
and Als7 (Hoyer and Hecht, 2000) have increased their capacity to adhere to host tissues 
and have usually been identified in biofilms due to their aggregation capacity. Als1, Als3 
(hyphae specific) and Als5 cell wall proteins present amyloid structures able to aggregate 
between them increasing the adherence in Candida-Candida interaction or Candida-






Hwp1 family: the adhesins included in this family are expressed under hyphae morphology 
such as Hwp1, Hwp2/Pga8 (hyphal wall protein) and Rbt1 (repressed by Tup1). They are 
involved in abiotic biofilm formation to polystyrol (Hwp1 and Eap1/Pga47) and silicone 
(Hwp2/Pga8), in biotic attachment to oral mucosa and epithelia, and they are also 
implicated in mating process (Nobile et al., 2008; Ene and Bennett, 2009). 
Iff/Hyr family: to date, it is constituted by adhesins mostly express in the hyphae form as 
the other two families (hyphally upregulated proteins) highlighting Hyr1, that controls host-
immune cell destruction, and the iff subfamily needed for adherence to epithelia and cell 
surface maintenance (reviewed by de Groot et al., 2013). 
 
1.8 Candida glabrata 
 
C. glabrata was described as imperfect non-dimorphic yeast (2.5 to 4.5 X 4.6 µm) that 
usually grows as blastoconidia (37°C) producing small, round and glossy-creamy colonies 
without mycelia development (Sinnot et al., 1987 and Kwon-Chung and Bennett, 1992). It 
can be identify in selective CHROMagar as round creamy green colonies but is nearly 
impossible to differentiate from other Candida species on Sabouraud-Dextrose-Agar (SDA) 
plates, unless for the small size (Figure 7). C. glabrata ovoid cells forms small chains 
connected to each other by multilateral buds (Saballs et al., 2000). It is haploid yeast that 








Figure 7. C.  glabrata morphology. Left, colony 
phenotype on Sabouraud´s agar. Right, round 
yeast cells in YPD liquid culture. 
 
 
Unless is still under investigation, some virulence factors are decisive for C. glabrata 
pathogenicity. Among them, we can underline the adherence to surfaces, the formation of 






2018). It has been also highlighted the importance of surface glycoproteins controlled by 
SIR and RAP1 subtelomeric silencing (De Las Peñas et al., 2003). Furthermore, it has been 
remarked the resistance to oxidative stress (reviewed by Vale-Silva and Sanglard, 2015) and 
the recently described CgDtr1 which has been involved in Galleria mellonella virulence 
(Romão et al., 2017). 
Contrary to C. albicans, the ability to only form budding cells, allows C. glabrata to create a 
compact microbial community constituted by yeast and ECM (Kucharíková et al., 2015) that 
behaves as a perfect deposit for consecutive infections. 
 
 
Figure 8. C. glabrata biofilm in vitro schematic model. Top row: C. glabrata biofilm formation in catheters 
(elastomers). Bottom row: biofilm formation capacity to acrylic dental prosthesis. Both procedures are 
divided in three major steps (early, intermediate and mature). In blue, extracellular matrix (ECM). 
 
Little is known about C.  glabrata biofilm composition excluding the ability to form dense 
communities divided into defined multilayers constituted by proteins, β-1, 3-glucans as 
well as ergosterol in the matrix (Nett et al., 2007; Silva et al., 2009). C. glabrata is able to 
form compact biofilms (Figure 8) in different biotic and/or abiotic materials used in 
nosocomial environments like silicone elastomers, polyvinyl, polystyrol (reviewed by 
Tournu and Van Dijck, 2012) or dental acrylic resins (Pathak et al., 2012). Currently, the 
majority of the biofilm formation tests have been performed in vitro using this medical 
devices (catheters, dentures) or standard materials (polystyrol) with hydrophobic surfaces. 
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As it has been addressed by (El-Kirat-Chatel et al., 2015), the adherence capacity of 
C. glabrata cells to negatively charged surfaces is higher compared to hydrophilic areas 
(Hazen et al., 1986; Luo and Samaranayake, 2002). C. glabrata biofilms display certain 
resistance against azoles and polyenes but are still susceptible to echinocandins (Seidler et 
al., 2006; Kucharíková et al., 2015). 
 
1.8.1 Candida glabrata cell wall proteins 
 
(Desai et al., 2011) indicated that C. glabrata genome contains more than 300 specific 
genes that are still not totally characterized but may influence in its virulence capacity. 
This assumption was subsequently investigated by Weig et al. (2004) and de Groot et al. 
(2008) showing that C. glabrata presents 67 sequences adhesion-specific in the cell wall of 
the type strain CBS-138. These are grouped in seven subfamilies attending to the binding 
domain, nevertheless, the function and role during fungal infections is still not well 
characterized for all. As it is shown in Figure 9, the adhesin-encoding genes are, in large 
part, present in the telomeric regions and controlled by subtelomeric silencing (Reviewed 
by De Las Peñas et al., 2015) .These genes have high tendency to present homologous 
recombination as well as gene rearrangements. The first two families differentiated in 
C. glabrata are the Epa family (epithelial adhesins) and the Pwp family (protective antigen 
wall proteins). Both families present the lectin binding domain PA14 (anthrax protective 
antigen). 
The Epa family (17 members) is a really well characterized adhesin group involved in host-
epithelia attachment (Cormack et al., 1999; Zupancic et al., 2008). According to the review 
of Timmermans et al. (2018), C. glabrata adhesins are classified in three different 
categories depending on their functionality: adhesins present in planktonic cells, adhesins 
involved in adherence and colonization and adhesins identified in biofilms. 
Together with the two previous groups, five different subfamilies were determined 
including the relevant Awp family (adhesin wall proteins). These adhesins are far related in 
terms of N-ligand-binding specificity and they are still not deeply characterized (Kraneveld 








Figure 9. Chromosomal distribution of putative C. glabrata adhesins-encoding genes (de Groot et al., 2013). 
Adhesins encoding genes are located in subtelomeric regions of 13 chromosomes (EL, ER; IL, IM, IR, LL, LR). 
Colours represent seven subfamilies of adhesins depending on the N-terminal binding domain. 
 
1.9 Candida parapsilosis 
 
C. parapsilosis presented round yeast cells and pseudohyphae at 37 °C. (Figure 10) This 
nosocomial pathogen has gained importance in the last years and as it has been described 
for C. albicans, the capacity of C. parapsilosis to switch between morphologies implicates a 
variation in the infection-relevant cell properties which help C. parapsilosis to adapt to 





Figure 10. C. parapsilosis CDC 317 morphology. Left, smooth 
colony morphotype on Sabouraud´s agar. Right, round yeast 
cells from smooth morphotype in YPD liquid culture. 
 





The biofilm formation process in C. parapsilosis isolates is still not well understood. 
Nevertheless, variations in biofilm formation capacity between bloodstream isolates (59%) 
and samples isolated from skin (39%) have been remarked (Růzicka et al., 2007; Shin et al., 
2002). Laffey and collaborators have remarked the importance or morphotypic switch and 
presence of farnesol mediating quorum-sensing process are, as well implicated in biofilm 
formation (Laffey and Butler, 2005). Lattif et al. (2010) have asserted that C.  parapsilosis 
biofilms are composed by clusters or yeast cells attached to the surface with a minimal 




Figure 11. C. parapsilosis in vitro schematic model. C. parapsilosis biofilm formation divided in three major 
steps (early, intermediate and mature) on catheters and medical implants with pseudohyphae development. 
 
1.9.1 Candida parapsilosis cell wall proteins 
 
Currently, less is known about C. parapsilosis cell wall, the phylogenetic relation with 
C. albicans (CTG clade), has indicated a similar distribution of the cell wall components. As 
it has been described before for C. albicans and C. glabrata, the cell wall is also composed 
with sugars located in the inner layer and highly glycosylated proteins in the outer part of 
the cell surface (Díaz-Jiménez et al., 2012). Studies based on N-and O-linked mannans have 
confirmed their importance in IL-1 β (O-linked mannans) and IL-6 and TNF-α (N- and O-
linked mannans) stimulation in the host-immune response (Pérez-García et al., 2016). 
pseudohyphae development (Candida parapsilosis) 
early intermediate mature














Bioinformatic approaches performed by Butler et al. (2009) have remarked the presence of 
five ALS family encoding-genes and six predicted GPI-anchored protein encoding-genes 
(Pga 30). 
Genome analyses have remarked small variations in lysophospholipases and peptidases 
between clinical isolates, thus, broad distribution of adhesion-encoding genes have been 
analyzed (Hoyer, 2001). A detectable variation in the presence of adhesins encoding genes 
has been found between C. parapsilosis isolates, indicating an unequal presence of ALS 
genes, involving deletion and recombination of genes (e.g. CPAR2_404800 and 
CPAR2_404780) or divergence events (CPAR2_404790) among C. parapsilosis strains 
(Pryszcz et al., 2013). 
 
1.10 Candida species interaction in host invasion  
 
Cell surface Candida proteins are important for colonization and invasion of human 
epithelia, adherence to epithelia human cells have been studied in the last years in Caco-2 
cells and also in fibroblast pointing the importance of the large cell surface proteins 
function for this purpose (Gabaldón et al., 2013b; Hoyer and Cota, 2016) focusing on the 
interaction between human epithelia and the N-terminal binding domain of the adhesins 
like proteins (lectin domain). In case of C. albicans the presence of the Als3 is known to be 
crucial for the penetration through the epithelia host barrier. According to the review by 
(Kühbacher et al., 2017), there two possible mechanism, remarking a passive endocytosis 
or an active penetration in which C. albicans ALS3 and HWP1 genes are clearly involved 
(Dieterich, et al., 2002). In agreement with this, more recently it has been shown the 
functionality of the secreted aspartyl protease and well as the gen ECE1 secreted a peptide 
toxin (Candidalysin) able to produce pores and damage the tissue under hyphal condition 
during the epithelia invasion (Moyes et al., 2016; Richardson et al., 2018). In case of 
C. glabrata, several studies pointed the possibility of a co interaction between C. glabrata 
and C. albicans (Alves et al., 2014). In case of NCAC species, the invasion process is still 
under investigation. Tati et al. (2016) has interestingly proposed that C. albicans may 
interact with C. glabrata during epithelia invasion. According to the authors, C. glabrata 
CWP will be responsible for the adhesion of yeast to C. albicans hyphae, allowing 





beneficial during the colonization and host-invasion. Regarding C. parapsilosis, differential 
functionality of chitinases, dehydrogenases or phosphatases, have been described in yeast 
form. Contrary, the pseudohyphal stage mainly presents proteins similar to a cell surface 
mannoprotein Mp65, chitinase and GPI-anchored or the Rbt1 cell wall protein. 
Nevertheless, cell wall proteins identification and cell-surface protein encoding genes are 
still under studied (Karkowska-Kuleta et al., 2015). 
AIMS OF THE STUDY 
 
25 
1.11 Aims of the study 
 
C. glabrata and C. parapsilosis are the two most common causes of non-Candida albicans 
Candida (NCAC) infections in the human host. The capacity to form biofilms on abiotic and 
biotic surfaces encased in extracellular polymeric matrix is thought to be a prerequisite for 
successful host colonization. Previous works have focussed on few laboratory strains. 
Therefore, with a focus on C. glabrata and C. parapsilosis clinical isolates, the major aim of 
this study was to further elucidate if and how phenotypic and morphological differences 
between and within clinical isolates are reflected on genome and proteome levels and how 
these differences correlate with the host infection process. 
Specifically, we sought to build and phenotypically classify C. glabrata and C. parapsilosis 
strain collections, attending to the cell surface-related properties and the capacity to form 
biofilms on abiotic surfaces. It is known that biofilm formation capacity can reduce 
antimycotic susceptibility, therefore, antifungal drugs susceptibility tests of a 
morphologically and phenotypically characterized clinical isolates were to be performed to 
confirm if phenotypic variations would predetermine MIC towards azoles, echinocandins, 
or polyenes. 
Furthermore, in this study, we sought to characterize variations between biofilm-forming 
clinical isolates and their virulence in the G. mellonella animal model as part of the still 
understudied mechanism of pathogenicity in C. glabrata and C. parapsilosis clinical isolates. 
It is known that genomic variability in genes encoding cell wall proteins in pathogenic 
Candida species is present. Therefore, in order to deeply investigate the importance of 
gene variation and cell wall proteins incorporation in both species as strategy associated 
with virulence, genome sequencing analyses and MS/MS spectrometry analyses of selected 
C. glabrata and C. parapsilosis clinical isolates were to be conducted to better understand 
variations as future diagnostic tools. 




2. Materials and Methods  
2.1 Materials 
 
General materials, chemicals and disposables, unless specified in Table 1, were purchased 
from Carl Roth GmbH (Karlsruhe, Germany), Eppendorf AG (Hamburg, Germany), Sigma-
Aldrich Chemie (Steinheim, Germany), Sarstedt AG & Co. KG (Nümbrecht, Germany), Merck 
KGaA (Darmstadt, Germany), Sartorius AG (Göttingen, Germany), and Thermo Fisher Scientific, 
GmbH (Darmstadt, Germany). 
 
Table 1. Chemicals and disposables used in this study 
materials  company 
5-Brom-4-chlor-3-indoxyl-β-D-galactopyranosid Sigma-Aldrich Chemie, Steinheim, Germany 
12-well microtiter plates Greiner Bio-One, Frickenhauser, Germany 
96-well microtiter plates Greiner Bio-One, Frickenhauser, Germany 
α-cyano-4-Hydroxycinnamic acid (C10H7NO3) Sigma-Aldrich GmbH, Steinheim, Germany 
Acetonitrile LC –MS Chromasolv ®  Fluka Analytical, Sigma-Aldrich GmbH, Steinheim, 
Germany 
AdvanDX C. albicans/C. glabrata DNA FISH® 
identification Kit  
AdvanDX A/S, Hvidovre, Denmark 
Ampicilin Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
Amphotericin B (C47H73NO17) SERVA-Feine Biochemica, Heidelberg, Germany 
Bacto TM Peptone BD, Becton Dickinson and Company, Le-Pont de-
Claix, France 
Bacto TM Yeast Extract BD, Becton Dickinson and Company, Le-Pont de-
Claix, France 
BBL™ CHROMagar™ Candida BD, Becton Dickinson and Company, Le-Pont de-
Claix, France 
BBL ™ Corn Meal Agar BD, Becton Dickinson and Company, Le-Pont de-
Claix, France 
Blankophor P Prechel GmbH, Schwetzingen, Germany 
Caspofungin (C52H88N10O15) Merck KGaA, Darmstadt, Germany 
 
Continued from previous page 
Columbia agar + 5 % sheep blood plates  BioMèrieux Germany GmbH, Nürtingen, 
Germany 




Commercial Sabouraud agar plates + glucose 
with gentamicin and chloramphenicol 
Oxoid ™ Germany GmbH, Wesel, Germany 
Crystal Violet Sigma-Aldrich GmbH, Steinheim, Germany 
D + Glucose Monohydrate Carl Roth GmbH, Karlsruhe, Germany 
DifcoTM Antibiotic Medium 3 BD, Becton Dickinson and Company, Le-Pont de-
Claix, France 
Dimethyl sulfoxide (C2H6OS) Sigma-Aldrich GmbH, Steinheim, Germany 
DNA Gel Loading Dye 6X Thermo Fisher Scientific, GmbH, Darmstadt, 
Germany 
Ethylenediaminetetraacetic acid (C10H16N2O8) Sigma-Aldrich GmbH, Steinheim, Germany 
Fluconazole (C13H12F2N6O) Discovery Fine chemicals, Wimborne, UK 
Flucytosine (C4H4FN3O) Sigma Aldrich Chemie GmbH, Steinheim, 
Germany 
Formic acid Rotipuran ® 98 % (CH2O2) Carl Roth GmbH, Karlsruhe, Germany 
GelRed ®, 10000X Genaxxon Bioscience, Ulm, Germany 
Glass beads, 0.5 mm BioSpec Products, Carl Roth GmbH, Karlsruhe, 
Germany  
HotStar Taq® DNA polymerase Kit Qiagen GmbH, Hilden, Germany 
Isavuconazole Discovery Fine Chemicals, Wimborne, UK 
Mast Cryobanks TM Mast Diagnostica GmbH, Reinfeld, Germany 
Micafungin (C56H71N9O23S) Astellas Pharma GmbH, München, Germany 
MidoriGreen Advance  Nippon Genetics Europe GmbH, Düren, Germany 
MSP 96 polished steel BC targets Bruker Daltonics, Bremen, Germany 
N-lauroylsarcosine sodium salt (C15H29NO3) Sigma-Aldrich GmbH, Steinheim, Germany 
Nucleospin® Gel and Clean-up Kit Macherey-Nagel, Düren, Germany 
PCR grade nucleotide Mix (dATP, dCTP, dGTP, 
dTTP) 
Roche Pharma AG, Grenzach-Wyhlen, Germany 
PCR reaction buffer + Mg (10X) Roche Pharma AG, Grenzach-Wyhlen, Germany 
Phloxine B Sigma-Aldrich GmbH, Steinheim, Germany 




Continued from previous page 
Posaconazole (C37H42F2N8O4) Discovery Fine chemicals, Wimborne, UK  
Potassium dihydrogen phosphate 99.8% 
(KH2PO4) 
Calbiochem, Merck KGaA, Darmstadt, Germany 
Proteinase K PanReac AppliChem GmbH, Darmstadt, Germany 
RNase (10 U/L).  Thermo Fischer Scientific GmbH, Darmstadt, 
Germany 
RPMI-1640 w L-glutamine w/o NaHCO3 Biochrom GmbH, Berlin, Germany 
Sabouraud´s agar plates + gentamicin and 
chloramphenicol 
Oxoid ™ GmbH, Wesel, Germany 
Silicone non-reinforced sheets  AMT Aromando Medizintechnik GmbH, 
Düsseldorf, Germany 
Taq DNA polymerase, 0.5 U  Hoffmann-La Roche, Basel, Switzerland 
Voriconazole (C16H14F3N5O) Discovery Fine chemicals, Wimborne, UK 
Zymolyase® 20T 20 U/mg Carl Roth GmbH, Karlsruhe, Germany 
 
Table 2. Media used in this study 
media components 
AM3 2X AM3 commercial medium + 2% (w/v) glucose 
D + monohydrate in dH2O 
CAC 1.5% (w/v) Chromagar™Agar, 1.02% (w/v) 
peptone, 2.2% (w/v) chromogenic mix, 0.05% 
(v/v) chloramphenicol (pH = 6.1± 0.2) 
CMA 1.7% (w/v) commercial Corn Meal agar in dH2O 
(pH = 6 ± 0.2) 
LB 0.5% (w/v) tryptone, 1% (w/v) yeast extract, 0.5% 
(w/v) NaCl 
modified 2X RPMI 2.08% (w/v) RPMI-1640 w glutamine w/o 
bicarbonate, 6.90% (w/v) MOPS, 3.6% (w/v) 
glucose in dH2O (pH = 7. with NaOH) 
RPMI RPMI-1640 
SAB/SDA 6.5% (w/v) Sabouraud´s agar in dH2O (pH = 5.6 ± 
0.2) 
YPD agar 1% (w/v) bacto yeast extract, 2% (w/v) bacto 
peptone, 2% (w/v) glucose and 2% (w/v) agar 
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YPD medium 1% (w/v) bacto yeast extract, 2% (w/v) bacto 
peptone, 2% (w/v) glucose in dH2O 
YPD + Phloxine B 1% (w/v) bacto yeast extract, 2% (w/v) bacto 
peptone, 2% (w/v) glucose, 2% (w/v) agar and 
0.5% (w/v) Phloxine B (filter sterilized) in dH2O 
 
Table 3. Solutions used in this study 
general solutions components 
PBS 10X 0.8% (w/v) NaCl, 0.02% (w/v) KCl, 0.14% (w/v) 
Na2HPO4, 0.24% (w/v) KHPO4 in a final volume of 
1 liter (pH = 7.4) 
SDS/EtOH 1 % SDS (w/v), 50 % (v/v) ethanol in 500 ml dH2O 
TAE 50X 0.024% Tris base, 5.71% (v/v) glacial acetic acid, 
500 mM EDTA (pH 8.0) in a final volume of 1 liter. 
Working solution: TAE 1X (49:1) (filter sterilized) 
 
Table 4. Solutions used in this study 
specific solutions components 
lysis buffer (genomic DNA isolation)  100 mM Tris-HCl (pH = 8), 50 mM EDTA, 1% (w/v) 
sodium dodecyl sulfate (SDS) 
matrix (MALDI-TOF) () HCCA in 50% (v/v) acetonitrile and 0.125% (v/v) 
TFA acid 
PFGE washing buffer  20 mM Tris-Hcl (pH = 8.0) and 50 mM EDTA in a 
final volume of 1 liter. 
proteinase K reaction solution  100 mM EDTA (pH  = 8.0), 0.2% Na deoxycholate 
97%, 1% N-lauroylsarcosine sodium salt and 1 
mg/ml proteinase K 
zymolyase solution  10 mM Tris-HCl (pH = 7.2), 50 mM EDTA, 0.1 
mg/ml zymolyase 20T 
 
All media and general solutions used in this study were sterilized for 15 min. at 121°C. The 
RPMI and AM3 used in the antifungal susceptibility as well as specific solutions with 
thermolabile additives (e.g. enzymes) tests were filter sterilized. 
2.1.1 Synthetic oligonucleotides  
 




Synthetic oligonucleotides used for Polymerase Chain Reaction (PCR) amplification and 
gene sequencing were purchased from Sigma-Aldrich (Steinheim, Germany) and detailed in 
Table 5. 
 
Table 5. oligonucleotides used for PCR amplification 
2.1.2 Candida spp. clinical isolates 
 
The C. glabrata, C. parapsilosis and C. albicans clinical strains isolated during the course of 
this study are detailed in the appendix (Appendix). 
 
2.1.3 Candida spp. reference strains 
 
Table 6. List of C.  parapsilosis reference strains used in this study  
name amplifies primer sequence (5´-3´) 
CPAR2_404800-ALS7-F central region 5’-CCAACCACCACAGTCACAACATCT-3’ 
CPAR2_404800-ALS7-R  central region 5’-GGAGACAGTAGATGATAATTGC-3’ 
CPAR2_403520-HWP1-F1 central region 5’-CTTGCTCGAATGGTGGATGC-3’ 
CPAR2_403520-HWP1-R1 central region 5’-ACCGTTGTTGTCTTGATCGA-3’ 
CPAR2_404790-F1 5’ region 5’-CACCACCGCATTTTGGACTG-3’ 
CPAR2_404790-R1 5’ region 5’-CACCTTCCCCAGTCCAGAAC -3’ 
CPAR2_303740-ERG11-F1 5’ region 5’-TAGTGGGATCGGTGGATCTT -3’ 
CPAR2_303740-R-ERG11-R1 5’ region 5’-CTTTATCTAAATCAGCATACAATTGAG-3’ 
CPAR2_303740-ERG11-F2 3’ region 5’-TCTAGATCCTTATTAGGAGAAGCAATG-3’ 
CPAR2_303740-ERG11-R2 3’ region 5’-ACTGACTCCTGCCCTCAGATT-3’ 
CPAR2_807270-MRR1-F1 5’ region 5’-CTGTATGGAGAGAGTGAGATTTTAGGTT -3’ 
CPAR2_807270-R-MRR1- R1 5’ region 5’-TCCTTGGTTACCTCATTGCTC -3’ 
CPAR2_807270-F-MRR1-F2 central region 5’-GGTGATGGGGCTGACTCAAA -3’ 
CPAR2_807270-R-MRR1-R2 central region 5’-GCTCCACCTTGCCAATTTGG-3’ 
CPAR2_807270-F-MRR1-F3 3’ region 5’-ATGGAGACCATTAATTTTTTTGACA-3’ 
CPAR2_807270-R-MRR1-R3 3’ region 5’-GAATGACTTCATTGAAATGTAATGCT-3’ 




clinical isolate genotype, source of 
isolation and origin 
collection reference provider 
CDC 317 ATCC® MYA-4646™, 
CDC 317, health care 
worker´s hand, 
unknown 
(1) American Type 
Culture Collection, 
ATCC®, Manassas, USA 
(Kuhn et al., 2004) (1) 
ATCC 22019 ATCC® 22019™, CBS 
604, DSMZ-5784, case 
of sprue, Puerto Rico 
(2) German Collection of 
Microorganisms and Cell 
Cultures, DSMZ, Leibniz 
Institute, Braunschweig, 
Germany 
Ashford, 1928 (2) 
CBS 1954 ATCC® 28474™ 
environmental, olive 
fruit, Italy 






CBS 6318 ATCC® 7330™, man 
healthy skin, USA 
American Type Culture 
Collection, ATCC®, 
Manassas, USA 
Meyer, 1994 CRG, 
Barcelona, 
Spain 
GA-1 SZMC 8110, clinical 











Table 7. List of C.  glabrata reference strains used in this study  
CBS-138 ATCC® 2001™, CBS 138, 
JCM 3761, NBRC 0622, 
NRRL Y-65, man feces, 
unknown 
(3) Westerdijk Fungal 
Biodiversity Institute, 
CBS-KNAW, Utrecht, The 
Netherlands 
Anderson, 1917 (3) 
ATCC90876-CRIB ATCC® 90876™ , human 
blood, Essen, Germany* 
Regional Centre for 
Biomedical Research, 
Albacete, Spain 
Dermoumi, 1994 (4) 
 
Table 8. List of C.  albicans reference strains used in this study  
SC5314  ATCC® MYA-2876™, 
clinical human 
specimen, unknown 
American Type Culture 
Collection, ATCC®, 
Manassas, USA 
(Gillum et al., 













2.2.1 Routine diagnostic procedures 
 
In order to routinely analyze clinical specimen for fungal growth, samples were provided 
from the diagnostic laboratory, where they were plated onto Sabouraud’s GC agar in 
addition to other agars and these incubated at 35°C overnight. Yeast species were 
restricted in order to ensure single pure cultures and identified using MALDI-TOF (MALDI 
Biotyper, Bruker Daltonics, Bremen, Germany) using the YOTL database (Bernhard et al., 
2014). Routinely susceptibility testing was performed on a VITEK2 system (BioMérieux, 
Nürtingen, Germany). 
 
2.2.2 Candida spp. strain maintenance and growth 
conditions 
 
Once transferred to the research laboratory, mixed cultures were further differentiated on 
YPD agar, C. parapsilosis clinical isolates (n = 220) plus the C. parapsilosis reference strains 
(n = 5) (Table 6) were replated onto Sabouraud’s GC, YPD agar (1% yeast extract, 2% 
peptone, 2% glucose, 2% agar) and YPD agar plus 5 mg/ml Phloxine B and subsequently 
incubated at 30°C and 37°C for pseudohyphae induction (Appendix). 
In contrast, all C. glabrata clinical isolates (n = 488) plus C. glabrata (n = 2), (Table 7) and 
C. albicans (n = 2), (Table 8) reference strains were plated onto SAB´s GC agar and 
Columbia (COS) blood agar and incubated at 37°C (mimicking human body temperature), 
(Appendix 1). 
Individual lineages obtained were long-term preserved at -70°C in cryovials. Independent 
Candida colonies from both species were routinely grown in 3 ml of liquid YPD (1% yeast 
extract, 2% peptone and 2% glucose) at 37°C and 220 rpm. Before each experiment, cells 








2.2.3 MALDI-TOF analyses species-identification 
 
Patient isolates were classified and plated in selected media, after a previous susceptibility 
test (VITEK®2, BioMérieux, Nürtingen, Germany), clinical samples were quickly 
characterized using species identification YOTL (Yeast On-Target-Lysis) preparation was 
conducted. Briefly, single colonies were streaked onto a steel MALDI target and one µl of 
70% formic acid Rotipuran® was added to lyse the cells. After drying, 1 µl matrix solution 
(α-cyano-4-hydroxycinnamic acid in 50% acetonitrile, 0.125% trifluoroacetic acid) was 
added and left to crystalize at room temperature. When no accurate identifications were 
obtained, full extractions of proteins were performed following the protocol provided by 
the manufacturer (Bruker Daltonics, Bremen, Germany). Several colonies from pure 
cultures were dissolved in 200 µl of milli-Q water. Nine hundred µl of absolute 100% 
ethanol were added to the cell suspension. Cells were mixed and 200 µl of the solution 
were centrifuged at 12000 rpm for 2 min. The supernatant was discarded and the pellet 
was dried out for 10-15 minutes. Between 25-50 µl of formic acid Rotipuran® ≥ 98% were 
added to the suspension. Cell solution was incubated for 10 min. at RT. Equal amount of 
MS-grade acetonitrile as formic acid was added and centrifuged for 2 min. at 12000 rpm. 
One µl of the proteins presented in the supernatant were dispensed on the target before 
adding the MATRIX solution. All sample preparations were done in duplicate and the 
spectra automatically analyzed by MALDI Biotyper 3.1 software on an Autoflex III mass 
spectrometer (both from Bruker Daltonics, Bremen, Germany). C. parapsilosis and 
C. glabrata reference strains spectra were already incorporated in the system and 
established as baseline for new specie-identification. Standard settings defined by the 
automated acquisition mode were used during the measurements. A recommended cut-off 
of log score value of ≥ 2.000 was used to discriminate false positives and valid 
identifications. 
 
2.2.4 C. glabrata biofilm formation capacity to polystyrol 
 
To analyze the capacity of C. glabrata clinical isolates to form biofilms in abiotic surfaces 
used in nosocomial environments, a modified quantitative CV-biofilm formation assay was 




performed (Figure 12) (Gómez-Molero et al., 2015; Kuhn et al., 2002; Ramage et al., 2001). 
C. glabrata clinical isolates (Appendix) plus the C. glabrata reference stains (Table 7) were 
cultured as detailed in 2.2.2. The optical density was measured (A600), (Smart Spec 3000; 
Bio-Rad) and adjusted to an OD = 2. Cell suspensions were diluted 1+3 to a total volume of 
200 µl YPD into the 96-well plates (Greiner Bio-One, Frickenhausen, Germany) and 
incubated at 37°C for 24h. Medium was removed putting the plates upside down. 
Planktonic cells were discarded tapping the plate gently and washing once with 200 μl of 

































Figure 12. Schematic C. glabrata biofilm formation to polystyrol. (A) C. glabrata incubation and species-
determination using MALDI-TOF Biotyper. (B) Cells adjustment to OD 600nm = 2. (C). Biofilm quantification by 
CV staining method. Total biofilm formation capacity to polystyrol was measured at (A490) and (A630). 




Excess dye was washed away once with 200 μl milli-Q water. Biofilms were disrupted by 
carefully mixing in 200 μl 1% (w/v) SDS in 50% (v/v) ethanol. Crystal violet staining intensity 
was measured at OD 490nm and OD 630nm (MRX-TC Revelation, Dynex Technologies GmbH, 
Denkendorf, Germany). All data shown is the average of two independent experiments 
with four biological replicates, classified in three different categories as LBF, IBF and HBF. 
Statistical unpaired t-test (Welch´s t-test) analyses compared with the CBS-138 were 
performed for all the clinical isolates of the study. 
 
2.2.5 C. glabrata biofilm formation capacity to silicone 
elastomers 
 
To analyze biofilm formation capacity to silicone elastomers (Gómez-Molero et al., 2015), 
C. glabrata clinical isolates (detailed in the Appendix) were incubated in SAB´GC agar and 
YPD agar section 2.2.2. Liquid cultures were grown overnight at 37 °C. The isolates were 
adjusted to and OD of 0.8 McFarland in 4 ml of NaClphysiol. One hundred µl of the solution 
were added to 15 ml glass tubes containing 1 piece of a 1cm X 1cm silicone squares cut 
from larger non-reinforced sheets (AMT Aromando Medizintechnik GmbH, Düsseldorf, 
Germany). The cells plus the piece of silicone were incubated in 4 ml of YPD medium in an 
orbital shaker at 37 °C overnight. The silicone pieces were deposited in a 12-well plate 
(Greiner Bio-One, Frickenhausen, Germany) and unbound cells were washed out with 1 ml 
of PBS 1X, the pieces of silicone were transferred to a new plate containing 1 ml of fresh 
PBS. The silicone was scratched to remove the Candida biofilms bound to the entire 
surface. Biofilm production was quantified by measuring optical density of a cells/PBS 
solution (1:100) on the MRX-TC Revelation microplate reader (Dynex Technologies GmbH, 
Denkendorf, Germany) at OD 600nm. The data shown were performed in duplicate and the 
average and standard deviation of each biological replicate calculated (Figure 13).  
























Figure 13. Schematic C. glabrata 
biofilm formation to silicone. (A) 
C. glabrata incubation and 
species-determination using 
MALDI-TOF Biotyper. (B) Cells 
adjustment to and OD of 0.8 
McFarland. (C) Silicone pieces 
were scratched and cells 
suspension quantified at (A600). 
 
 
2.2.6 C. parapsilosis biofilm formation capacity to polystyrol 
 
To assess C. parapsilosis biofilm quantification, stable morphotypes and phenotypic switch 
have to be determined (Anderson and Soll, 1987 ; Laffey and Butler, 2005). Colonies were 
plated and incubated on selective media (2.2.2) at 30 °C for 96 h. After four days of 
incubation, independent colonies presented defined morphotypes (e.g. “smooth”, “crater”, 
“concentric” or “crepe”). Biofilm production of C. parapsilosis clinical isolates to plastic 
materials (polystyrol) was quantified by CV staining as described before for C. glabrata 
(2.2.4).The clinical isolates used in this study are detailed in the (Appendix). Statistical 
analyses using unpaired t-test (Welch´s t-test) were conducted and all data shown is the 
average of at least two independent biological experiments with four technical replicates 




each (Figure 14). A modified biofilm quantification assay was performed to increase 
accuracy in colony-morphotype biofilm quantification. The optical density of single colonies 
was determined using a McFarland standard n° 4 (A600 nm = 0.431 with a Compact 
Benchtop Densitometer, DEN 1A, SIA BioSan, Riga, Latvia) dissolved in 4 ml of NaClphysiol. 
The cell suspension was measured again at (A600) (Ultrospec 1000) and adjusted to a value 
of 2 using sterile NaClphysiol. The cells were diluted 1+3 to a final volume of 200 µl YPD in 96-
well microtiter plates. Biofilms were incubated ON at 37°C (pseudohyphae induction 
temperature) and biofilms were measured as detailed before for C. glabrata. The data 
shown is the average of at least two independent biological experiments with four 
technical repeats each. 
 
 
Figure 14. Schematic C.  parapsilosis biofilm formation capacity to polystyrol. Top row: MALDI-TOF 
identification of C. parapsilosis colony morphotypes. Middle row, cell adjustment to an initial OD = 0.5 in non-
treated 96-well microtiter plates. Bottom row: cell Incubation for 24 h. at 37°C and biofilm quantification by 
CV staining. Colorimetric determination on MRX-TC Revelation microplate reader at 490 nm and 600 nm. 




2.2.7 Antifungal susceptibility test 
 
To determine the minimal inhibitory concentration towards FLU, ISA, VOR, POS, MICA, CAS, 
5FC, AMB for C. glabrata and C. parapsilosis in our clinical strain collection (Appendix), 
antifungal susceptibility tests were performed based on the protocols previously described 
by (Arendrup et al., 2012) and determined according to EUCAST EDef 9.0 method. Prior to 
analysis, the clinical isolates were replated overnight onto SAB´s GC agar plates (Oxoid ™ 
GmbH, Wesel, Germany). Cells were adjusted to a target value of 0.5 McFarland with 
NaClphysiol. A 10 fold dilution was prepared and 100 μl of the suspension were added to 96-
well microtiter plates that already contained serial antifungal dilutions as defined by 
EUCAST standardized broth microdilution (Table 9) method v 9.0 The antifungal stocks 
solutions of 5FC, CAS, and MICA were dissolved in mQ water, the FLU was dissolved in 75 % 
methanol and the DMSO was the solvent selected to dilute VOR, ISA, and AMB. Antifungal 
dilutions were resuspended in 2X RPMI-1640 medium (FLU, ISA, VOR, POS, MICA, CAS, 5FC) 
and AM3 (AMB). Plates were incubated 24 and 48h. at 37°C and cell density was read at 
A530 (MRX-TC Revelation microplate reader). The MIC values were calculated according to 
EUCAST guidelines (*). Clinical isolates were classified as susceptible isolates, when the 
minimal inhibitory concentration (MIC) was equal or lower than the clinical breakpoints 
and non-susceptible or resistant isolates, when the minimal inhibitory concentration values 
were higher than the EUCAST breakpoints (Orasch et al., 2014). Cross-resistance is defined 
by non-susceptibility for at least two drugs in the same classification group (azoles or 
echinocandins) and multi-resistance species presented values higher than the clinical 
breakpoints for, at least, two kinds of antifungals at the same time. 
Table 9. Description of antimycotic dilutions used in antifungal susceptibility test 
antimycotic serial inhibitory concentrations (µg/µl) 
AMB polyene 4 3 2 1.5 1 0.750 0.500 0.375 0.250 0.188 0.125 
5FC nucleoside 32 16 8 4 2 1 0.500 0.250 0.125 0.063 0.031 
FLU triazole 256 128 64 32 16 8 4 2 1 0.500 0.250 
POS triazole 4 2 1 0.5 0.250 0.125 0.063 0.031 0.016 0.008 0.004 
VOR triazole 32 16 8 4 2 1 0.500 0.250 0.125 0.063 0.031 
CAS echinocandin 4 2 1 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 
MICA echinocandin 4 2 1 0.500 0.250 0.125 0.063 0.031 0.016 0.008 0.004 




2.2.8 Agar invasion capacity 
 
Agar invasion capacity of C. parapsilosis colony morphotypes was tested based on the 
protocols described by (Laffey and Butler, 2005). Cells taken from colonies with distinct 
morphotypes were plated on commercial SAB´s GC agar plates (control) and YPD agar 
plates supplemented with 5 mg/ml of Phloxine B (2.2.2). Plates were incubated for 10 days 
at 30°C, recording the morphotype once per day, starting from day 4, recording the state 
photographically for selected plates. Plates were finally scored before and after wash cells 
out the agar plate under running water on day 10. Morphotypically mixed plates were also 
checked determining different gradients of invasion on agar depending on the morphotype 
observed. Ranked classification of agar invasion used was defined as: low invasion (1), low-
medium (2), medium (3), medium-high (4), high (5) and very high (6, cells could not be 
removed after the plate were rinsed). 
 
2.2.9 Optical and phase-contrast microscopy 
 
To visualize variations in cell morphology between different clinical morphotypes, 
independent colony-phenotypes were routinely prepared as detailed in 2.2.2. Cells were 
adjusted to an OD = 2 (A600) and washed two times with PBS. For aggregation analyses, cells 
from defined colony-types were grown ON in 3 ml YPD and YPD medium plus 2.5 mg/ml 
Phloxine B in an orbital shaker. Cell density was adjusted to an OD600 = 2 and washed twice 
with PBS. Aggregation was observed at 10X magnification (Axiovert 200M, Carl Zeiss AG, 
Oberkochen, Germany). For an accurate determination of cell morphologies, ON cultures 
were adjusted to the exponential phase in fresh YPD and stained with 200 µl of 0.1% 
Blankophor P solution for 20 min. at RT. Cells were washed with PBS and fixed with 200 µl 
100% methanol for 5 min. After washing the cells twice with PBS, cells were embedded in 
Mowiol® 4-88 and observed at 100X magnification with immersion oil. Cell-morphology 
variability between morphotypes was analyzed by the imaging software Axiovision 2.05 
(Carl Zeiss, Oberkochen, Germany). 
 




2.2.10 Sedimentation assay of clinical morphotypes 
 
To analyze the sedimentation speed of C. parapsilosis strains with different morphotypes, 
the protocol previously published for C. glabrata (Gómez-Molero et al., 2015) was used. 
Strains selected were grown as described in section 2.2.2. Colonies were inoculated into 3 
ml YPD medium and grown ON at 37 °C. The cultures were pelleted and washed with PBS 
and the optical density was measured (A600), the experiment was performed in duplicate 
and the samples were adjusted to the lowest OD per replicate. The initial optical density 
was measured and calculated as T=0, and the cell suspensions were regularly measured 
(Smart Spec 3000; Bio-Rad) (A600) with an interval of 15 minutes until the final time point 
T=120 was achieved. The capacity (%) of sedimentation of each colony morphotype was 
calculated using (OD600t=1/OD600t=0)*100. The sedimentation percentage of each isolate 
at each time point is the average of two biological replicates and two technical repetitions. 
 
2.2.11 Electrophoretic karyotyping of colony morphotypes 
 
Intact chromosomes were separated by pulsed-field gel electrophoresis (PFGE) as 
described before by (Bader et al., 2012; Carreté et al., 2018). C. parapsilosis and 
C. glabrata cells were prepared as detailed in 2.2.2 Equal amount of cell suspension and 
2% agarose (1:1) both preheated to 60°C were mixed and cast in a 1 x 0.5 x 0.1 casing cell. 
The blocks were left to solidify at 4°C for approximately 30 minutes and then transferred 
into 5 ml of a zymolyase solution (10 mM Tris-HCl (pH = 7.2), 50 mM EDTA and 0.1 mg/ml 
zymolyase 20T). The samples were incubated ON at room temperature (RT) with gentle 
shaking. Plugs were washed four times with 5 ml washing buffer (20 mM Tris-HCl (pH = 
8.0) and 50 mM EDTA) and transferred to fresh tubes. Five ml of proteinase K reaction 
solution (100 mM EDTA (pH = 8.0), 0.2% Na deoxycholate 97%, 1% N-lauroylsarcosine 
sodium salt and 1 mg/ml proteinase K were incubated with gentle shaking for 24 hours. 
The blocks were washed four times with washing buffer solution (20 mM Tris-HCl, pH = 
8.0 and 50 mM EDTA) and stored at 4°C. Agarose blocks containing C. parapsilosis and 
C. glabrata DNA were cut in pieces of approximately 0.25 cm (“plugs”) and cast in a 1% 
agarose gel. The gels were placed in a PFGE running chamber (CHEF-DR II Electrophoresis, 




Bio-Rad laboratories, München, Germany) containing 1X TAE buffer (40 mM Tris (pH = 
7.6), 20 mM acetic acid and 1 mM EDTA). Running conditions for C. glabrata were 
adapted to using 1.2% agarose at 17°C and pulse times from 40-100 sec. for short 
chromosomes and 60-140 sec. for large chromosomes. In case of C. parapsilosis, running 
time was increased in 4 h. (initial pulse time 70 sec., final pulse time 140 sec., 26h run 
time in 1X TAE at 200V and 17°C) for better resolution. The gels were stained ON with 3 µl 
10000X GelRed ® in 30 ml of dH2O. Chromosome distributions were analyzed by Gel Doc 
XR imaging software (Bio-Rad Laboratories GmbH, München, Germany). 
 
2.2.12 Genomic DNA isolation 
 
To analyze the variability of adhesin-encoding genes between C. parapsilosis clinical 
isolates, stable morphotypes were cultured overnight in YPD medium at 30ºC. (2.2.2). Cells 
were harvested by centrifugation at 7168 g for 5 min in screw cap tubes. After washing the 
cells with 200 µl Tris-HCl, 200 µl of genomic DNA lysis buffer 100 mM Tris-HCl (pH = 8), 50 
mM EDTA, 1% (w/v) SDS and 0.5 mm glass beads were added (two times the amount of 
pellet used). Two hundred µl of 25:24:1 phenol/chloroform/isoamyl alcohol were 
incorporated to the samples, and the cells were lysed by 2X fastprepping (Thermo Savant 
FastPrep® FP 120 cell homogenizer, Qbiogene, Cedex, France) at 4.5 m/s for 30 sec. After 
fastprepping, phases were separated by centrifugation for 5 min at 16128 g, and 
supernatant was collected. One ml of 100% cold ethanol was gently added in 200 µl 
supernatant and stored for 30 min. at -20 °C for DNA precipitation. The solution was 
centrifuged at 4ºC for 5 min. at 16128 g and the supernatant discarded. Excess of EtOH was 
dried out and DNA was resuspended in 25 -30 µl TE-buffer containing RNase A. DNA quality 
was checked by running a 1% agarose gel, and DNA concentration was determined (Nano 
Drop 2000TM, Thermo Fisher Scientific, Darmstadt, Germany). 
 
 




2.2.13 Polymerase chain reaction analyses of adhesin-
encoding genes in clinical morphotypes 
 
To analyze the gene variability of adhesin repeat regions within clinical morphotypes (bsc-
1700, nsc-170, tsc-1702, ncc-1701, tcc-1702), PCR analyses of selected C. parapsilosis 
adhesin-encoding genes were tested including CDC 317, ATCC 22019, CBS 1954, CBS 6318 
and GA-1 as reference strains. PCR reactions contained 80-100 ng of genomic DNA plus 0.2 
µM of CPAR2_404790-F1, CPAR2_404790-R1; CPAR2-404800-ALS7-F, CPAR2-404800-ALS7-
R and CPAR2_403520-HWP1-F, CPAR2_403520-HWP1-R, (Table 5), 200 µM PCR grade 
nucleotides (dNTPs), 1X PCR reaction buffer + Mg (5 µl/50 µl PCR) and 2 units/50 µl PCR of 
Taq DNA polymerase in a final volume of 50 µl. The reaction was run in a T100™ 
Thermocycler (Bio-Rad laboratories, München, Germany). PCR reaction conditions consist 
on a denaturation step for 1 min at 95°C, followed by 30 cycles of 30 sec. at 95°C, 4 min. at 
a corresponding annealing temperature of 68.2°C and an elongation step of 5 min. at 72°C 
with a final 5 min. extension step at 72°C. 
To analyze azole-resistant genes in selected C. parapsilosis clinical isolates (PEU651, 
PEU768, PEU941, PEU950), PCR reactions were performed as the reactions specified before 
and amplified with CPAR2_303740-ERG11-F1, CPAR2_303740-ERG11-R1, CPAR2_303740-ERG11-
F2; CPAR2_303740-ERG11-R2; CPAR2-807270-MRR1-F1, CPAR2-807270-MRR1-R1; CPAR2_807270-
MRR1-F2, CPAR2_807270-MRR1-R2 and CPAR2_807270-MRR1-F3, CPAR2_807270-MRR1-R3, 
(Figure 5). General PCR reaction conditions for adhesin-encoding genes amplification 
started with a denaturation step for 1 min at 95ºC, followed by 30 cycles of 30 sec. at 95°, 1 
min. at a corresponding annealing temperature of 60°C and 65°C (depending on the length 
of the fragment), an elongation step of 3 min. at 72°C with a 5 min. final elongation at 72°C 
after which, the samples were cool down to 4°C. 
DNA fragments were analyzed using a 1% agarose gel at 130 volts for 45 minutes. All gels 
were prepared in a final volume of 100 µl and 140 µl of TAE 1X and developed using Bio-
Rad Chemidoc software (Bio-Rad Laboratories GmbH, München, Germany). 
 
 




2.2.14 DNA Sanger sequencing 
 
PCR products were purified using Nucleospin® Gel and Clean-up DNA purification Kit 
(Macherey-Nagel, Düren, Germany). PCR products of C. parapsilosis adhesin-encoding and 
azole´s-resistant genes were sequenced applying Sanger technology by Microsynth Seqlab 
(Göttingen, Germany), the same set of oligonucleotides employed in Polymerase Chain 
Reaction were used for standard sanger sequence analyses and detailed in Table 5. 
For a proper Sanger sequence, 18 ng per 100 bp of purified PCR product and 30 pmol of 
specific F or R CPAR2-oligonucleotides (Table 5) in a final volume of 12 µl were processed 
by Microsynth Seqlab, Göttingen, Germany. 
 
2.2.15 Candida cell wall isolation 
 
Prior to performing mass spectrometry analyses to identify specific cell wall proteins, 
C. parapsilosis and C. glabrata cell walls were isolated in collaboration with Dr. Piet de 
Groot (Department of Medical Mycology, Centre for Biomedical Research (CRIB), Albacete, 
Spain). Cell walls were prepared following the protocol previously described (Gómez-
Molero et al., 2015; de Groot et al., 2004, 2008). Clinical isolates (Appendix) were cultured 
overnight in YPD medium at 37ºC (2.2.2), after which the cells were harvested. The cells 
were washed and resuspended in 10 mM Tris-HCl at pH 7.5 in 2 ml). Glass beads, Tris 
buffer and protease inhibitor were added to the screw cap tubes. Six rounds of disruption 
for 30 seconds at 6.5 m/s in a Fastprep machine (Fast-Prep®-24, MP Biomedicals GmbH, 
Thüringer, Germany) were enough for cell full breakage, and this was verified under the 
microscope. After cell breakage, cell wall material was once washed with 1 M NaCl, and 
boiled twice for 5 min with SDS extraction buffer (50 mM Tris HCl, 2% SDS, 100 mM Na-
EDTA, 150 mM NaCl, and 0.8% (114 mM) β-mercaptoethanol, pH 7.8). After the SDS/β-Me 
extraction step, the cells were washed extensively with mQ water. Finally, the cell wall 
material was frozen in liquid nitrogen, lyophilized and stored at -20ºC. 




2.2.16 Candida spp. genome sequencing analyses 
 
C. parapsilosis and C. glabrata genome sequences were determined in collaboration with 
the group of Dr. Toni Gabaldón (Centre for Genomic Regulation (CRG) Barcelona, Spain). 
Strains were sequenced following the protocol already described by (Carreté et al., 2018; 
Pryszcz et al., 2013; Carreté et al., 2019) using either Illumina Genome Analyzer IIx (GA) or 
HiSeq 2000 (HS) sequencing platforms. All sequence data were deposited after publication 
in Sequence Read Archive (SRA, NCBI) (Carreté et al., 2018). 
2.2.17 In vivo infection analyses using the Galleria mellonella 
animal model 
 
For analysis of the virulence potential of different C. parapsilosis and C. glabrata clinical 
isolates, the animal model Galleria mellonella were used (Ames et al., 2017; Gácser et al., 
2007; Németh et al., 2013). These analyses were performed in collaboration with Dr. Attila 
Gácser, Department of Microbiology, University of Szeged, Hungary. G. mellonella 
caterpillars (R.J. Mous Live Bait, Balk, The Netherlands) were selected with the same body 
size and previously incubated at 30°C ON. C. parapsilosis and C. glabrata clinical isolates 
used in this study were listed in the Appendix 1 plus the CDC 317, ATCC 22019 (both 
C. parapsilosis) and CBS-138 (C. glabrata), respectively. Strains were grown as described in 
section 2.2.2. G. mellonella caterpillars were inoculated with 10 μL of the Candida spp. 
suspensions diluted in PBS 1X containing 6.10^6 yeast cells injected in the last left proleg of 
the caterpillar using a 26 gauge needle with Hamilton® syringe. The infected caterpillars 
were placed in an incubator at 37 ºC, and survival scored for a period of seven days. Time-
dependent survival was calculated using Graphpad PRISM 7 software. Data shown is always 
the average of two independent biological replicates. Ten non-manipulated caterpillars 
were used as untreated control and another 10 caterpillars were injected with 10 μL of PBS 
1X as negative control. 
 
 




2.2.18 C. albicans and C. glabrata identification from patient 
blood cultures 
 
Candida spp. infected blood cultures were selected from patients with a previous 
diagnostic of C. glabrata infection (Appendix). To easily determine the presence of single 
specie or mixed cultures (C. albicans and C. glabrata), The AdvanDX (Woburn, MA, EE.UU.) 
PNA FISH Kit was used. Candida spp.-identification in blood cultures was performed as 
described before by (Rigby et al., 2002) according to the manufacturer guidelines. The 
method consists on fluorescence in-situ hybridization (FISH) labels with peptide nucleic 
acid (PNA) probes. The technique is based on the hybridization selected peptide nucleic 
acid to the specific C. albicans or C. glabrata specific ribosomal RNA (rRNA), which directly 
discriminate between C. albicans and C. glabrata from positive-blood-culture bottles The 
C. glabrata blood bottles were stored at -20°C until used. Ten µl of the culture were 
transferred to a microscope slide that previously contained one drop of the fixation 
solution (phosphate-buffered saline with detergent). One drop of PNA probes (1.5 ml of 
PNA probes contains 30% of formamide) was added to the microscope slide that already 
contains the smear. The coverslip was placed on the drop avoiding bubbles in the probe 
and the slides were incubated for 30 minutes at 55°C in a water bath. The solution was 
mixed and let it dry. The smears were fixed by flame-fixation. The test (the C. albicans PNA 
FISH method) is based on a fluorescein-labeled PNA probe that targets C. albicans 26S 
rRNA. The PNA probe is added to smears made directly from the contents of the blood 
culture bottle and hybridized for 90 min at 55°C. Unhybridized PNA probe is removed by 
washing of the mixture (30 min), and the smears are examined by fluorescence microscopy  
 
2.2.19 C. albicans and C. glabrata interaction under phase-
contrast microscopy 
 
To analyze C. albicans/C. glabrata in vitro cell interaction,, we adapted the protocols 
already described by Tati et al. (2016). Selected C. glabrata clinical isolates plus two 
reference strains (ATCC90876, CBS-138, PEU52, PEU45, PEU382, PEU427) were grown as 
detailed in section 2.2.2. C. albicans reference strain (SC5314) and the genetically modified 




green fluorescence C. albicans WT (SC5314-GFP) (Table 8) were culture in 3 ml of liquid 
YPD at 30°C, ON. C. albicans cells were adjusted to an OD 600nm = 0.5 and let them grow for 
5 h. at 37°C to induce hyphae. Both, C. glabrata and C. albicans were adjusted to an OD 
600nm = 1, and co-incubated at 1:1 ratio in fresh YPD for 2 h. Suspensions were filtered and 
washed with PBS 1X to remove unbound C. glabrata. Cells were stained with 200 µl of 0.1% 
Blankophor P solution for 20 min. at RT, washed with PBS 1X, fixed with 200 µl 100% 
methanol (Carl Roth Chemie GmbH, Karlsruhe, Germany) for 10 min. and finally embedded 
in Mowiol® 4-88 (Polyscience Europe GmbH, Hirschberg an der Bergstraße, Germany). 
Samples were observed at 100X magnification with immersion oil and fluorescent Cy2 filter 
(534 nm) and DAPI filter (409 nm) to differentiate C. albicans cells and hyphae using the 
imaging software Axiovision 2.05 (Carl Zeiss, Oberkochen, Germany). To discriminate GFP 
fluorescence intensities for individual yeast cells and hyphal form (C. albicans) from non-








3.1 Genomic plasticity enhances phenotypic diversity in 
Candida glabrata clinical isolates from different clades 
 
3.1.1 Changes in the genome of hyper-biofilm-forming 
C. glabrata isolates 
 
To assess genomic plasticity and phenotypic variability between clinical isolates with 
respect to biofilm formation, thirty-three genome sequenced Candida glabrata clinical 
isolates from different body sites and global sources were analysed in collaboration with 
Dr. Toni Gabaldón (CRG, Barcelona, Spain). The study performed by the partner group 
(Carreté et al., 2018) included genome sequence analyses to stratify differences among 
clinical isolates with a focus on gene copy number and single nucleotide polymorphisms. In 
addition, we performed phenotypic and karyotypic analyses. 
The collection was composed of isolates from three different body sites. Two hyper 
biofilm-forming clinical isolates PEU382 (urinary tract) and PEU427 (respiratory tract) 
(Gómez-Molero et al., 2015), and the reference strain CBS-138 were used as controls. 
Gastrointestinal tract isolates conformed 18% of the collection, 70% were defined as 
derived from invasive candidiasis, and 12%, were isolated from oral cavity. SNP-based 
analyses (Carreté et al., 2018) classified the thirty-three isolates into seven genetic clades, 
again falling into two larger group sets (Figure 16). Group 1, included clusters I, II, III, and 
group 2 was constituted by the clusters IV, V, VI, and VII. 
First, we examined if genomic and phenotypic variations corresponded with karyotypic 
changes. Indeed, electrophoretic karyotyping showed chromosome variability between 
isolates. Only short chromosomes (A-J) of isolates from the same clade follow a similar 
distribution pattern (Figure 15). This could be observed in certain isolates of clades VI and 
VII (P35-2, P35-3 = EG01004, F15021, F03013, BG2); I and II (CST34= CST35) and four 





the long chromosomes (ChrL, M, and K in CBS138) were observed in the HBF isolates. A 
correlate to ChrL was not detectable in isolate F15021, possibly due to a rearrangement. 
Together with coverage analyses (Toni Gabaldón, CRG, Barcelona), aneuploidies in 
chromosome E (clade differences) and G, as well as a duplication of chromosome J in F2229 
were observed (Carreté et al., 2018). 
 
Figure 15. Electrophoretic karyotyping of C. glabrata clinical isolates divided in 7 different clades. PFGE of 
isolates including the control strains used. Top panels show large chromosomes (2240 kb – 1302 Kb). Bottom 
panels show small chromosomes (1302 Kb -485 Kb). Color code: red, hyper biofilm-forming isolates; green, 
azole resistant isolates; blue, EB101M/BO101S, B1012S/B1012M and P35_2/P35_3 represent pairs of isolates 

























































































































































To determine if karyotypic and phenotypic variations between isolates correlated with 
changes in MIC, susceptibility towards eight different antifungal compounds was 
measured. All isolates were susceptible to AMB and thirty-one isolates (31/33), including 
CBS-138, only showed a low to intermediate range of growth inhibition by azoles (Table 
10). 
However, M7, M6, and M17 showed reduced susceptibility to one (M17) and four (M7, 
M6) compounds out of the eight tested: They were 8-16, 32, and up to 2-fold, respectively, 
times less susceptible to FLU than the control CBS-138. Differential distribution of MICs 
among the two groups (Figure 16 and Table 10) was observed for POS, but not for the 
other seven antifungal drugs (AMB, 5FC, ISA, FLU, VOR, CAS, and MICA). Genome analyses 
indicated no mutation for the resistant-related genes ERG6, FKS1 and FKS2, but an amino 
acid exchange (I390K in M6, I378T in M7, and N306S in M17) in the azole transcriptional 
regulator PDR1 was identified. No global correlation between susceptibility data and 
source of isolation were found in this collective. 
Interestingly, M7, M6, and M17 were also all isolated from blood but only classified as LBF 
(M7, M6) or IBF (M17) (Table 10). Isolates M7 and M6 were highly resistant to azoles (FLU, 
VOR, POSA, ISA), but had echinocandin MIC values similar to CBS-138. Isolate M17 was 
partially resistant to FLU (8 µg /µl), but no differences for CAS and MICA were observed. 
Despite low MIC values, HBF isolates F15021 and F03013 were on the borderline of clinical 
resistance to MICA (0.032-0.064 µg/µl). Both LBF and IBF isolates varied with respect to 
susceptibility towards VOR, ISA, and MICA and no azole-susceptibility differences between 
IBF isolates and HBF were found. (Table 10). 
Next, we determined biofilm formation capacity in this isolate set (Figure 16). Only 3 
isolates other than controls, showed high (F03013, 0.6205 ± 0.054) or intermediate-high 
ability to form biofilms on polystyrol (F15021, 0.33 ± 0.066 and CST35, 0.2841 ± 0.045). All 
these three were obtained from blood cultures. The biofilms formed by three HBF/IBF 
isolates were 3- to 6.7-fold larger than those formed by CBS-138. Still, this was between 
1.3- to 3-fold smaller than those of the two positive controls. However, 22 isolates (22/35) 
were still significantly different (Figure 16) from the reference strain, but not at levels that 





Table 10. Distribution of MIC values of the eight antifungal drugs in the total number of isolates and selected multi resistant clinical isolates. 
µg/ml 
AMB 5FC c FLU VORC POS c ISA c MICAd CAS c 
aMIC 90 S/I/R aMIC 50 MIC 50 S/I/R MIC 50 MIC 50 MIC 50 MIC 50 S/I/R MIC 50 
M17b-IBF* 0.004 S >64 4 – 8 I 0.125 0.500-1 0.032-0.064 0.032-0.064 I-R 0.064-0.125 
F1019-LBF** 0.004 S 0.032-0.064 2 – 4 I 0.125 0.500-1 0.032-0.064 0.032 S 0.032-0.125 
F1822-LBF 0.004-0.008 S 0.032-0.064 8 I 0.125-0.500 0.500-1 0.064-0.250 0.008-0.032 S 0.064-0.125 
M12-LBF 0.004 S 0.032-0.064 8 I 0.064-0.250 0.500-2 0.125 0.016-0.032 S 0.064-0.125 
CST78-LBF 0.004 S 0.032 4 – 8 I 0.125 0.500-1 0.064 0.008-0.032 S 0.064-0.125 
F2229-LBF 0.004 S 0.032-0.064 4 I 0.125 1 0.064-0.250 0.032-0.064 I-R 0.064-0.125 
I1718-LBF 0.004 S 0.032 1 I 0.125-0.250 0.500-1 0.032-0.064 0.004-0.032 S 0.064-0.125 
EB0911-IBF** 0.004 S 0.032-0.064 4 – 8 I 0.032-0.125 0.500-1 0.032-0.125 0.016-0.032 S 0.125 
CST35e-HBF*** 0.004 S 0.064 8 – 16 I 0.32-1 0.500-2 0.064-0.125 0.032 S 0.032-0.125 
CST34-LBF 0.004 S 0.032-0.064 4 – 16 I 0.250-0.500 1 0.064-0.250 0.032 S 0.064-0.125 
CST109-LBF 0.004-0.032 S 0.032-0.125 4 I 0.064-0.125 0.250-0.500 0.032 0.032-0.064 I-R 0.064-0.125 
CST80-LBF 0.004 S 0.032-0.064 1 – 8 I 0.125 0.500-1 0.032-0.064 0.008-0.032 S 0.064-0.125 
M7 b-LBF 0.004 S 0.032-0.064 32-64 R 2 >8 0.250-1 0.032 S 0.064-0.125 
EB101M-LBF 0.004-0.008 S 0.032-0.125 1 – 8 I 0.125-0.250 1 0.125 0.032-0.064 I-R 0.064-0.125 
BO101S-LBF 0.004-0.008 S 0.032-0.064 4 – 8 I 0.064-0.125 0.500-1 0.032-0.064 0.008-0.064 S 0.064-0.125 
B1012S-LBF 0.004 S 0.032-0.064 1 – 4 I 0.064-0.250 0.500-1 0.032 0.032-0.064 I-R 0.032-0.125 
B1012M-LBF 0.004 S 0.032-0.064 2 – 4 I 0.125 0.500-1 0.032 0.032-0.064 I-R 0.064-0.250 
EF1237-LBF 0.004 S 0.032-0.064 1 – 8 I 0.064-0.125 0.500-1 0.032-0.064 0.0032 S 0.064-0.125 
EI1815-LBF 0.004-0.008 S 0.064-0.125 2 – 4 I 0.032-0.064 0.250-0.500 0.032-0.250 0.032-0.064 I-R 0.064-0.125 
EF1620-LBF 0.004 S 0.032-0.064 4 – 8 I 0.064-0.250 0.500-1 0.032-0.064 0.032 S 0.064-0.125 





Continued from previous page 
µg/ml 
AMB 5FC c FLU VORc POS c ISA c MICAd CAS c 
aMIC 90 S/I/R MIC 50a MIC 50 S/I/R MIC 50 MIC 50 MIC 50 MIC 50 S/I/R MIC 50 
F15-LBF 0.004-0.008 S 0.032-0.064 4 – 8 I 0.125-0.250 1 0.064 0.008-0.032 S 0.064-0.125 
F11-IBF 0.004-0.008 S 0.032-0.064 1 – 4 I 0.064-0.125 0.500-1 0.032-0.064 0.032-0.064 I-R 0.064 
E1114-LBF 0.004 S 0.032-0.125 4 – 8 I 0.032-0.250 0.250-2 0.032-0.125 0.032 S 0.064-0.125 
M6 b-LBF 0.004 S 0.032-0.064 128 R 4 >8 2 – 4 0.032-0.064 I-R 0.032-0.125 
CST110-LBF 0.004 S 0.032-0.064 4 – 8 I 0.125 0.500-1 0.032-0.064 0.008-0.032 S 0.064-0.125 
EG01004-LBF 0.004 S 0.032-0.064 4 – 16 I 0.25 1-2 0.064-0.250 0.032 S 0.064-0.125 
F15021 e-HBF 0.004 S 0.032-0.064 4 – 8 I 0.125 0.500-1 0.032 0.032-0.064 I-R 0.064-0.250 
F03013 e-HBF 0.004 S 0.032 4 – 8 I 0.125 0.500-1 0.032 0.032-0.064 I-R 0.064-0.125 
BG2-LBF 0.004-0.008 S 0.032-0.064 16 I 0.125-0.250 1 0.064-0.250 0.032 S 0.064-0.125 
P35_2-LBF 0.004 S 0.032-0.064 4 – 16 I 0.25 1-2 0.064-0.250 0.032 S 0.064-0.125 
P35_3-LBF 0.004 S 0.064 4 – 16 I 0.5 1-2 0.125-0.250 0.032 S 0.064-0.125 
CBS138-LBF/IBF 0.004 S 0.032 4 I 0.064 0.5 0.032 0.016-0.032 S 0.064 
a broth microdilutions MIC 50 and MIC 90 of corresponding antifungal drugs compared with EUCAST values. b boldfaced: names and values of isolates with MIC values 
deviating from the wild type distribution breakpoint interpretations according to EUCAST breakpoints, Table v. 9.0, valid from February 2018. c no species-specific clinical 
breakpoints for 5FC, VOR, POS, ISA and CAS. d measured MIC range in most isolates (three technical repeats) encompasses both “susceptible” and “resistant” 
interpretations according EUCAST clinical breakpoint definition: S≤0.032, R>0.032 for MICA. e isolates in italics are the three HBF isolates to polystyrol. * Low biofilm-







Figure 16. Biofilm formation capacity to polystyrol of thirty-three clinical isolates. Displayed are average 
biofilm formation values representing three biological with four technical replicates each. Source of isolation: 
red, blood (invasive); yellow, oral cavity; dark green, urine; bright green, respiratory tract. Colored panels 
represent the seven C. glabrata clades, described in Carreté et al., 2018 The seven clades were subsequently 
divided in group 1: I, II, III and group 2: IV, V, VI, VII. CBS-138, PEU382 (urinary), and PEU427 (respiratory 
tract) were used as controls. Asterisks represent isolates significantly different compared to CBS-138. Biofilm 
formation capacity was classified as: low biofilm formers, 0 ≤ X ≥ 0.1392; intermediate, 0.1392 ≤ X ≥ 0.2785 
and high, X ≥ 0.2785. Red and blue lines, cut-off: 0.2785 and 0.1392. 
 
When these biofilm formation data were eventually correlated with cell wall-protein 
encoding gene copy numbers from the above genome analyses, all three hyper-adherent 
isolates F03013, F15021, and CST35 showed independent duplications of the PWP4 gene, 
and deletions of the gene encoding adhesin wall protein AWP13. This puts Pwp4 into focus 
when attempting to explain the capability of these isolates to create biofilms in the 
colonization process. 
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3.1.2 Genomic changes between time-resolved C. glabrata 
isolates 
 
Next, we analyzed how genomic properties varied between isolates obtained from the 
same patient with respect to biofilm formation. Three independent genome sequenced 
isolates from a patient with acute myeloblastic leukaemia and subsequent candidiasis 
obtained from bronchiolo-alveolar secrete (SAT01, EF54001Bal), peritoneal liquid (SAT02, 
EF54001Per), and blood culture (SAT03, EF54001Blo) were again provided by the group of 
Toni Gabaldón (CRG, Barcelona). The three isolates were from in the same clade and 
separated only by a low number of SNPs. Mutations were accumulative, remarking a 
significant degree of genetic variation in the host (Carreté et al., 2019). Using this 
information as a starting point, we analyzed phenotypic properties. 
Biofilm quantification classified all three isolates as LBF (CBS-138 = 0.060 ± 0.03), however 
significant quantitative differences between the source of isolation were seen (P < 0. 05 
and P ≤ 0. 0001): EF54001Blo displayed the lowest adherence capacity compared to the 
CBS-138 (P ≤ 0.01) and both other matched isolates (Figure 17A). Indeed, EF54001Blo 
carried a non-synonymous mutation in SIR4 that may correspond with differences in 
adherence capacity and subtelomeric silencing (Iraqui et al., 2005). No differences 
regarding azoles susceptibility were found (Table 12B). Three additional pairs of isolates 
already discussed in section I1 (BO101S/EB101M, B1012S/B1012M and the P35-2/P35-3), 







Figure 17. C. glabrata phenotypic analyses of three clonal clinical isolates. (A) Biofilm formation capacity to 
polystyrol. Light grey bars: reference strains. Red line: CBS-138 biofilm formation capacity (A490 ~0.060), 
EF54001Bal (SAT01), EF54001Per (SAT02) and EF54001Blo (SAT03). (B) Minimal Inhibitory Concentration 
































* P < 0.05
*** P < 0.001
*** P < 0.001
MIC (µg/ml) AMB 5FC FLU VOR POS CAS MICA
24 h. 0.125 0.0625 4 0.125-0.250 0.5 0.25 0.031
48 h. 0.125 0.0625 8 0.125-0.25 0.5 0.25 0.031
24  h. 0.125 0.0625 2-4 0.125 0.5 0.25 0.031
48 h. 0.125 0.0625 4 0.125 0.250-0.5 0.25 0.031
24  h. 0.125 0.0625 8 0.125-0.25 0.250-0.5 0.25 0.031
48 h. 0.125 0.0625 8 0.25 0.5 0.25-0.500 0.031
CBS-138 24  h. 0.125 0.032-0.064 2-4 0.125 0.125 0.032-0.064 0.016
PEU382 (c*) 24  h. 0.125 0.032 4-8 0.250-0.500 0.250 0.016-0.125 0.016-0.032












3.2 Phenotypic variability in C. glabrata clinical isolates 




Figure 18. Cell aggregation capacity of selected biofilm-forming C. glabrata clinical isolates under 
planktonic and biofilm conditions. Isolates were categorized depending on their biofilm formation capacity 
(LBF, IBF, HBF). 
 
Next, we sought to confirm the above findings in larger isolate cohorts. In a first approach 
we further characterized a set of strains which were previously selected for such purposes 
randomly, with a focus on the cell aggregation capacity (Figure 18) and biofilm formation 
capacity to polystyrol (Figure 19). Qualitative cell aggregation analyses indicated that 
isolates with LBF and IBF tended to flocculate less compared with HBF isolates, except for 
the clinical isolate PEU52 which presents an aggregation capacity comparable with the HBF 
PEU382 and PEU427. Then, the facility of the cells to form clumps apparently contribute to 
sediment faster and it was better detectable under biofilm conditions than the planktonic 
stage, (Figure 18), therefore, we proposed a possible correlation between biofilm 
formation capacity and cell aggregation observed in A. 
In order to use these strains as controls for further downstream experiments, these eight 
clinical isolates were qualitatively (Figure 19A) and quantitatively (Figure 19B) 
characterized towards biofilm formation capacity to polystyrol. These isolates were 





















PEU123) and HBF (PEU45, PEU382, PEU427). Based on these results, isolates PEU45, 
PEU382 and PEU427 quantitatively presented strong capacity to produce biofilms on 
polystyrol (Figure 19B) being approximately 7-fold more adherent than the CBS-138 (P ≤ 
0.0001). No statistical differences regarding polystyrol biofilm formation intra-categories 
were remarked (P ≥ 0.05). 
 
Figure 19. Biofilm formation analyses of eight selected clinical isolates + CBS-138. (A) Qualitative biofilm 
formation capacity of selected LBF (PEU30, PEU52), IBF (PEU123, PEU235, PEU259) and HBF (PEU45, PEU382, 
PEU427). Arrows indicate cell aggregates formed by the LBF PEU52 isolate removed after washing unbound 
cells out. (B) Quantitative biofilm formation analyses to polystyrol. Results shown are the average of two 
independent biological tests with four technical replicates. Red line, two-fold mean cut-off: 0.222. Red 
square, selected two HBF isolates for subsequent analyses of cell surface-related properties. 
 
CBS-138, PEU382, and PEU427 were then used to assess variations in cell sedimentation, 
antifungal susceptibility against seven major antifungal drugs and virulence properties 
between hyper-adherent isolates in vivo, in G. mellonella caterpillars. Cell surfaces 
properties analyses of these clinical isolates were detailed in Figure 19 and Figure 20.  
biofilm formation 24 h. 37°C
biofilm formation after washing with PBS1X


























































Susceptibility testing against seven major antifungals drugs indicated differences between 
the two HBF and the CBS-138 for FLU, VOR, and POS (P < 0.05), but no MIC differences for 
echinocandins, ISA and 5FC were observed (Figure 19C).  
Sedimentation capacity partially correlated with cell aggregation in the PEU382 (Figure 
20A) showing that HBF isolate PEU382 (64.2%) was different compared to PEU427 (43.5%) 
and CBS-138 (36%) (P ≤ 0.01). The PEU382 settled approximately 1.80 and 1.47-fold faster 
than CBS-138 or PEU427, respectively (Figure 19B). 
With respect to virulence capacity of these selected isolates, statistically significant (P < 
0.0001) differences between the three isolates tested were indeed observed (Figure 6D). 
Nevertheless, Only the HBF PEU382 showed significant variations in virulence capacity 
compared to the reference strain CBS-138 (80%). The isolate PEU382 (100%) were more 
virulent than the PEU427 (90%) showing no G. mellonella survival at day 3 post-infection. 
 
Figure 20. Cell surface analyses of reference isolates. (A) Qualitative cell aggregation of selected PEU382 and 
PEU427 under confocal microscopy. Cell walls are detectable with CFW staining remarking chitin distribution 
along the cell wall and budding yeast cells (Gómez-Molero et al., 2015). (B) Cell sedimentation after 120 
minutes (C) MIC values of PEU382 and PEU427 against seven major antifungal drugs. Table sums up the 
average of two independent experiments. (D) Kaplan-Meier survival curve of G. mellonella infected with the 
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Mantel-Cox and Breslow-Wilcoxon test **** P < 0.0001




strain acronym CBS-138 PEU382 PEU427
FLU (µg/µl) 2-4 4-8 8-16
POS (µg/µl) 0.125 0.250 0.250-0.500
VOR (µg/µl) 0.125 0.250-0.500 0.500-1
ISA (µg/µl) 0.032 0.032 0.032
CAS (µg/µl) 0.032-0.064 0.016-0.125 0.032
MICA (µg/µl) 0.016 0.016-0.032 0.016-0.125
5FC (µg/µl) 0.032-0.064 0.032 0.032-0.064
5 µm





3.2.1 Biofilm formation capacity to polystyrol of a large 
C. glabrata clinical strain collection 
 
We next systematically collected C. glabrata isolates from routine diagnostic procedures, a 
process that was previously initiated and established in our laboratory (Ichsan et al., 2014). 
Isolates were grouped into nine different classes depending on the source of isolation 
(Figure 21A, B). 
 
Figure 21. C. glabrata clinical isolates stratified according to body sites of isolation and quantitative biofilm 
formation capacity to polystyrol. (A) Percentage of C. glabrata isolates per source of isolation. Isolates were 
divided into nine different specimen groups. Dark grey bars represent infrequent source of isolation and black 
and white bars correspond with frequently-collected isolates. Red line indicates the minimal number of 
clinical isolates collected per source of site. (B) Biofilm formation distribution per source of site among the 
collection of 453 clinical isolates. (C) Biofilm formation capacity to polystyrol of the entire collection (n=453). 
Isolates above the cut-off represent IBF and HBF isolates, and isolates below the cut-off correspond with LBF 
isolates. (D) Biofilm formation capacity of 115 clinical isolates selected for downstream experiments with 
respect to their ability (IBF, HBF) or incapacity (LBF) to form biofilms on polystyrol surfaces. Red line in (B-D): 






















































































































In total, 453 isolates were included in the collection with the goal to accumulate at least 40 
isolates per group. Once 40 isolates were achieved, systematic inclusion of further isolates 
into that particular group was reduced, but not stopped. With the exception of category 9 
(blood culture), this was achieved after a collection time frame of ~4 years (Figure 21A, B). 
Isolates from primary sterile sites (invasive), gastrointestinal tract, respiratory tract, urine 
catheters, and urinary tract were collected more frequently compared with samples 
isolated from general devices, skin, or epithelia and blood cultures. 
3.2.2 Virulence of C. glabrata isolates in the 
Galleria mellonella model 
 
We next investigated the existence of virulence differences between isolates as a function 
of their adherence capacity. Therefore, 47 LBF and 30 HBF isolates from 8 different site 
groups were selected (Figure 21A, except from blood isolates, which were not available at 
the time) and the virulence potential assessed using G. mellonella caterpillars as a systemic 
animal infection model (Ames et al., 2017; Borghi et al., 2014; Junqueira et al., 2011). 
Within both the LBF and HBF groups, differences between individual isolates were 
observed. Out of the 47 LBF-group clinical isolates tested, only twelve (24%) had a killing 
rate less than 100% at day seven. Isolates PEU531 (50%), PEU294 (60%) and PEU523 (60%) 
had the lowest killing rate on day 7. Eight out of these twelve (Figure 22A) were isolated 
from urine catheters (PEU531, PEU523, PEU364, PEU494, PEU541, PEU29, PEU519, 
PEU527), the other four were isolated from oral cavity (PEU52), respiratory tract (PEU322), 






Figure 22. Kaplan-Meier G. mellonella survival curves infected with 77 C. glabrata clinical isolates + CBS-138 
classified attending to their biofilm formation capacity. (A) LBF C. glabrata clinical isolates to polystyrol. (B) 
HBF clinical isolates to polystyrol. Colored lines represent isolates with survival rate equal or higher than 10% 
on day 7. Reference strain CBS-138/ATCC 2001 is highlighted in purple. Colored boldfaced u.c and o.c 
represent urine catheter and oral cavity respectively. 
 
In case of HBF isolates, seven of thirty isolates analyzed presented a killing rate lower than 
100% after a seven-days experiment. Out of these, isolates PEU386 (50%), PEU1360 (60%), 
PEU1270 (70%), and PEU542 (70%) had the lowest killing rate at day 7. Three isolates out of 
seven were isolated from oral cavity (PEU1360, PEU1270 and PEU542) and the other four 
were, respectively, isolated from urine catheter (PEU386), urinary tract (PEU400) and 
respiratory tract (PEU427 and PEU1330) (Figure 22B). Comparing both groups depending 
on their capacity to adhere to polystyrol, both categories approximately presented a 
similar percentage of isolates with a killing rate lower than 100%, (23%-25%) (Figure 22). 














































Mantel-Cox and Breslow-Wilcoxon test **** P < 0.0001














Mantel-Cox and Breslow-Wilcoxon test **** P < 0.0001

































































Table 11. Virulence capacity of C. glabrata isolates stratified by adherence capacity and site of isolation 
 
To conclude, intra-groups differences towards virulence capacity in C. glabrata clinical 
isolates were described. High variations in virulence capacity were found in isolates with 
LBF and HBF capacity to polystyrol. Samples isolated from urine catheters and oral cavity 
presented the highest level of survival rate in both groups independently to their capacity 
to form biofilms (Figure 22), In contrast, samples isolated from invasive candidiasis, medical 
devices, urinary tract and GI were, on average, more virulent. A partial correlation between 
non-adherence capacity and high survival rate was only remarkably observed in strains 
isolated from urine catheters (Table 11).  
Although statistical differences within the two adherence categories were observed, no 
differences were detected inter-groups (P > 0.05). No global correlation between hyper-
adherent clinical isolates and virulence capacity was significantly remarkable but a partial 
correlation was detected in strains isolated from skin, but these parameter has to be 
deeply analyzed increasing the study population. We proposed that virulence capacity is 
strain specific and partially correlated with the site of isolation. However, no apparent 
correlation between the ability to form biofilms on polystyrol and virulence capacity were 
seen amongst the 77 clinical isolates tested (P > 0.05) (Figure 23). 
 total isolates % survival LBF HBF 
origin % from n = 77 n % per group % n % n 
urine 
catheter 16% 12 75 75 9 25 3 
device 10% 8 0 63 5 38 3 
GI 16% 12 9 67 8 33 4 
invasive 18% 14 7 79 11 21 3 
oral cavity 9% 7 57 57 4 43 3 
respiratory 12% 9 33 44 4 56 5 
skin 4% 3 0 33 1 67 2 






Figure 23. C. glabrata correlation analyses between virulence capacity and adherence to polystyrol. Isolates 
were tested in the in vivo G. mellonella infection model. 
 
3.2.3 Variations in C. glabrata biofilm formation capacity to 
silicone elastomers 
 
On the reference material polystyrol, a total of 83% isolates had quantitative biofilm 
formation values lower than what was considered as elevated (2-fold median of the whole 
cohort 0.222), leaving only 17% of the isolates to produce strong biofilms on this material 
(Figure 21C), and this independently of the body site of isolation. Isolates from the three 
categories previously detailed were subsequently analyzed using silicone elastomers as a 
model substrate to reflect biofilm development on urine catheters, prostheses, parenteral 
nutrition or such (Trofa et al., 2008). From the collection of 453 isolates, a total of 115 were 
selected based on their high ability or disability to form biofilms on polystyrol (Figure 21D). 
Out of these, 22% formed biofilms only on silicone elastomers, 44% only on polystyrol, 19% 
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Again, no correlation between body site of isolation and biofilm formation on either 
material tested was observed. The widest distribution of biofilm sizes was seen among 
isolates from urinary tract and urine catheters as compared to the other seven categories 
(Figure 21B). From this we concluded, that the formation of biofilms was independent for 
each material and only strain-dependent factors determine either phenotype. 
 
Figure 24. Correlation between biofilm formation capacity to silicone and polystyrol from 115 selected 
C. glabrata clinical isolates. (I) Isolates adherent only to silicone. (II) Isolates adherent to both materials. (III) 
Isolates that do not adhere to any material and (IV) Isolates that only formed biofilms on polystyrol. 
 
In order to further investigate biofilm formation capacity to medical devices on the genome 
level, thirty-two clinical isolates were, once more, selected to reflect these subgroups, and 
sent for subsequent genome sequencing (ongoing collaboration with Dr. Toni Gabaldón). 
The isolates were selected according to the degree of adherence to silicone and polystyrol 
as well the site of isolation. Statistical differences between biofilm formation capacity to 
both materials were confirmed (P ≤ 0.01). Within the group, nineteen of them, presented 
LBF capacity to polystyrol (abs. ≤ 0.222) and fourteen were HBF isolates to polystyrol (abs. 
≥ 0.222). Twenty-eight isolates displayed intermediate- to high adhesion capacity to 






























Figure 25. Biofilm formation capacity to abiotic surfaces of selected thirty-two C. glabrata clinical isolates + 
CBS-138. Red boldfaced line represents the cut-off mean for polystyrol (0.222) and blue line represents cut-
off mean for silicone (0.054 nm). Isolates above lines a (polystyrol) and b (silicone) were considered strong 
biofilm-forming isolates for each material. Red square, selected C. glabrata clinical isolates for MS/MS 
analyses. 
 
3.2.4 Different adhesins are present in hyper biofilm-forming 
clinical isolates  
 
It is generally accepted that at the basis of linkages needed to form biofilms cell wall 
proteins are found. We therefore characterized the cell wall proteome in selected isolates 
from our study, namely of the eight phenotypically best characterized HBF isolates PEU382 
and PEU427, PEU30, PEU45, PEU52, PEU123, PEU235, and PEU259. MS/MS analyses of 
isolated cell walls (in collaboration with Dr. Piet de Groot, Regional Center for Biomedical 
Research, CRIB, Albacete, Spain) identified a total of 35 authentic GPI-CWPs. Ninety-nine 
percent of these peptides belonged to covalently linked cell wall proteins, indicating 


















silicone polystyrol* P <  0.05
*** P <  0.001
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a*** P < 0.001






proteins (Table 13) were consistently identified in the nine isolates tested. This core 
proteome was mainly composed of proteins from the Gas/Phr (Gas 1, Gas2, Gas4 and 
Gas5) family with β-1, 3-glucanosytansferase activity. Putative structural glucan-
crosslinking proteins were Pir proteins (Pir1, Pir2, Pir3 and Pir4), the GPI-linked cell wall 
proteins Cwp 1.1, Cwp 1.2, and the mannoprotein Tir1. Pir proteins are lacking a GPI-
anchor and were observed in HBF PEU382, PEU427 and PEU45; however, Pir1 was detected 
in six isolates, excluding the hyper-adherent PEU382 and the CBS-138 (Gómez-Molero et 
al., 2015). Proteins with phospholipase activity were represented by Plb1 (not present in 
CBS-138 and PEU-52) and Plb2. Four other proteins with unknown function were also 
detected, namely proteins belonging to Ecm33 family (Ecm33 and Pst1), the GPI-CWP Ssr1 
and the Srp/Tir family protein Tir2. 
In contrast, a total of twenty GPI-CWPs proteins were not unanimously identified among 
the isolates. This variable proteome differed between the nine isolates, ranging between 
three (PEU30) and eleven (PEU45) adhesins in the cell wall (Table 12). The adhesin proteins 
expressed under biofilm conditions to abiotic materials (polystyrol), were mainly 
represented by the Epa family (Epa3, Epa6, Epa7 and Epa22) and the Awp family. Inside this 
family, twelve adhesins including Awp1, Awp2, Awp3, Awp4, Awp6 (de Groot et al., 2008; 
Kraneveld et al., 2011; Weig et al., 2004), and six newly identified proteins Awp8, Awp9, 
Awp10, Awp11, Awp12 and Awp13 (Gómez-Molero et al., 2015) were detected. From the 
ten CWPs identified here for the first time by proteomic analyses, the four proteins 
CAGL0L00227g (PEU52, PEU45), CAGL0F09273g (PEU123), CAGL0A04873g (PEU45), and 
CAGL0H00132g (PEU45) are still not classified into a protein family group. 
On a global scale, increased numbers of different adhesins wall proteins were found in IBF 
and HBF isolates as compared to the reference strains CBS-138 (six) and ATCC90876 (one) 
and the LBF PEU30 (five proteins) (Table 13), with the one exception of LBF PEU52 (five 
proteins). In the LBF PEU30, PEU52, and the controls mainly adhesins belonging to the Epa 
family (Epa3, Epa6, Epa7 and Epa22), Awp1, and the newly described CAGL0L00227g were 
observed. Among these, CAGL0L00227g, a putative GPI-protein with glycine and serine rich 
tandem repeats of unknown function was found only in the two most flocculent isolates 
PEU52 and PEU45 indicating a possible involvement in this process. In contrast, Awp family 





and high biofilm formation capacity to polystyrol contained between six and eleven 
adhesins in the cell wall, with PEU235 and PEU382 (eight), PEU123 (nine), PEU427 (eleven), 
and PEU45 (eleven proteins) being the isolates with highest number of GPI-CWPs. 
Looking only at results from analyses under biofilm-formation conditions, isolates with low 
degree of adherence to polystyrol (isolates highly flocculent or adherent to silicone), and 
thus remaining mainly in their planktonic state, presented both lower number of adhesins 
and core proteins (e.g. Plb1, Tir1, Gas5, Tir2). In contrast, hyper-adherent C. glabrata 
isolates contained a high number of different adhesins as well as core proteins in the cell 
wall. The newly described adhesins (Awp8, Awp9, Awp10, Awp12, Awp13, CAGL0F09273g, 
CAGL0A04873g, and CAGL0H00132g) were mainly present in isolates with high adherence 
capacity. 
These results underlined that the core proteome (Table 13) is quite consistent and stable 
among C. glabrata clinical isolates, including GPI-phospholipases, putative glucan-
crosslinkers and GPI-carbohydrate-active enzymes. In contrast, the adhesin set is highly 
diverse and strain-specific, conferring a unique and exclusive cell-surface proteome, which 







Table 12. Variable proteome of selected hyper biofilm-forming isolates under biofilm conditions in this study 
 
 
clinical isolates ATCC90876a CBS-138a CBS-138 b PEU52 c PEU30 c PEU123 c PEU235 c PEU259 c PEU382 b PEU427 b PEU45 c 
biofilm formation capacity polystyrol LBF LBF LBF LBF LBF IBF IBF IBF HBF HBF HBF 
biofilm formation capacity silicone LBF LBF LBF LBF HBF LBF HBF LBF IBF LBF IBF 








protein cluster and  protein type  
Epa3/ CAGL0E06688g cluster I; GPId - + + + + + - + + + + 
Epa6/ CAGL0C00110g cluster I; GPI - + + + + + + + + + + 
Epa7/ CAGL0C05643g cluster I; GPI - - - + - + + + + + + 
Epa22/ CAGL0K00170g cluster I; GPI - - - + - - - - - - - 
Awp13/ CAGL0H10626g cluster III; GPI - - - - - - - - - + - 
Aed1 (Awp5)/ 
CAGL0K13024g cluster III; GPI - +
e - - - - - - - - - 
Awp6/ CAGL0G10175g cluster IV; GPI - + + f - - - - + + + - 
Awp2/ CAGL0K00110g cluster V; GPI - + + - - - - + + + - 
Awp4/ CAGL0J11990g cluster V; GPI - + + - - + + + + + + 
Awp8/ CAGL0B00110g cluster V; GPI - - - - - + + + + + + 
Awp9/ CAGL0B05093g cluster V; GPI - - - - - + - - - + + 
Awp10/ CAGL0F00110g cluster V; GPI - - - - - + + - - + + 
Awp11/ CAGL0M00110g cluster V; GPI - - - - - - - + + - + 
Awp1/ CAGL0J02508g cluster VI; GPI + - - - + - - - - - - 
Awp3/ CAGL0J11891g cluster VI; GPI - +e - - - - - - - - - 
Awp12/ CAGL0G10219g cluster VII; GPI - - + - - + + - - + - 
CAGL0A04873g cluster III; GPI - - - - - - - - - - + 
CAGL0L00227g cluster V; GPI - - - + - - - - - - + 
CAGL0F09273g cluster V; GPI - - - - - + - - - - - 





Table 13. Core proteome of selected hyper biofilm-forming isolates under biofilm conditions in this study 
clinical isolates ATCC90876 CBS-138 CBS-138 PEU52 (HF) PEU30 (S) PEU123 PEU235 PEU259 PEU382 PEU427 PEU45 
biofilm formation capacity polystyrol LBF LBF LBF LBF LBF IBF IBF IBF HBF HBF HBF 
biofilm formation capacity silicone LBF LBF LBF LBF HBF LBF HBF LBF IBF LBF IBF 
 
protein protein type                                              carbohydrate-active enzymes 
Crh1/ CAGL0G09449g GH16; GPI + + + + + + + + + + + 
Utr2/ CAGL0C02211g GH16; GPI + + + + - + - - + + + 
Gas1/ CAGL0G00286g GH72; GPI + + -f + + + + + + + + 
Gas2/ CAGL0M13849g GH72; GPI + + -f + + + + + + + + 
Gas4/ CAGL0F03883g GH72; GPI + + + + + + + + + + + 
Gas5/ CAGL0F01287g GH72; GPI + + + + - - + + + + + 
Scw4/ CAGL0G00308g GH17 + + + + + + + + + + + 
putative glucan crosslinkers 
Cwp1.1/ CAGL0F07601g Pir repeat; GPI + + + + + + + + +g +g + 
Cwp1.2/ CAGL0F07579g Pir repeat; GPI + + + + + + + + + + + 
Pir1/ CAGL0F07579g 8 Pir repeats + - - + + + + + - + + 
Pir2/ CAGL0I06182g 9 Pir repeats + + + + + + + + + + + 
Pir3/ CAGL0M08492g 9 Pir repeats + + + + + + + + + + + 
Pir4/ CAGL0I06160g 2 Pir repeats + + + + + + + + + + + 
Tir1/ CAGL0F01463g Srp1/Tip1 family; Pir repeat; GPI + + + - - - - - + + + 
phospholipase 
Plb1/ CAGL0J11770g GPI - - - - + + + + + + + 
Plb2/ CAGL0J11748g GPI + + + - + + + + + + + 
unknown function 
Ecm33/ CAGL0M01826g Ecm33 family; GPI + + + + + + + + + + + 
Pst1/ CAGL0E04620g Ecm33 family; GPI + + + + + + + + + + + 
Ssr1/ CAGL0H06413g GPI + + + + + + + + + + + 
Tir2/ CAGL0F01485g Srp1/Tip1 family; GPI - + + - + - - - + + + 
a data from de Groot et al., 2008 and Kraneveld et al., 2011. b data of CBS-138 and hyper-adherent PEU382 and PEU427 are published in (Gómez-Molero et al., 2015). c proteomic data from HBF and LBF 
clinical isolates identified in this study were performed in ongoing collaboration with Dr. Piet de Groot (CRIB, Albacete, Spain) (unpublished data); these isolates were initially selected and partially 
phenotypically characterized by Mr. Ichsan (UMG, Göttingen, Germany). d adhesin cluster classification was detailed by de Groot et al., 2008 and 2013. e data compiled from Groot et al., 2008 and Kraneveld 
et al., 2011, Awp3 were only identified in cell walls harvested under log. phase at 30 °C, and Aed1 was identified in stationary phase cells. f non-unique peptides identified. g positive Mascot determination of 
unique peptides presented in CWP 1.1 and CWP 1.2.  Red boldfaced, novel adhesins identified in hyper-adherent clinical isolates not described before in previous studies (Gómez-Molero et al., 2015). Blue 





3.2.5 Hyper biofilm-forming C. glabrata clinical isolates’ 
adherence to C. albicans. 
 
Based on interaction studies performed by (Tati et al., 2016) between C. albicans and 
C. glabrata, we hypothesized a correlation between biofilm formation capacity/presence of 
cell wall adhesins and capacity to adhere to C. albicans hyphae would be present among 
our isolates. To determine the relation between the abundance of identified cell wall 
adhesins in HBF isolates and interaction with C. albicans hyphae, isolates PEU52, PEU45, 
PEU382 and PEU427 were co-incubated with GFP-tagged C. albicans SC5314 and examined 
by fluorescence microscopy.  
The attachment of C. glabrata yeast cells to C. albicans hyphae was quantified showing an 
increased number of C. glabrata yeast cells adhered to C.a-GFP-SC5314 hyphae (expressed 
as C. glabrata cells/ µm C. albicans hyphae) in the HBF clinical isolates and the highly 
flocculent strains PEU52, as compared to the two LBF reference strains (CBS-138 and 
ATCC90876) (Figure 26). C. glabrata cell aggregation capacity was significantly higher in 
PEU382 (P < 0.012, 0.068 ± 0.038), PEU427 (P ≤ 0.038, 0.068 ± 0.047) and the HF PEU52 
(P < 0.0091, 0.116 ± 0.078). A qualitative intermediate degree of interaction was described 
in the lower biofilm-forming HF-PEU52. The control PEU52 was extremely flocculent and 
tended to adhere to the edges of C. albicans hyphae and surrounding C. albicans freshly 
germinated cells as big aggregates, leaving the longer C. albicans hyphae free of C. glabrata 
cells (Figure 26, intermediate row, left panel). 
Among the selected C. glabrata clinical isolates, the HBF PEU382 (P ≤ 0.001) and PEU427 
(P ≤ 0.05) presented significantly higher adherence to C. albicans hyphae compared to the 
CBS-138 and the ATCC90876 (Figure 26). The range of C. glabrata adherence capacity to 







Figure 26. C. glabrata: C. albicans-GFP-SC5314 interaction in vitro model. Left panels, fluorescence microscopy quantification of C. glabrata cells adhesion to C. albicans hyphae. DAPI (blue) and 
CY2 (green) fluorescence was used for a better differentiation of C. albicans germinated structures (bright green), hyphae forms (light cyan) and C. glabrata yeast cells (dark grey). * indicates the 
hyphae length: ATCC90876, 68.07 µm; CBS-138, 40.34 µm; PEU52, 70.21 µm; PEU45, 75.3 µm; PEU382, 48.17 µm and PEU427 55.52 µm. Right panels, cell wall adhesins identification in LBF, IBF 
and HBF clinical isolates. The variable proteome was represented based on genomic distribution previously described for the C. glabrata reference strain CBS-138 (de Groot et al., 2013). Red 
boldfaced, adhesins newly identified in this study that belongs to the Awp family (Gómez-Molero et al., 2015). Blue boldfaced, adhesins newly described not yet categorized (CAGL0L00227g, 
CAGL0A04873g and CAGL0H00132g). Adhesin proteins distribution is mainly located in subtelomeric regions. Cell wall protein genes color code corresponds with family clusters distribution 


























































Table 14. Percentage of Candida spp. interaction between selected C. glabrata clinical isolates and GFP-
SC5314 C. albicans reference strain 
 
% of interaction C. g: C. a-GFP-SC5314, (n° C. glabrata yeast cells/C. albicans hyphae length /10 µm).  
 
3.2.6 C. albicans and C. glabrata mixed culture analysis  
 
Following the hypothesis, that attachment of C. glabrata to C. albicans aids C. glabrata in 
penetration into tissues and subsequently into the bloodstream (Tati et al., 2016), we 
searched medical records for further evidence. Between 2010 and 2016 we found n = 
biofilm formation silicone 
biofilm formation polystyrol 
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15532 specimen processed in the microbiology lab of the University Medical Hospital in 
Göttingen from which either C. glabrata, C. albicans or both were cultured (Table 15). 
Table 15. Frequency of C. glabrata and C. albicans infections (n = 15532) per source of isolation.  
* Mixed cultures diagnosed as C. glabrata infection were represented as total % (right column). Isolates 
were categorized nine different categories. a absolute value of C. glabrata identified in mixed cultures per 
source of site. Cut-off value: 0.110 ± 0.04. C. glabrata. Bolfaced percentages represent the most frequent 
source of isolation identified as C. glabrata in mixed cultures. 
 
Out of these, 78.5% had only C. albicans, 19.0% C. glabrata, and 2.5% contained both. The 
highest number of mixed cultures was obtained from the respiratory tract (33.0%), while 
the lowest number was obtained from blood cultures (Figure 27). Next, we wanted to 
corroborate if the frequency of mixed cultures was increased relative to the total number 
of C. glabrata findings in those specimen groups, where C. glabrata was expected not to 
penetrate without the help of C. albicans (blood cultures and invasive isolates). However, 
this was not the case. No statistical differences between the source of isolation and the 
presence of C. glabrata infections in mixed cultures were found (P >0.05) (Table 15). 
source C. albicans C. glabrata mixed ratioa % C. glabrata in mixed culturesb 
invasive 1805 415 53 0.139 11% 
GI 500 245 55 0.144 18% 
device 884 213 33 0.086 13% 
skin 1720 227 19 0.049 8% 
respiratory 3597 818 128 0.335 14% 
oral 1339 182 37 0.097 17% 
urine catheter 840 318 26 0.068 8% 
urine 1084 398 21 0.055 5% 
blood culture 423 143 9 0.023 6% 





Table 16. C.  glabrata blood cultures identification in CHROMagar 
a CBS-138 and SC5314 were used as C. glabrata and C. albicans reference strains, respectively. Bc-395 and 
bc-494 were used as positive control with mixed infections previously identified. 
 
  
Figure 27. General distribution of single and mixed Candida spp. infections caused by C. albicans and 
C. glabrata. Red squares, mixed infections identified in cultures isolated from invasive infections (e.g. sterile 






























isolate CHROMagar  isolate CHROMagar  isolate CHROMagar isolate CHROMagar  
bc 1035 c. g bc 1046 c. g bc 1056 c. g bc 1066 c. g 
bc 1036 c. g bc 1047 c. g bc 1057 c. g bc 1067 c. g 
bc 1037 c. g bc 1048 c. g bc 1058 c. g bc 1068 c. g 
bc 1038 c. g bc 1049 c. g bc 1059 c. g bc 1069 c. g 
bc 1039 c. g bc 1050 c. g bc 1060 c. g bc 1070 c. g 
bc 1040 c. g bc 1051 c. g bc 1061 c. g bc 1071 c. g 
bc 1041 c. g bc 1052 c. g bc 1062 c. g SC5314a c. a 
bc 1042 c. g bc 1053 c. g bc 1063 c. g CBS138a c. g 
bc 1043 c. g bc 1054 c. g bc 1064 c. g bc 395a c. g+c. a 





There is the possibility that C. albicans was simply not detected in plates inoculated from 
blood cultures due to overgrowth of C. glabrata in the liquid culture. For example, when 
we spiked C. glabrata into blood culture bottles (CBS-138) were detected after 
approximately 20h. Meanwhile, C. albicans (SC5314) was positively determined around 17 
h. after incubation. We therefore took 36 blood cultures plus two reference strains and 
two mixed cultures (controls) which had been stored for quality control purposes and 
plated these on selective chromogenic agar (CHROMagar, Oxoid) for quick determination 
of C. albicans (green) and C. glabrata (red). All thirty-six blood cultures tested were 
identified as C. glabrata (Table 16) with no apparent identification of C. albicans green 
colonies in the samples (Figure 28A). To increase the accuracy of mixed cultures 
determination, selected bottles were investigated using direct PNA-FISH (Figure 28B). 
Indeed, the specimen C. g-bc-PEU1038, previously diagnosed as C. glabrata infection 
(Figure 28B) was the only blood cultures identified as a mixed culture. However, blood 
culture bottles from isolates C. g-bc-PEU1035, C. g-bc-PEU1036, C. g-bc-PEU1037 and C. g-
bc-PEU1039 were only found to contain as C. glabrata infections. In summary, no 
evidence of remarkably increased identification of C. albicans in mixed cultures was 
observed and remarkable differences between the origin of the culture and the presence 
of C. glabrata is evident, but nevertheless the percentage of finding C. glabrata in cultures 
is slightly more frequent in samples isolated primary sources, gastrointestinal tract, 








Figure 28. C. albicans and C. glabrata identification from infected-patient´s blood cultures. (A) CHROMagar 
species determination. Green colonies C. albicans, dark red colonies, C. glabrata. (B) Fluorescence in-situ 





















3.3 Pheno- and genotypic analyses of Candida parapsilosis 
clinical isolates 
3.3.1 Establishing a classification reference 
 
Candida parapsilosis’ morphology-switching is proposed to be involved in this organism 
adherence and pathogenicity processes. In order to analyze C. parapsilosis phenotypic and 
genotypic divergences within a large clinical strain collection, we initially classified 
different colony morphotypes according to the existing nomenclature proposed in the 
literature (Enger et al., 2001; Laffey and Butler, 2005; Lott et al., 1993). 
 
 
Figure 29. Morphogenic switching in a C. parapsilosis non-biofilm forming clinical isolate (PEU582). Left, 
colony morphology on SAB agar. Right, morphotypic switch on SAB´s agar and exponential phase liquid 
cultures showing frequency changes between smooth and crepe I morphotypes. The phenotypic switch from 
“smooth-glossy” to “crepe I” was 4 times faster (2X10-1) than the switch observed from “crepe I “to 
“smooth-glossy”, (5X10-2). 
 
In the example from our collection shown here (Figure 29A), the phenotype smooth was 
comparable with those described by (Lott et al., 1993) and (Nosek et al., 2009), presenting 
initially as round glossy colonies with delimited border. The final crepe colony morphology 










matte surface with “crepe” wrinkles, but no concentric distribution. Smooth colony 
morphotypes correlate with round yeast cells in liquid YPD media; in contrast, crepe 
colony morphologies develop long pseudohyphae (Figure 29B).  
While working with increasing numbers clinical C. parapsilosis isolates and prolonged 
incubation times, numerous intermediate and novel colony forms were observed. 
Therefore, a new classification key chart was developed, incorporating colony border, 
surface color, as well as microcolony shape on agar- and cell shape in liquid cultures. 
Microcolony morphology on Corn meal agar (Figure 30B) varied between defined round 
structures (regular) and filamentous microcolonies (spider). Biofilm formation capacity 
and cell aggregation were classified as “low”, “intermediate” and “high”, (Figure 30B). Cell 
shape morphology under exponential phase growth conditions were grouped into three 
different categories prevailing yeast cells (0), elongated pseudohyphae (2) or mixed 
cultures (1) including a combination of yeast and/or pseudohyphae development (Figure 
30C). 
Additionally, agar invasion capacity of each colony type (A) was ranked between “low” (1 
and 2) with no clear agar imprint detectable after flushing the plates with water, 
“medium” (3 and 4) with slightly colony border imprints on agar, and “high” with 
detectable concentric rings on the agar (5) as well as occasional resistance of the colony to 
removal with flushing water(6), a feature used to further discriminate “crepe I” and “crepe 
II” colonies (Figure 30D).  
In total this resulted in definition of eleven different observed colony types of varying 







Figure 30. General characterization of C. parapsilosis cell-related properties. (A) Microcolony morphology 
on Corn meal agar: (R) regular, (S) spider. (B) Biofilm formation capacity to polystyrol: low (0), intermediate 
(1), high (2). (C) Cell shape morphologies associated with colony types: yeast (0), mixed (1), pseudohyphae 
(2). (D) Agar invasion capacity on SAB´s and Phloxine B agar ranked as: low (1), low-medium (2), medium (3), 
medium-high (4), high (5), very high (6). 
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Figure 31. Classification references of C. parapsilosis colony morphologies on SAB´s and Phloxine B agar 
produced in this work. (A) Major morphotypes: smooth-glossy (s-g), smooth-matte (s-m), smooth-
concentric (s-cn), wrinkled (wr), crepe I and II (cr). (B) Infrequent colony phenotypes: concentric (cn), 
concentric-crepe (cn-cr), concentric-crater (cn-crt), crater (crt), derby (d) and snowball (sn). Left row: colony 
morphology after 96 h. incubation. Right row: agar imprinting on SAB´s and YPD + Phloxine B agar after 
washing colonies with running water. 
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Table 17. C. parapsilosis colonies morphology identification key chart. 
morphotype colony border 
colony color on agar microcolony 
cell shape 
YPD Phloxine B Corn meal 
smooth-glossy (s-g) regular cream, bright bright pink regular yeast 
smooth-matte (s-m) regular cream, matte matte pink regular yeast 
smooth-concentric (s-cn) regular cream, matte magenta regular yeast 
derby (d) regular cream, matte magenta regular yeast 
snowball (sn) regular cream, matte pink velvet regular mixed 
wrinkled (wr) partially irregular cream, matte magenta spider mixed 
crater (crt) irregular cream /brown, matte magenta spider mixed 
concentric-crater (cn-crt) irregular cream, matte magenta spider mixed 
concentric-crepe (cn-cr) irregular cream, matte magenta spider mixed 
concentric (cn) irregular cream, matte magenta spider pseudohyphae 
crepe (I and II) irregular cream/brown, matte magenta spider mixed 
 
3.4 Candida parapsilosis polymorphism drives differences 
at morphological and genotypic level in isolates from a 
single patient 
 
After being confronted with diagnostic agar plates presenting C. parapsilosis with two 
different colony morphologies cultured from a single specimen, we investigated to what 
degree these phenotypic differences correlated with clinically relevant features. Several 
specimens from the same patient were cultured in the diagnostic laboratory, and yeast 
growth was obtained (in chronological order) from bronchial secrete, blood culture (BC), 
nose-oral swab, stool and central venous catheter (CVC). Samples from BC and swabs 
were collected for following studies and identified as C. parapsilosis sensu stricto. Early 
undifferentiated fungal growth from the bronchial secrete and the isolate from the CVC 
sample was not available for subsequent analyses; these values were taken from 







Figure 32. Colony morphology in routine culture. (A) Mixed C. parapsilosis growth from original routine 
plates from (left) nose swab (specimen 1701), (middle) throat swab (specimen 1702) and (right) blood 
culture (specimen 1700). (B) Isolated morphotypes from nose swab (B, left): nsc-1701 (nose swab, smooth 
colony) and ncc-1701 (nose swab, crepe colony), from throat swab.(B, middle): tsc-1702 (throat swab, 
smooth colony) and tcc-1702 (throat swab, crepe colony) and bsc-1700 (blood smooth colony). All cultures 
were isolated on Sabouraud´s agar and Columbia blood agar plates (bsc-1700). 
 
One nasal and one oropharyngeal swab each grew colonies of two different morphotypes: 
cream, matte, round colonies (“smooth-matte” type) and irregular, asymmetrical, cream 
matte colonies (“crepe I” type); the BC isolate presented single colony morphology 
(smooth-glossy). As species-identification routine diagnosis, all stable morphotypes from 
BC and swabs were re-identified as C. parapsilosis by MALDI-TOF (see legend to Figure 32 
for isolate naming). 
After 96 h. incubation, three stable colony-types (smooth, crepe, and concentric) were 
produced from the five clinical isolates. Isolates from nasal and tracheal swabs appeared 
as both smooth and crepe I (s, cr-I) morphotype on Phloxine B agar (Figure 33, top row). 































type. The isolated swab samples reproducibly had two independent morphotypes (s-m 
and cr I) per source of isolation.  
The five reference strains used at this point were CDC 317 (s-g), CBS 6318 (s-g), GA-1 (s-
m), ATCC 22019 (cn-cr) and CBS 1954 (cr I). Three of the five reference strains produced 
only one representative phenotype per isolate, while CBS 1954 and ATCC 22019 regularly 
switched between morphotypes. The major colony-types in those were crepe (cr I) and 
concentric-crepe (cn-cr), respectively. Strain ATCC 22019 also switched to rough colony 
morphotype (~90%) and several infrequent smooth morphotypes (~10%, not shown). In 
case of the reference strain CBS 1954, the percentage of rough (cr I) morphotype was 
~80% and smooth colonies ~20%, (Figure 33, top row). Microscopically, cells from smooth 
(s) colonies appeared round and regular shaped. In contrast, concentric (cn) and crepe (cr-
I, cr-II) colony morphotypes correlated with clearly elongated pseudohyphal cells in 
isolates ATCC 22019-cn-cr and CBS 1954-cr-I, respectively. CBS 1954 also produced the 
strongest and most evident crepe colony morphotype, fully devoid of yeast-form cells. In 
contrast, the clinical isolates ncc-1701 and tcc-1702 produced a combination of round-







Figure 33. Morphological variations between clinical morphotypes. Top row: colony morphology on 
Phloxine B agar. Bottom row: cell shape and cell aggregation at 100X magnification in phase-contrast. 
 
To analyze variations on adhesion-related properties, we tested the biofilm formation 
capacity to polystyrol, the cellular aggregation and agar invasion capacity of each 
morphotype. There was no strict correlation between biofilm formation capacity to 
polystyrol and colony morphotype in the five reference strains. However, among the 
patient isolates, only the two crepe clinical isolates (ncc-1701 and tcc-1702) showed a 
significantly higher capacity to form biofilms on non-charged polystyrol (P < 0.001), on 
average 50-fold higher than the control. The ranking of biofilm formation capacity to 
polystyrol (from least to highest capacity) was: nsc-1701 < CDC 317 < tsc-1702 < bsc-1700 
< GA-1 < CBS 6318 < CBS 1954 < ATCC 22019 < ncc-1701 and tcc-1702 (Figure 34A). In 
addition, cell aggregation correlated with morphology, and thereby with biofilm formation 
capacity. Only the two isolates with hyperbiofilm-forming ability (ncc-1701 and tcc-1702) 
tsc-1702 tcc-1702nsc-1701 ncc-1701




















also developed aggregates in YPD growth cultures. The isolate ncc-1701 produced 
intermediate aggregates; meanwhile the tcc-1702 developed better-defined clumps in 
liquid cultures. The two reference strains with concentric and crepe I morphotypes (ATCC 
22019, CBS 1954) did not form aggregates in liquid media, which also correlated with an 
absence of biofilm formation capacity to plastic materials (Figure 34B). 
 
 
Figure 34. Biofilm formation-related phenotypes. Top row: representative colony morphologies used below 
(A-C). (A) Biofilm-formation capacity on polystyrol. The values are the means ± standard deviations (error 
bars) of each isolate. Each experiment is the average of the absorbance of four technical measurements. 
Isolates were statistically compared with the CDC 317 using independent two-tail paired student T–test. The 
asterisks represent the 95% (α = 0.05) confidence interval of the analyses. (B) Cell aggregation tests. Arrows 
indicate clumps in hyperbiofilm-forming isolates ncc-1701 and tcc-1702. (C) Agar invasion. Top row: colony 
growth on Phloxine B agar. Bottom row: agar invasion after washing the plates with running water. Arrows 
indicate partial agar imprinting corresponding with low to medium agar invasiveness. (L), low; (L-M), low-
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*** P < 0.001
ns, P > 0.05





Finally, isolates with crepe and concentric morphotypes invaded the agar better than 
smooth colony type. Our results showed a moderately increased agar invasion in crepe 
and concentric morphotypes as compared to smooth morphologies (Figure 34C). The 
strongest invasiveness was detected in CBS 1954, ncc-1701, and tcc-1702. A positive 
correlation between the three phenotypic properties (biofilm formation, aggregate 
formation, and invasiveness) was only evident in the two crepe clinical isolates.  
Antifungal susceptibility testing showed that the reference strain CDC 317 (smooth) was 
intermediate against FLU (4 µg/ml), as previously reported (Grossman et al., 2015). There 
were only slight differences between patient isolates: MIC values towards azoles in the 
ranged between 0.016 and 0.125 µg/ml, in case of Echinocandins the MIC values varied 
between 0.250 µg/ml for CAS and 2 µg/ml for MICA (Table 18). Variations in 5FC 
susceptibility were apparently influenced by morphotype variability and source of 
isolation (bsc-1700: 0.032 µg/µl and ncc-1701 and tcc-1702: 0.064-0.125 µg/µl, Table 18). 
All patient isolates were susceptible to the antifungal drugs tested. Only CAS MIC values 
for concentric (cn) morphotype in the control strain ATCC 22019 was slightly lower than 






Table 18. Summary of clinically relevant properties in C. parapsilosis colony morphotypes  
a morphology according to (Laffey and Butler, 2005); b obtained with YOTL-database (Bernhard et al., 2014) by on-target-lysis; c biofilm formation capacity to 
polystyrol. CV absorbance measured at 490 nm. Cut-off value = 0.0771; d all EUCAST broth microdilution against FLU (Fluconazole), POS (Posaconazole), VOR 
(Voriconazole), CAS (Caspofungin), MICA (Micafungin) and 5FC (5-Fluorocytosine).  
strain acronym CDC 317 CBS 6318
e
 GA-1 ATCC 22019 CBS 1954 bsc-1700 nsc-1701 tsc-1702 ncc-1701 tcc-1702 CVC 




PEU-1700 PEU-1701 PEU-1702 PEU-1701 PEU-1702 not applicable 
c
 
DSMZ-5784 day 16 day 20 day 20 day 20 day 20 day 31 








smooth smooth smooth concentric crepe smooth smooth smooth crepe crepe not recorded 
MALDI Biotyper 
identification C. p C. p C. p C. p C. p C. p C. p C. p C. p C. p C. p 
log score
 b






























FLU (µg/µl) 4 1 0.500 1 1 0.500 0.500 0.500 0.500 0.250-1 S 
POS (µg/µl) 0.032 0.032 0.032 0.032-0.064 0.032 0.032 0.032-0.064 0.032 0.016-0.032 0.032 n.d. 
VOR (µg/µl) 0.125 0.032 0.032 0.032 0.032 0.032 0.032 0.032 0.032 0.032 S 
CAS (µg/µl) 1 0.500 1 0.500 0.500 0.500 0.250-0.500 0.250-0.500 0.500 0.25-1 n.d. 
MICA (µg/µl) 2 2 2 1-2 2 2 1-2 1-2 1-2 1-2 S 





3.4.1 The five clinical isolates are distributed into three 
different genetic categories 
 
Morphologically, the three smooth isolates were highly similar, differing only in bsc-1700’s 
slightly increased biofilm formation capacity to polystyrol. Among the non-smooth types, 
aggregation of tcc-1702 was stronger than in ncc-1701. Despite the notable variation in 
their adhesion phenotypes, our hypothesis was that they represented stable forms of the 
same clonal population, and sought to confirm this by determining the karyotypic profile 
and genetic patterns. 
Electrophoretic karyotyping differentiates eight somatic and the mitochondrial 
chromosome in the reference strain CDC 317 (Figure 35A). All were also detectable in the 
ten samples analyzed. However, differences in chromosome sizes were observed among 
patient isolates, mainly among the intermediate-sized (1-2 mbp) chromosomes with high 
diversity, potentially conferring to Chr. 3, 4, and 8. Low biofilm-forming isolates, nsc-1701 
and tsc-1702 presented similar karyotypic pattern, visually close to tcc-1702. Conversely, 
the crepe isolate ncc-1701 resembled the smooth isolate bsc-1700, although they were 
not identical. Therefore, unexpectedly, variation between patient isolates was evident, 
resembling the variation range also seen between independent reference strains. 
Since karyotyping results above were inconclusive, we next conducted whole genome 
analyses in collaboration with Dr. Toni Gabaldón Estevan (CRG, Barcelona, Spain) to clarify 
the genomic diversity. Whole genome sequencing indicated 3846 single nucleotide 
polymorphisms (SNPs) between the five strains compared to the CDC 317 (Figure 35B). 
The blood culture isolate bsc-1700 and nsc-1701 shared > 98.1 % SNPs (Table 19), 
indicating high similarity between both isolates. Meanwhile, the strain tsc-1702 was a 
genetic outsider (45-68% shared SNPs with the other groups). Similarly, the two hyper 
biofilm-forming crepe isolates ncc-1701 and tcc-1702 shared 99.2% of SNPs. In contrast, 
the number of shared SNPs between the bsc-1700 and the two crepe clinical isolates were 





shared close to 65% of SNPs. A PCA-based population analysis (Carreté et al., 2018) 
including previously genome sequenced control strains (Pryszcz et al., 2013) suggested a 
genetic distance between the three clusters similar to the independent reference strains. 
Table 19. Percentage of Single Nucleotides Polymorphisms (SNPs) similarity between five clinical isolates  
(%) SNPs shared between clinical isolates 
  bsc-1700 nsc-1701 tsc-1702 ncc-1701 tcc-1702 
 bsc-1700 NA 98.1 68.2 14.6 14.8 
 nsc-1701 98.1 NA 69.2 15.2 15.1 
 tsc-1702 68.2 69.2 NA 45.4 45.4 
 ncc-1701 14.6 15.2 45.4 NA 99.2 
 tcc-1702 14.8 15.1 45.4 99.2 NA 
 
The percentage of shared SNPs between the bsc-1700 and nsc-1701 (99.2%) pointed to a 
close distance between both isolates. This was also indicated by a principal component 
analysis (Figure 35C) which placed bsc-1700 and nsc-1701 near clonality, as well as ncc-
1701 and tcc-1702. Finally, tsc-1702 was found to be an independent genetic outlier. 
 
 
Figure 35. Genome sequencing analyses. Strain typing and genome sequencing. (A) Pulse-field gel 
electrophoresis suggests the isolates are not clonal. (B) Numbers of unique and shared SNPs between the 5 
patient isolates and subsequent (C) PCA cluster analysis of the SNPome placing the 5 patient isolates (blue) 
into the context of other genome-sequenced strains (red), relative to CDC 317, indicates the presence of 3 

























































3.4.2 Isolates strongly vary in their adhesion genes 
 
To further explain the phenotypic properties, C. parapsilosis adhesin-encoding genes were 
analyzed to see if modification in gene-size and gene-presence varied between clinical 
morphotypes. Based on the previous analyses (3.4.1) C. parapsilosis clinical isolates 
differed in the number of SNPs shared and the morphotype they presented (Figure 35). 
Divergences on gene-size indicated possible deletions, duplications and recombination 
events involving seven adhesins. Isolates bsc-1700, nsc-1701 and tsc-1702 presented a 
similar tandem repeats pattern distribution compared with the two crepe reference 
strains (ncc-1701 and tcc-1702). Based on SNPs shared between clinical morphotypes, we 
remarked variations in the low complexity domain for CPAR2_500600, CPAR2_404780, 
CPAR2_404790, CPAR2_404800, CPAR2_403510 and CPAR2_403520. In contrast, no clear 
divergences in the agglutinin-like sequence ALS3 were observed (Figure 36A). Deletions 
events involved CPAR2_500660 (2.2-2.7 Kb), CPAR2_404790 (2.5-4 Kb) and CPAR2_404780 
(2.25-2.75 Kb) in the ncc-1701 and tcc-1702. Another possible deletion (reduced read 
numbers) event in the ALS7 was observed in bsc-1700, nsc-1701 and tsc-1702. Nucleotide 
duplications (increase read numbers) in five adhesin-encoding genes were identified and 
detailed in Figure 36A. Increased number of SNPs (green pannel, Figure 36A) were 
identified in the two crepe morphotypes in the gene encoding Hwp1 CWP protein. 
Genomic DNA amplification of selected CPAR2_404790, CPAR2_404800 (ALS7) and 
CPAR2_403520 (HWP1) confirms gene-size variations between smooth and crepe 
morphotypes (Figure 36C) and most strikingly in the HWP1. 
To sum up, we associated morphotypic switch differences and variations in the degree of 
biofilm formation capacity to polysytyrol, with modifications in the tandem repeats copy 
number of seven adhesin-encoding genes (Figure 36). Correlation between the number of 
SNPs shared within smooth and crepe isolates positively correlates with deletion, 
duplication events in these adhesin genes. Variations in adhesin encoding-genes 





CPAR2_403520 were observed between smooth (bsc-1700, nsc-1701 and tsc-1702) and 
crepe morphotypes (ncc-1701 and tcc-1702), (Figure 36A). This large plasticity in gene 
sequence may induced variations in adhesin´s tandem repeats region length (Figure 36B). 
No remarkable genomic variations were observed in isolates displaying the same 
morphotypic switch, independently of the site of isolation. 
 
Figure 36. C. parapsilosis adhesin-encoding genes analyses. (A) Genome sequences of seven main adhesin-
encoding genes of five different C. parapsilosis isolates. Raw Illumina reads mapped onto the CDC 317 
reference sequence and counted (grey). SNPs are indicated by read, green, blue, or orange vertical dashes. 
Yellow boxes: increased read numbers, indicating repeat number extension; pink boxes: reduced read 
numbers indicating repeat number reduction. Colored arrows below sequence alignments, tandem repeat 
region (TRRs). (B) Selected PCR amplicons of repetitive regions in CPAR2_404790, CAPR2_ 404800, and 




















































































































































3.5 Candida parapsilosis phenotypic cell surface variations 
correlate with differences at a proteomic level among 
isolates from a clinical strain collection 
 
Based on the observations described above for a small set of isolates, we next created and 
characterized a collection of clinical C. parapsilosis isolates arising from the routine 
diagnostic laboratory. Examples of cultures with multiple phenotypes isolated on SAB´s 
agar (s-cn-cr) are shown in Figure 37. 
 
 
Figure 37. Colony morphology on SAB agar. Mixed cultures present (cr) crepe morphotype; (cn) concentric 
morphotype and (s) smooth colonies after 96 h. incubation time. 
 
In total, 215 isolates were collected and characterized over the study period (2015-2017). 
Biofilm formation capacity on polystyrol surfaces were quantified and the isolates 
stratified into nine different groups according on the isolates’ body site of isolation. The 
distribution of the clinical samples depending on the origin of isolation is detailed in Figure 
38A. The majority of the isolates received from the diagnostic laboratory were obtained 
from ear-nose swabs (30%) and isolates from gastrointestinal tract or oral cavity were the 






Figure 38. C. parapsilosis clinical isolates distribution. (A) Isolates classified according to the body site of 
isolation (n= 215). Green and red lines indicate the two-fold median cut-off. (B) Isolates stratified according 
to biofilm formation capacity to polystyrol. Three groups selected for subsequent experiments (red boxes): 
LBF (0.054-0.080), IBF (0.153-0.370) and HBF (0.445-1.360). Intersection of black lines: approximated cut-off. 
 
Based on the degree of biofilm formation capacity to polystyrol, three isolate groups were 
selected for subsequent analyses: 39 LBF, 39 IBF and 39 HBF (Figure 38B), including two 
reference strains (CDC 317, ATCC 22019) to a total of 119 isolates. Predominant 
morphotypes in the collection were determined to estimate the correlation between 
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Figure 39. Clinical isolates biofilm formation capacity. (A) Colony morphology and (B) agar invasion on YPD 
+ Phloxine B agar, tested by scraping with inoculation loop; both stratified by adhesion capacity. Distribution 
of colony morphotypes in a ten days experiment: isolates with low biofilm formation capacity (LBF, left), 
intermediate biofilm formation capacity (IBF, middle) and high biofilm formation capacity (HBF, right). 
Colony morphotype classification in (A): smooth-glossy (dark blue), smooth-matte (blue), smooth-concentric 
(purple), wrinkled (yellow), crepe I/II (orange), mixed snowball/wrinkled/crepe (yellow-orange) and mixed 
morphotypes (other). Color code (grayscale) in (B) represents invasiveness classification in six defined 
categories: low, low-medium, medium, medium-high, high and very high. 
 
In the LBF group, all 39 isolates produced smooth (s-g, s-m and s-cn) phenotype after 96 h 
of incubation at 30 °C. From day 5 on, wrinkled and crepe phenotypes emerged with 
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increasing frequency up to day 10 (7.5% and 2.5%, respectively on day 10). The smooth-
glossy phenotype (s-g) was the most prevalent morphotype among LBF isolates, 
decreasing in frequency by 30% along five days in favour of non-smooth (10%) and mixed 
morphotypes (20%) until day 10. 
In the IBF group, smooth-matte was the most frequent (68.2%) colony morphology at day 
4 (96 h), decreasing to 37.5% on day 10, surpassed by wrinkled or crepe (up to 40%). 
In contrast, HBF isolates mainly produced wrinkled and crepe morphotypes (25% and 
47.5%, respectively) with a decreased number of smooth strains (17.5%) right from the 
beginning on day 4. The majority of the isolates which display more than one morphotype 
presented a final crepe morphology at day 10. 
Using two different strategies to test agar invasion capacity on Phloxine B we found that 
the LBF isolates tended to be less agar invasive than the IBF and HBF isolates. Scoring agar 
invasiveness along ten days with scraping a small part of the growth off the agar (strategy 
1) indicated that approximately a 95% of the LBF isolates presented only low-medium 
invasion capacity. Almost 40% of the IBF isolates developed medium agar invasion 
capacity, and the HBF group isolates displayed a wider range of invasion intensity, 
predominantly the medium-high agar invasion category (~85%) (Figure 39B). 
In accordance with the values described above (Figure 39B); the low and low-medium (cat. 
1 and 2) invasion intensity in the LBF isolates was evident (37/39) when plates were 
washed on the final day under running water (strategy 2). In case of IBF isolates, 67.5% of 
the isolates previously classified as medium (cat. 3) were reclassified as medium-high (cat. 
4) agar invaders, as imprints were observable here. Among HBF isolates close to ~45% of 
the strains were placed in subgroup 4 and another 45%, were ranked as high (cat. 5) or 
super high (cat. 6) as colonies remained intact after washing (Figure 40). In summary, 
there was a clear correlation between the capacity to form biofilms on abiotic surfaces, 







Figure 40. Correlation between agar invasion and biofilm formation capacity. Final scoring on day 10 in an 
agar invasion experiment (see Figure 39), removing the cells off the agar with running water instead of 
scraping with inoculation loop. Left, LBF (low biofilm-forming isolates); middle, IBF (intermediate biofilm-
forming isolates); right, HBF (high biofilm-forming isolates). Color code (grayscale) represents invasiveness 
classification in six defined categories (see Figure 30D). 
 
3.5.1 C. parapsilosis isolates present variations in antifungal 
susceptibility based on the biofilm formation capacity 
to abiotic surfaces 
 
The 117 selected and 2 reference strains of the clinical collection were tested for 
susceptibility to selected azoles (FLU, POS, VOR), echinocandins (CAS, MICA), and one 
polyene (AMB). Only 4 isolates plus the reference strain CDC 317 showed highly elevated 
MIC values of 4-16 µg/µl for FLU. These isolates originated from the IBF group, and from 
diverse sites of isolation, including nasal swabs (PEU768 and PEU950), medical devices 
(PEU651), or invasive candidiasis of the backbone (PEU941). 
As it was already described by Souza et al., 2015, that a point mutation, in the position 
132 of the gene CPAR2_303740-ERG11 is involved in a reduced susceptibility to FLU. In 
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317. Gene sequencing analyses of ERG11 and MRR1 for the selected FLU resistant isolates 
(4-16 µg/µl) with intermediate biofilm formation capacity were performed and no point 
mutation was remarked. Only in PEU651 MRR1 contained non-synonymous SNPs (leading 
to amino acid exchanges. Since we could not exclude a potential influence of such 
mutations, PEU651 data was excluded from further analyses. 
To assess the impact of morphology on drug susceptibility, the inoculum was prepared 
once after 24h and once after 8 days of maturation on agar, excluding the four resistant 
isolates mentioned above. IBF isolates showed a wider morphotypic variability; in HBF 
isolates the crepe I and II morphotypes (~75%) prevailed. The range of biofilm formation 
capacity to polystyrol of these isolates varied between 0.183 (LBF) to 0.348 (HBF), where 
the latter is 14-fold more adherent than the reference strain CDC 317. 
After 24 h. pre-culture, LBF and HBF isolate groups differed slightly, but with statistically 
significance for FLU and POS susceptibility (2-3 log2-fold differences). Also in case of 
echinocandins, differences between LBF-HBF against CAS were found. No apparent 
differences for either VOR or AMB were seen (Figure 41A). The analysis after eight days of 
colony development indicated significant variations only between IBF-HBF and LBF-HBF 
towards FLU and POS but not for VOR. No differences for CAS within the three groups 
were observed. 
In summary, this showed that susceptibility rates of C. parapsilosis clinical isolates for two 
azoles (FLU and POS) and two type of echinocandin (CAS and MICA) were slightly 
influenced by morphotype and biofilm-forming capacity (Figure 41). However, in none of 
the cases, the observed MIC differences resulted in a major change in clinical classification 






Figure 41. Drug susceptibility test of one hundred seventeen clinical isolates + two reference strains (CDC 317, ATCC 22019). Biofilm formation-phenotype 
dependent susceptibility testing where inoculum was prepared from cells after 1 d growth (young colonies) on SDA (grey boxes) and after 8 d growth (mature 
colonies), (white boxes) of the identical plates, when colonies had fully developed morphologies. Red lines: EUCAST clinical breakpoint (R>); green lines, 
susceptible cut-off (S ≤). MIC values were calculated after 24 h. The results are the average of two independent experiments. *, Welch T-test with unequal 






























3.5.2 Morphotype generally predetermines other 
phenotypic properties in C. parapsilosis clinical isolates  
 
To investigate C. parapsilosis agar invasion capacity and its correlation with morphotype 
switching capacity as well as cell-morphology two controls and seven isolates from the 
collection were selected to reflect a range of morphotypic variations (Figure 42). Three of 
the strains (CDC 317, PEU501, and PEU651) produced only the smooth morphotype. Two 
isolates (PEU495 and PEU582) produced both smooth and crepe morphotypes. Isolates 
PEU486 and PEU586 showed one major morphotype (crepe), but with low frequency also 
smooth or concentric colony types. Finally, isolates PEU496 and the ATCC 22019 reference 
strain frequently switched between four colony morphologies each, the crepe morphology 
being most frequent. When linages derived from each isolates’ morphology were tested 
for their ability to form biofilms on polystyrol (Figure 42B), large differences were still 
observed between isolates, but only less so between linages derived from a single isolate. 
For example, variation in biofilm formation capacity based on the morphotypic switch 
significantly differ in three HBF isolates (P < 0.01), meanwhile the IBF isolate PEU582 did 
not present differences between smooth and crepe morphologies. The largest differences 
in biofilm formation capacity intra-strains were displayed by the isolates PEU495 (smooth 
<> crepe) and PEU586 (crepe <> concentric). 
In summary, hyper biofilm-forming isolates were statistically different (P < 0.01) to the 
CDC 317 (s) and ATCC 22019 (s, crt, cn and cr) at all times, independently of the 
morphotype observed. Intra-strains differences were significantly high in HBF isolates, 
mostly, concentric and crepe morphotypes displayed strong biofilms compared with 








Figure 42. Morphologic variation of nine C. parapsilosis isolates on SAB agar plates. (Aa) Major colony 
morphotypes of clinical isolates selected for downstream analyses. (Ab) Less frequent morphotypic 
variation. (B) Biofilm formation capacity quantification assay of morphologically different linages derived 
from individual isolates. Stars, “most representative” morphotype in each clinical isolate. 
a
b
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Next, we determined if the different colony morphologies in this set led to changes in drug 
susceptibility. No general variations on the MIC between different colony morphotypes 
were observed (Table 20) with the exception of the PEU486-cn which showed eight and 
fifteen times reduced susceptibility to VOR and POS, respectively, compared to smooth 
and crepe morphologies. In case of the PEU486-cr, PEU496-cr and PEU586-cr, the 
susceptibility against CAS was reduced between two-four times compared to smooth and 
concentric morphotypes (Table 20). Clinical isolates were classified sensitive to all drugs 
tested, with the exception of CDC 317 and PEU651, which were FLU resistant. 
Table 20. Antifungal susceptibility test of the morphtypic switchs (smooth<>crepe<>concentric) of nine 
selected C. parapsilosis isolates 
clinical isolates FLU (µg/ml) VOR (µg/ml) POS (µg/ml) CAS (µg/ml) MICA (µg/ml) 
CDC 317s 4-16 0.125-0.250 0.125-0.250 1 1-2 
ATCC 22019s 0.500-1 0.032-0.064 0.064-0.125 0.500-1 0.500-1 
ATCC 22019cn 1 0.032 0.064 1 0.500 
ATCC 22019cr 1 0.032 0.064 1-2 1-2 
PEU501s 0.250-0.500 0.032-0.064 0.064-0.125 0.250-0.500 1-2 
PEU651s 4 0.032-0.064 0.064-0.125 0.5-1 0.125-0.250 
PEU582s 0.500-1 0.032 0.064-0.125 0.500-1 2 
PEU582cr 2 0.064 0.064 1-2 1 
PEU495s 0.500-1 0.032 0.064-0.125 1-2 2 
PEU495cr 0.500-1 0.125-0.250 0.032-0.064 1-2 1-2 
PEU586cr 1 0.032 0.125 2 2 
PEU586cn 1 0.125 0.064-0.125 0.250-0.500 0.500-1 
PEU486s 0.500-1 0.032 0.032-0.064 0.250 1-2 
PEU486cr 1 0.032-0.064 0.032-0.064 1 1-2 
PEU486cn 0.5 0.250 0.500 0.500 1 
PEU496s 0.5 0.032 0.016 0.5 2 
PEU496cr 0.5 0.032 0.064 2 2 
PEU496cn 1 0.125-0.251 0.064-0.125 0.250-0.500 0.500 






To verify if morphotypic variations within isolates could carry chromosomal alterations, 
karyotypic analyses (Shin et al., 2001) of one HBF clinical isolate with three different 
morphotypes were performed. No apparent differences between rough morphotypes 
were observed, in contrast, slightly differences between “smooth” and “rough” 
(concentric and crepe) morphotypes were identified in the intermediate chromosomes 
(chr. 3, 4 and 8), (Figure 43), but the data is still inconclusive, further experiment will be 




Figure 43. Electrophoretic karyotyping of C. parapsilosis PEU468 morphotypes. C. parapsilosis 
morphotypes produced by linages of PEU486 were analyzed and compared with C. parapsilosis reference 
strains CDC 317. 
 
After confirmation that morphotypic differences did not correlate with gross 
chromosomal alterations in PEU486, the predominant colony type of each clinical isolate 
was selected for the subsequent analyses. Seven different phenotypic parameters of the 

























PEU501, PEU651, and PEU582 showed a major smooth morphology on Phloxine B agar 
plates, PEU486, PEU495, PEU496 and PEU586 had crepe morphotype and ATCC 22019 was 
frequently identified as concentric-crepe. Regular colony border was observed in the 
smooth morphotypes, weavy colony border was found in three crepe morphotypes, and 
two of the nine isolates (PEU495-cr and ATCC 22019-cn-cr) presented a rough colony 
border with pseudohyphae development after 24h. Microcolonies on Cornmeal agar 
showed the distinctive “spider” phenotype typically produced due to pseudohyphae 
development with crepe and concentric-crepe colony morphology. Isolate PEU582 also 
showed preliminary spider structures, probably explained by the dual morphotypic switch 
(smooth <> crepe). A qualitative biofilm formation analyses between the colony 
morphotype and the capacity to establish a biofilm asserted a positive relation between 
smooth type and absence of adherence (e.g. PEU501), and non-smooth phenotype with 
adhesiveness (e.g. PEU495), (Figure 44F and G). These parameters also matched with agar 
invasiveness, (Figure 44H and I). Cell shape morphology were classified into three groups 
as round yeast cells, mixed yeast and pseudohyphae in cr strains and single elongated 
pseudohyphae form in cn-cr morphotypes (Figure 44E). 
Crepe isolates PEU486cr, PEU495cr, PEU496cr and PEU586cr showed strong capacity to 
establish biofilms on polystyrol after 24 h from initial YPD liquid cultures. In contrast, 
smooth phenotype-cells were not able to produce biofilms (Figure 44A). Smooth colonies 
made around 20-60 % less biofilm than the HBF crepe morphotypes, generating 70-95% 
less biofilm compared to the PEU-586-cr, which had the highest biofilm formation capacity 
in this strain subset. Isolates were ranked according to their capacity to adhere to 
polystyrol as PEU586-cr > PEU486-cr > PEU496-cr > PEU495-cr > PEU651-s > PEU582-s > 
ATCC 22019 > CDC 317 > PEU501-s (Figure 44A). Similarly, differences between adhesion 
(90 min.) and biofilm formation capacity to polystyrol (24 h) from independent colonies 








Figure 44. Phenotypic and morphological differences in nine C. parapsilosis clinical isolates. (A) Major 
colony morphotypes on YPD + Phloxine B. A1-4, smooth morphotype (s). A5-8, crepe (cr). A9, concentric-
crepe. (B) Colony border under optical microscope 10X. B1-4, regular colony border. B5, B7 and B8, wavy 
colony border (emerging pseudohypahe formation). B6 and B9, rough colony border (pseudohyphae 
formation). (C) Microcolonies in corn meal after 48 h. incubation time.C1-3, regular microcolony. C4-9, 
spider microcolony. (D) Microcolonies in corn meal agar after 96 h. incubation time. D1, spider microcolony 
(incipient pseudohyphae). D2-3, regular microcolony. D4-9, spider microcolony (pseudohypohae 
development). (E) Cell shape under contrast-phase microscope 100X (immersion oil). E-1:E-4, round yeast 
cells. E-5:E-8, mixed yeast and pseudohyphae form. E9, pseudohypal cells. (F) Biofilm formation to 
polystyrol. F1-2 and F9, low biofilm. F3-4, intermediate biofilm formation. F5-8, high biofilm formation. (G) 
Biofilm formation using crystal violet quantification assay. (H) Colony morphology on Phloxine B agar plates. 
(I) Invasiveness after ten days incubation on Phloxine B agar. I1-2, low agar invasion. I3-4 and I9, medium 
and medium-high agar invasiveness. I5-8, high agar invasion (5). Arrows indicated colony imprints on agar 
after removing the colonies with water at day ten. 
 























3.5.3 Biofilm formation capacity on silicone 
 
The importance of abiotic materials as polystyrol and silicone in terms of nosocomial 
infections let us to analyze variations in biofilm formation within our selected HBF isolates 
also on silicone. The seven clinical isolates, plus the reference strain CDC 317, were 
classified in four different groups (Figure 45A) depending on their adhesion capacity to 
these materials. Two of the eight isolates had no capacity to adhere to any material 
(PEU501s, CDC 317), two adhered only to polystyrol (PEU582s and PEU651s), and the 
other four were able to establish biofilms on both, polystyrol and silicone (PEU486-cr, 
PEU495-cr, PEU496-cr and PEU586-cr). The ability to form biofilms on silicone apparently 
correlated with the crepe morphotype but more strains should be analyzed to confirm 
these preliminary data. There were no isolates that adhered to silicone only. All HBF 
isolates attached to both materials (Figure 45B) and differences between the CDC 317 and 
the clinical isolates, were evident using polystyrol materials (IBF and HBF), but no 
differences for silicone were found within isolates with smooth morphotype (P > 0.05), 
(Figure 45B). Again, the capacity to adhere to abiotic devices varies significantly between 
different clinical isolates and “rough” morphotypes usually present strong capacity to 








Figure 45. C. parapsilosis biofilm formation to polystyrol and silicone from a strain collection of clinical 
isolates. (A) Correlation between biofilm formation capacity to polystyrol and silicone of seven clinical 
isolates + CDC 317 (*). Four groups were classified as: I adherent to silicone; II, adherent to both materials; 
III (adherent to any material; IV, isolates adherent to polystyrol). Red diamonds, LBF; green diamonds, IBF 
and blue diamonds, HBF. (B) Biofilm formation to polystyrol and silicone of seven selected isolates. Results 
were the average of two independent biological replicates and each replicate represented the average of 
four technical repetitions. Red and blue lines correspond with polystyrol and silicone cut-offs (X ~ 0.290 and 
X ~ 0.045, respectively). 
 
3.5.4 Sedimentation rates differ between colony 
morphotypes 
 
Cell sedimentation analyses also showed variations between morphotypes and isolates. 
Isolates with smooth (73-80%) and crepe colony types (76-83%) were slower to sediment 
as compared to those producing mixed colony morphotypes and those with clear 
pseudohyphae development. Isolates PEU582, PEU586 and ATCC 22019 sedimented 
fastest after 120 min. (93%, 88 % and 80%, respectively). A correlation between the 
morphotype and the capacity to sediment was observed between clinical isolates. Within 
the same morphotype, a positive correlation between strain-sedimentation and level of 
aggregation was seen (PEU582 > PEU586 > ATCC 22019; PEU486 > PEU495 > PEU496; 



























































**** P < 0.0001
** P ≤ 0.01







significantly faster (P < 0.05) and sedimentation capacity of clinical isolates was most 
strongly associated with pseudohyphae development and cell aggregation (Figure 46), 
which was higher both in concentric colony types and absent in smooth colony 
morphologies. 
 
Figure 46. C. parapsilosis sedimentation capacity between different clinical morphotypes. Clinical 
morphotypes were classified in three groups, as low, intermediate and high-sedimentation capacity. Student 
t-test analyses were performed indicating statistically significant differences between PEU582 and PEU586 
and all remaining isolates tested except PEU486-cr. 
 
3.5.5 Clinical C. parapsilosis isolates show virulence 
differences. 
 
Virulence differences between selected C. parapsilosis clinical isolates were measured 
using G. mellonella as an in vivo animal model for systemic infection. Isolates with HBF 
capacity (PEU486-cr, PEU495-cr and PEU496-cr) and LBF (PEU501-s) were tested at two 
different inoculum concentrations to detect differences between clinical isolates with 
different main morphotypes. The C. parapsilosis dose injected in the caterpillars was 
reduced from 2X10ˆ6/10 µl (A) to 106/10 µl (B) to increase accuracy among clinical 
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from isolates PEU501s, PEU582s and PEU651s had a killing rate of 95%, 95% and 75%, 
respectively, on day 9 p.i. The isolates with predominant crepe morphotype had a killing 
rate of 100%, and no caterpillar’s survival after nine days of incubation at 37°C was 
observed (PEU486-cr, PEU495-cr and PEU496-cr). Surprisingly, also a single hyperbiofilm-
forming isolate (PEU-586cr) was less virulent than the other three with crepe 
morphotypes (1.25x). Hyperbiofilm forming isolates had a killing rate of 100% (n = 20) at 
day 4 (PEU486), 6 (PEU495) and 7 (PEU496) respectively, correlating with a high biofilm 




Figure 47. Galleria mellonella infection animal model. Survival curves. (A) first virulence assay using n = 10 
G. mellonella caterpillars injected with 2X10 ^6/10 µl cells of three HBF and one LBF C. parapsilosis clinical 
isolates. Caterpillar survival at 37° was scored for six days. (B) low inoculum of selected LBF, IBF and HBF 
isolates, 1X10 ^6/10 µl cells were injected into n = 20 caterpillars per isolate, survival at 37°C scored along 
nine days. 
In summary, a partial correlation between major colony morphotype and killing rate was 
found: Smooth isolates were less virulent than those with crepe morphotype, which 
apparently correlates with the capacity to form stronger biofilms on abiotic devices, as 
inoculum: 10^6/10 µlA Binoculum: 2X10^6/10 µl
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well as the presence of pseudohyphae development on liquid cultures at human body 
temperature. 
 
3.5.6 Differences in the cell wall proteome among clinical 
isolates 
 
Finally, we addressed the cell wall proteome of the selected isolates, to investigate 
possible links between cell surface composition, cell and colony morphology, as well as 
biofilm formation. 
The clinical isolates varied in several morphological features. Mass spectrometric analyses 
of the selected nine C. parapsilois isolates were conducted in collaboration with Dr. Piet 
de Groot (CRIB, Albacete, Spain). Briefly, cells were grown into biofilms on polystyrol 
dishes or in planktonic culture for those that did not form biofilms, the cells harvested and 
the cell wall fraction extracted using hot SDS. This procedure was previously established 
for other Candida species. Cell surface proteins were classified in as previously described 
before for C. albicans and C. glabrata (Gómez-Molero et al., 2015; de Groot et al., 2013)  
Principally, a core proteome (e.g. aspartyl proteases, phospholipases, and carbohydrate-
active enzymes) and a variable proteome (mainly adhesin-like proteins) were found. 
The core proteome, defined by its presence in nearly all samples (Table 21), was 
consistently present under biofilm conditions and plaktonic growth. It constituted twelve 
different protein classes. These included the CFEM family (common in fungal extracellular 
matrix) involved in iron acquisition (Ding et al., 2011), the Gas/Phr family, Blg2 family, and 
the Crh family. The chitinases belonging to the Crh family, were mainly represented by an 
ortholog of the CaCht2 enzyme of C. albicans (CPAR2_502140), which was identified in all 
isolates. In contrast, the CPAR2_502120 chitinase could be only identified when cells were 





least one family member each of the Sun Family, Tos Family, Pir Family (Protein with 
internal repeats), and the Pga 30 family were presented in all strains analyzed.  
Some core proteins, were not identified in all strains or conditions, but still frequently 
observed. This included Sod4/Pga2 (CPAR2_213080) which was not identified in PEU582 
and the hyperbiofilm-forming isolate PEU586; the aspartic protease CPAR2_702730 which 
was expressed in all isolates but the CPAR2_702720 was only identified in the HBF 
PEU486. The CPAR2_500920 ortholog of the CaSap10 was not identified in the CDC 317, 
the PEU-501s and three of the four hyperbiofilm forming isolates. The proteins of the 
Pga30 family CPAR2_200370, CPAR2_107500 and CPAR2_400900 were not identified in 
the LBF isolates, except in PEU501-s. The cell wall protein CPAR2_402010/RHD3 ortholog 
of the Pga29 of C. albicans was present in the hyperbiofilm-forming isolates and the LBF 
smooth PEU501. 
Subsequently, we focused on the variable proteome, constituted by adhesins which 
clearly differed among strains and conditions. The most frequent cell wall GPI-linked 
adhesin identified in the HBF isolates only was CPAR2_806670; this ortholog of the 
CaYwp1 of C. albicans was present in all the HBF isolates including CDC 317-s. 
The ortholog of the CaAls3 (orf 19.5741/ALS1) was identified in the PEU501-s and the four 
HBF isolates but not detected in either CDC 317-s, PEU582-s, or PEU651-s. In contrast, the 
ortholog of the cell wall protein CaAls6 (CPAR2_404790, orf 19.7414), was found in CDC 
317-s, PEU582-s, PEU486-cr, PEU495-cr, and PEU496-cr, but was not identified in the LBF 






Table 21. Summary of proteomic analyses using seven + CDC 317 of the selected C. parapsilosis clinical isolates 
variable proteome CDC 317 ATCC 22019 PEU501 PEU651 PEU582 PEU486 PEU495 PEU496 PEU586 
origin isolate RS RS ear-nose device urine skin urine ear-nose ear-nose 
morphotypes s s,crt,cn,cr s s s,cr s,cn,cr s,cr s,crt,cn,cr s,cn,cr 
frequent morphotype s cn-cr s s s cr cr cr cr 
adhesiveness to polystyrol LBF LBF LBF IBF IBF HBF HBF HBF HBF 
adhesiveness to silicone LBF ND LBF LBF LBF HBF HBF HBF HBF 
virulence (10 ^6cells/10 µ) (% killing rate) 100% 100% 95% 75% 95% 100% 100% 100% 80% 
Als family 
CPAR2_404790 / CaAls6_ortholog + (log.)a NDb - - + + + + - 
CPAR2_404780 / CaAls3_like or 
CPAR2_404800 / CaAls7_ortholog 
- ND + - - + + + + 
CPAR2_404800 / CaALS7_ortholog - ND - - - + + + + 
CPAR2_404780 / CaAls3_like - ND (pep.)c + (pep.) +d + + + 
Hwp1 family 
CPAR2_403510 / Rbt1 / CaRbt1_ortholog - ND - (pep.) (pep.) + + + + 
CPAR2_806670 / CaYwp1_ortholog + ND + + + + + + + 
CPAR2_603340 / CaPga59_ortholog + ND + - - - + + - 
Iff/Hyr family 
CPAR2_600430 / CaIff3_like_nr2 - ND - - (pep.) + + + + 








core proteome I CDC 317 ATCC 22019 PEU501 PEU651 PEU582 PEU486 PEU495 PEU496 PEU586 
 CFEM family (common in fungal extracellular membrane) 
CPAR2_402910 / CFEM2/CaRbt5_like + ND + + + + + + + 
CPAR2_300120 / CFEM6/CaCsa1_ortholog - ND - - - + + - + 
Gas/Phr family CaZye GH72 
CPAR2_302140 / CaPhr1_ortholog  + ND + + + + + + + 
CPAR2_109660 / CaPhr2_ortholog + ND + + + + + + + 
CPAR2_100110 / CaPga4_ortholog + ND + + + + + + + 
Bgl2 family CaZy GH17 
CPAR2_407410 / CaMP65/Scw1_ortholog + ND + + + + + + + 
CPAR2_401600 / CaBgl2_ortholog + ND + + + + + + + 
CPAR2_502160 / CaScw11_ortholog + ND - - - - - - - 
Crh family CaZy GH16 
CPAR2_400860 / CaCrh11_ortholog + ND + + + + + + + 
CPAR2_503190 / CaUtr2_ortholog + ND + + + + + + + 
CaZy GH18 Chitinases 
CPAR2_502140 / CaCht2_ortholog + ND + + + + + + + 
CPAR2_502130 / CaCht2_like_nr2 + ND + + + + + + + 
CPAR2_502120 / CaCht2_like_nr3 - ND - - - + (PS)f + (PS) - + (S) g 
Sun Family 







core proteome II CDC 317 ATCC 22019 PEU501 PEU651 PEU582 PEU486 PEU495 PEU496 PEU586 
Tos family 
CPAR2_503650 / CaTos1_ortholog + ND + +(stat) +(stat.) + + + +(stat.) 
superoxide dismutase 
CPAR2_213080 / CaSod4/Pga2_ortholog + ND + + 
 
+ + + - 
aspartic proteases 
CPAR2_702730 / CaSap9_like_nr4 (pep.) ND (pep.) + + + + + + 
CPAR2_702720 / CaSap9_like_nr5 - ND - - - + - - - 
CPAR2_102610 / CaSap9_ortholog - ND - - - (pep.) (pep.) (pep.) (pep.) 
CPAR2_500920 / CaSap10_ortholog - ND - + (PS) + (PS) + (PS) - - - 
CPAR2_702810 7 CaYps7_ortholog - ND - + - - - - - 
phospholipases 
CPAR2_804680 / CaPlb5_ortholog + ND + + + + + + + 
CPAR2_808920 / CaPlb5_like_nr2 + ND + + + + + + + 
CPAR2_701130 / CaPlb3_like_nr2 - ND - - - - - + (PS) - 
Pir family putative β-1,3-glucan crosslinker 















+ ND + + + + + + + 
CPAR2_402010/RHD3 / 
CaPga29_ortholog 
(stat.)h ND - + + - - - - 
CPAR2_301540 / CaSsr1_ortholog + ND + + + + + + + 
CPAR2_200370 / CaPga1_ortholog + (37°C)i ND - - - + (stat.) + (stat.) + (stat.) - 
CPAR2_107500 / CaPga26_ortholog + (37°C) ND + - - + - + (stat.) - 





GPI-CWPs with unknown function 
Ecm33 family 
CPAR2_108560 / CaEcm33_ortholog + ND + + + + + + + 
CPAR2_100710/ECM331 / 
CaEcm331_ortholog 
+ (37°C) ND + + + + + + + 
Proteomic data evaluation was performed by Dr. Piet de Groot (CRIB, Albacete, Spain), (unpublished data). MS proteomic analyses was performed using 
ESI-Q-TOF MS/MS. MS raw data was batched using data analysis software (Bruker, Bremen, Germany), results were processed with Mascot software (v. 
2.5.1) and peptides compared with CDC 317 protein sequences provided by NCBI database as well as ORF of putative proteins. a(log.), adhesins were 
identified in cell walls isolated from cultures harvested at logaritmic phase. bND, not determined, c(pep.), only one peptide of the specific adhesins were 
determined. d “+” Peptides were identified in biofilms (polystyrol and silicone) and stationary phase growing conditions. eCaZy, carbohydrate active 
enzymes. fPS, adhesins were identified under biofilm conditions in abiotic surface (polystyrol). g S, adhesins were identified under biofilm conditions using 







The pathogenic capacity of Candida spp. is determined by the host immune response as 
well as pathogen cell-surface structures (reviewed by Richardson and Moyes, 2015). 
Candida spp. can invade the bloodstream leading into sepsis and the death of the patient 
(Pappas et al., 2018). Candida albicans is the most frequent cause of invasive candidiasis 
globally, but over the last decades, non-Candida albicans Candida (NCAC) species have 
become more medically relevant. Candida spp. are able to exist inside the human host, 
having developed different pathogenicity and antifungal drug resistance strategies 
(reviewed by Cavalheiro and Teixeira, 2018). Most microbes live as microbial communities 
encased in an extracellular polymeric substance, including NCAC species, which form 
biofilms on abiotic and biotic surfaces, composed of only single but also mixed species. 
Candida glabrata and Candida parapsilosis are the two most common causes of NCAC 
infections. Their relevance has been attributed to the ability to form biofilms on non-living 
surfaces and the increased multidrug resistance capacity, together leading to different 
levels of pathogenicity. 
Both species display superficial, mucosal and systemic infections associated with medical 
devices (reviewed by van Asbeck et al., 2009; Rodrigues et al., 2017) presenting clear 
morphologic and phenotypic differences between them (reviewed by Rodrigues et al., 
2017; Trofa et al., 2008). C. glabrata and C. parapsilosis each belong to two different 
Candida clades with strong differences on genomic and pathogenic levels (Butler et al., 
2009). This phylogenetic distance is also reflected by variations in cell wall organization 
including its proteome (reviewed by Gabaldón et al., 2016). The fungal cell wall is the 
outermost layer involved in host-pathogen recognition, cell structure, permeability, 
protection, and virulence. Particular differences in cell wall proteins composition between 





Thus, we here investigate cell wall molecules to be used as putative targets in NCAC 
infections (Rodrigues et al., 2017; Silva et al., 2017) or diagnostic markers. Based on this, 
we investigated how phenotypic and morphological differences within intra- and inter- 
NCAC species (C. glabrata and C. parapsilosis) are reflected in genomes and proteomes, 
and how these variations may reflect different pathogenic strategies during the infection 
process. 
In addition to smaller strain sets also analyzed here, we created prospective strain 
collections for each as starting points to classify clinical isolates with different cell surface 
properties to subsequently analyze in depth the cell wall proteomes and genomes of 
selected isolates.  
C. parapsilosis has the capacity to switch between yeast and pseudohyphal cellular 
morphologies as also described for C. albicans (Slutsky et al., 1985), where this ability to 
switch between these and other morphologies is an important virulence factor. In 
C. albicans, the frequency of change is approximately 1.4x10-4 when using the absence of 
amino acid supplement or UV light as stimulus. This is less compared with the frequency 
rate described by Laffey and Butler (2005) and Lott et al. (1993) for C. parapsilosis (ranging 
from 10-1 to 10-3). In C. parapsilosis, the change of cellular morphology is visible also as a 
colony phenotype. In our study, we calculated the morphotypic switch rate for one clinical 
isolate (PEU582), which was in the range described earlier from smooth (2x10-1) colonies 
to crepe colonies (5x10-2) with two morphotype varieties (Figure 29). 
To more deeply analyze the morphotypic switch, we initially characterized five clinical 
C. parapsilosis sensu stricto isolates with different stable morphotypes (e.g. the absence 
of further switching on culture plates after replating) from one single patient including 
one from a positive blood culture. The five isolates (bsc-1700, nsc-1701, tsc-1702, ncc-
1701 and tcc-1702) were isolated from nose (n=2), throat (n=2), and blood culture (Figure 
32), respectively, and phenotypically represented biofilm formation capacities ranging 
from LBF (low biofilm-forming isolates) HBF (high biofilm-forming isolates). Based on the 





1993) we hypothesized that lineages isolated from the same source of site were different 
morphotypic forms of the same strains after switching (Figure 32). To confirm the genetic 
relations between the five isolates, karyotypic analyses were performed; however, this 
remained inconclusive as variations between the isolates (Figure 35A) were in accordance 
with both, switched forms of the same isolate (Nosek et al., 2009) (Figure 43), as well as 
unrelated isolates (Figure 35A). 
Subsequent analyses on the genome level, surprisingly, concluded that the five isolates 
did not originate from a single clonal origin, but rather belonged to three independent, 
mostly clonal groups (Figure 35C): Within this defined set of isolates, those with “smooth” 
vs. “crepe” morphotypes were only distantly related. Smooth isolates were further divided 
into two clonal groups, one constituted by tsc-1702 and the other by bsc-1700 and tsc-
1701 (Table 19, Figure 35B). These data show that the colonies originally classified as 
different morphotypes of a single clonal origin were indeed not representative for a 
morphotypic switch (Figure 33). 
However, we could also show that the control ATCC 22019 produces, at least, four 
different morphotypes, showing a reduced-frequency of smooth morphotypes (~20%) 
compared with concentric-crepe (cn-cr) morphologies (≥ 80%) (Figure 42A). Our data is an 
addition to previous analyses (Laffey and Butler, 2005) of the reference strain (ATCC 
22019, there called “CLIB 214”) where a switch to a smooth morphotype was not shown. 
These observations reveal two biological possibilities: the three clonal groups could have 
colonized and invaded the patient independently, or have diverged into different clonal 
subsets within the host. Our analyses show that smooth and crepe morphotypes (ncc-
1701 and tcc-1702) were located at a distance of >3800 SNPs (Figure 35B), which was 
comparable with unrelated clinical isolates (Pryszcz et al., 2013). Together, this renders 
the possibility of adaptive evolution within this patient unlikely, and underlines the need 






Stability of the observed morphotypes, e.g. the absence of switching upon replating, is 
important as it strongly influences the outcome of phenotypic experiments. When we 
followed this up in individual clinical isolates, several observations, which were in 
contradiction to the existing literature, were made. In our collection, we observed that 
around a 34% of the isolates tested along ten days present more than one morphotype 
and we proposed that a morphotypic switch mechanism has occurred. Most importantly, 
we observed that biofilm formation was a strain-specific attribute, and was less influenced 
by the morphotype: For example, stable linages with different morphotypes (smooth and 
crepe) derived of isolate PEU582 displayed intermediate biofilm formation capacity to 
polystyrol. The reference strain ATCC 22019 displayed four colony morphotypes with no 
significant differences in the capacity to form biofilms, and HBF isolates PEU586, PEU496 
and PEU486 show, at least, three (smooth and rough) colony types (Figure 42), though the 
capacity to form biofilms was relatively strong in all of them. To complicate matters, rare 
switched smooth forms of the - originally crepe - HBF isolate PEU495 displayed a LBF 
phenotype (Figure 42B). 
The capacity to form cell aggregates has also been described to correlate with rough 
morphotypes and complex “spider-like” structures, which are able to produce robust 
biofilms (Pannanusorn et al., 2013). This was also apparent among our isolates and 
colonies mainly constituted by mixed (yeast/pseudohyphae) or single pseudohyphae cells 
displayed thicker biofilms and stronger agar invasion. Isolates with round yeast cells 
usually correlate with smooth morphotypes and low biofilm forming capacity (Figure 44B, 
C, D, and E). Nevertheless, some exceptions (i.e. less than 1% of smooth colony 
morphotype in the present collection with high biofilm-forming capacity to polystyrene 
and strong agar invasion ability) were scored along ten days (Figure 39A, right, blue bars) 
(Pannanusorn et al., 2013). These isolates would be interesting candidates for further 
epithelia invasion assays. 
Many virulence factors are involved in C. parapsilosis pathogenesis, among which also 
biofilm formation to biotic and abiotic surfaces is a key player (Kuhn et al., 2002a). One of 





biofilms on abiotic surfaces of implants, catheters, prosthesis, or wiring for parenteral 
nutrition in neonates (reviewed by Trofa et al., 2008). When we scored biofilm formation 
capacity among 215 clinical C. parapsilosis isolates and categorized these into LBF (0.054-
0.080), IBF (0.153-0.370), and HBF (0.445-1.360) (Figure 38B), the collection represented a 
wide range of biofilm development, from negligible amounts of biofilm intensities to 
massive amounts of biomass (Figure 39A). However, the biofilm formation phenotype was 
independent of the isolates’ source of isolation (Figure 38A) (Silva-Dias et al., 2015; de 
Toro et al., 2011). 
On a phenotypic level, variation in the colony morphology as well as the capacity to invade 
agar (Figure 39B) was positively correlated with the biofilm formation capacity: more than 
87% of the isolates with LBF capacity present smooth morphotypes, and around 45-50% of 
the HBF display crepe morphologies (Figure 39A). We also observed that rough colonies 
with HBF capacity were the best agar invaders on Phloxine B agar plates (Figure 39B and 
40). A possible explanation of the morphotypic switch’ link to biofilm formation capacity 
(Pannanusorn et al., 2013) is the development of pseudohyphal growth from the basal 
part of the colony conferring the capacity to form thicker biofilms (Figure 31). 
In addition to the colony morphologies “smooth”, “snowball”, “rough”, “crater”, “crepe”, 
and “concentric” already described (Enger et al., 2001; Laffey and Butler, 2005; Lott et al., 
1993), we extended this panel to twelve different morphotypes. For colony morphotype 
identification, our analyses followed the same procedure performed by Laffey et al., 2005. 
These studies used YPD medium containing Phloxine B, as it is routinely used to detect 
white–opaque switching in C. albicans (Anderson and Soll, 1987). We also used 
Sabouraud´s agar plates, rich in dextrose, which facilitate the growth and morphotypic 
development of C. parapsilosis colonies (Branchini et al., 1994; Shin et al., 2002) including 
those six already described (Enger et al., 2001; Lott et al., 1993; Nosek et al., 2009). These 
fall into only two categories when stratified by observation frequency in our study: major 
colony morphologies (smooth-glossy, smooth–matte, smooth-concentric, wrinkled, and 
crepe (I, II) represented > 60% of the isolates tested and infrequent colony morphologies 





represented 6% of the total (Figure 31B). The remaining 34% was constituted by mixed 
morphotypes, e.g. frequently switching strains producing more than one colony type per 
plate. 
Even though, while we confirmed that morphotypic switching is present in C. parapsilosis 
clinical isolates, the high frequency described in previous studies (Laffey and Butler, 2005) 
was not observed. In contrast, our data suggests that biofilm formation capacity is rather 
predetermined within the clinical isolate and the specific morphotype will only in- or 
decrease the biofilm formation capacity within a certain range, possibly as a survival 
strategy in the host. 
Biofilm formation is known to reduce the effect of antifungal drugs (Katragkou et al., 
2008) and it was proposed as one of the major virulence factors in C. parapsilosis (Silva et 
al., 2012). Despite C. parapsilosis producing less structured biofilms than C. albicans, both 
species easily develop reduced susceptibility especially towards azoles during the first 
stage of biofilm formation (Kuhn et al., 2002). This type of antifungal resistance is still 
understudied, and only little is known about the underlying mechanism. This is especially 
true for C. parapsilosis, where biofilms are usually constituted by cells aggregates (Kuhn et 
al., 2002) of less complexity than in C. albicans. They strongly vary depending on the cell 
density, the presence of “persister” cells, the morphotypic switch, and the strain-specific 
morphotype reviewed by Silva et al. (2017). 
Together with the group of G. Quindós, we confirmed for six selected biofilm-forming 
isolates (two smooth IBF isolates and four crepe HBF isolates) that fungal cells embedded 
in preformed biofilms were reduced in susceptibility to azoles but not for echinocandins 
and a polyene also in our strain set (Gómez-Molero, unpublished data). Additionally, we 
also observed the previously reported dependency on glucose levels in echinocandin and 
polyene activity (Pereira et al., 2015). In contrast, we confirmed that MICA and AMB 
inhibit their growth by antifungal concentration increment (Guillermo Quindós, personal 
communication). Nevertheless, azoles are the most frequent antifungals administered 





Using the standard EUCAST edef 8.1 procedure we tested the three LBF, IBF and HBF sets, 
how this would be reflected with drug susceptibility towards commonly used azoles, 
echinocandins, and polyenes. Values observed for the six antifungal drugs tested were 
similar to the ranges previously described (Espinel-Ingroff et al., 2013; Melo et al., 2011; 
Sóczó et al., 2007). With the exception of minute quantitative deviations in FLU, POS and 
CAS (Figure 41), no substantial qualitative differences between LBF, IBF and HBF against 
drug susceptibility were observed. These observations are remarkably important, because 
while the degree of biofilm formation will not antifungal drug susceptibility for azoles, it is 
not predictable from EUCAST data. 
For C. albicans is was previously shown that the visually apparent change from white to 
opaque phenotype can alter epithelial invasion and susceptibility against antifungal drugs 
(Solis et al., 2018; Vargas et al., 2000). We analyzed if colony morphology “maturation” of 
C. parapsilosis (Figure 39B) would affect antifungal drugs susceptibility testing using 
matured colonies (96h) instead of young (~16h) (Figure 41), (Pfaller et al., 2005). Globally, 
we did not find significant differences between such young and mature colonies for any 
antifungal drug except for CAS, and few single isolates increasing their MIC by one log2-
fold change. These observations could indicate that antifungal drugs could be 
administered during the first 96 h. because no general differences between “young” and 
“mature” colony susceptibility rate were observed. Particularly, a positive correlation 
between high morphotypic switch and increased of azoles resistance was described by 
Vargas and colleagues for C. albicans supporting the idea that resistant-gene-regulation is 
controlled by phenotypic switch as it has been also observed in C. tropicalis (Moralez et 
al., 2014). 
Although we did not observe global qualitative variations between susceptibility data for 
young and mature colonies, we did identify small but significant MIC differences towards 
caspofungin for three individual HBF clinical isolates displaying rough (“crepe”) 
morphotypes (Table 20). These morphotypic variations correlate with the idea that 
biofilms are less susceptible to antifungal drugs. Nevertheless, it is striking for CAS, 





echinocandins (Ferreira et al., 2009). According to our observations (Figure 42A), the 
mean susceptibility to antifungals partially shifted with the capacity to form biofilms in 
three of the six compounds tested, and this is indirectly reflected in the colony 
morphology. 
Therefore, we conclude C. parapsilosis clinical isolates present a high phenotypic 
variability with a wide range of biofilm formation intensities compared with other 
NCAC spp. (Silva-Dias et al., 2015). This heterogeneity was already described for “slime” 
production by Branchini et al. (1994) and Pfaller et al. (1995). We observe a general 
correlation between colony morphotype and adhesion properties and biofilm formation 
capacity would usually reduce azole’s susceptibility independently on the biomass 
produced. 
Cell surface phenotypic properties are strongly strain-specific in C. parapsilosis clinical 
isolates. Following the same hypothesis, we wanted to analyze phenotypic variants in 
C. glabrata and how such properties are reflected at genome and proteome level. 
C. glabrata belongs to the only distantly related Nakaseomyces group and is one of the 
few pathogens present in this clade (Kurtzman and Robnett, 2003). It has been described 
as close relative to Saccharomyces cerevisiae for the incapacity to develop hyphae, and 
having evolved from a common origin with a whole genome duplication event along the 
time (Kurtzman and Robnett, 1998). Initially, the first C. glabrata genome sequencing was 
published by Dujon et al. (2004) and was more deeply described by Gabaldón et al. (2013). 
To get a general overview over C. glabrata variability, karyotypic analyses of 33 selected 
clinical isolates indicated a high between. We observed large differences in both copy 
number and chromosome distribution between isolates (Figure 15). Karyotypic differences 
were particularly evident between the seven clades suggesting possible microevolutions 
or chromosome replacement as base of genetic variations (Carreté et al., 2018). A large 
genomic and phenotypic plasticity is also observed in other collections (Müller et al, 2009) 





To investigate if genomic plasticity correlated with variations at phenotypic level, we 
characterized a large clinical strain collection towards the capacity of C. glabrata to form 
biofilms on polystyrol plastic and silicone. The ability of a C. glabrata biofilm to adhere to 
host surfaces is conferred yeast cells at the basal part, embedded in an extracellular 
matrix with high amounts of carbohydrates (Seneviratne et al., 2009; Silva et al., 2009). 
Over the course of two years a 453 clinical isolates belonging to nine different categories 
of source of isolation were screened for their capacity to adhere to abiotic surfaces. When 
the isolates were classified according to their capacity to form biofilms on polystyrene, a 
clear correlation of biofilm formation capacity to cell aggregation (Figure 18) was evident. 
In this study, we differentiated LBF, IBF and HBF (Figure 19) clinical isolates depending on 
the degree of biofilm produced (Fonseca et al., 2014; Rodrigues et al., 2014; Silva et al., 
2009). No correlation between the site of isolation and the capacity to adhere to silicone 
elastomers and polystyrol (Figure 24) was observed, and a high variability on biofilm 
formation intensities was identified as it has been already described by Estivill et al., 2011. 
Only a 17% percent of the 453 clinical isolates tested presented strong capacity to form 
biofilms on abiotic surfaces (Figure 21) producing typical structures (Davey and O’toole, 
2000; Kucharíková et al., 2015) constituted by round yeast cells in the lower layer of the 
biofilm embedded in the EPS (Figure 19). 
We used these screening analyses to mimicking the putative host-colonization capacity of 
a large C. glabrata strain collection. As in C. parapsilosis, these analyses again suggested 
strong strain-specificity and a large inter-strain variation regarding biofilm formation 
capacity and antifungal drugs susceptibility (Figure 16 and Figure 20). This has also been 
described for other isolate collections (Parahitiyawa et al., 2006). A relation between 
biofilm formation capacity and reduced susceptibility was shown in two different HBF 
isolates (Figure 22) displaying MICs towards FLU; VOR and POS between 2 and 8 fold 
higher than the reference strain. Contrary, three LBF-IBF isolates (M6, M7 and M17, Figure 
16) from blood cultures with a strongly reduced susceptibility against all the azoles (M6 
and M7) and the nucleoside 5FC (M17) (Table 10), present individual point mutations in 





2006) which gains of function (Vale-Silva et al., 2013) predetermine a positive increase in 
host adherence and virulence. 
We also observed that serial isolates from clonal populations (SAT01, SAT02 and SAT03, 
Figure 17B) which are susceptible to major antifungal drugs tested are lacking of non-
synonymous mutations in specific genes involved in antimycotic regulation (Carreté et al., 
2019). 
In fungi, the cell wall proteome composition is a strong influencer of biofilm formation as 
well as a main virulence (Cormarck et al., 1999, Cabral et al., 2014; Verstrepen et al., 2006; 
Martínez-Gomariz et al., 2009; reviewed by Klis et al., 2009). In this study, we investigated 
the differences and constituents of C. parapsilosis and C. glabrata cell wall proteomes 
under biofilm conditions stratified by phenotypic and genomic variations. The main factors 
involved are GPI-anchored adhesin proteins covalently bound in the cell wall (de Groot et 
al., 2008; Kraneveld et al., 2011; Gómez-Molero et al., 2015). Cell wall composition 
differences between C. glabrata and C. parapsilosis are evident: C. glabrata encodes at 
least 67 adhesins (Weig et al., 2004; De Groot et al., 2008) mainly located in subtelomeric 
regions. In contrast, the C. parapsilosis reference genome only encodes five different 
adhesins of the ALS family, one RBT1-like gene, and the BCR1 effector (Hoyer et al., 2001; 
Butler et al., 2009; Pryszcz et al., 2013; reviewed by de Groot et al., 2013, Rossignol, 
2009). 
Therefore, using a workflow already established for biofilms of C. glabrata (Gómez-Molero 
et al., 2015; de Groot et al., 2008; Weig et al., 2004), we identified several known and 
novel adhesins being incorporated into the cell wall of biofilm forming C. parapsilosis and 
C. glabrata clinical isolates (Table 13 and Table 21). The total number of different adhesins 
incorporated correlate with the capacity to form biofilms either under logarithmic or 
stationary phase (Figure 21D and Figure 38B) on abiotic materials. 
As described for S. cerevisiae (Groot et al., 2008), a standard core- and a variable 
proteome can be stratified in both species (Table 13 and Table 21). A strong similarity is 





2013) although there are important differences between both species (Butler et al., 2009): 
The C. parapsilosis core proteome was observed in all the isolates tested independently 
on their adhesion capacity, except for CPAR2_502160, the ortholog of Scw11 of 
C. albicans. This protein is a glucanase only described in the reference strain CDC 317 that 
responds to different iron levels (Lan et al., 2004) The core proteome of C. parapsilosis is 
mainly constituted by chitinases, aspartic proteases, superoxide dismutases, putative β-
1,3-glucan crosslinkers, other carbohydrate active enzymes, and phospholipases (Table 
21). 
The C. glabrata core proteome followed the same pattern as seen for C. parapsilosis and 
phospholipases, putative glucan crosslinkers and carbohydrate-active enzymes (Table 13) 
mainly constitute it. Other proteins identified in C. glabrata core proteome were the GPI-
cell wall protein Ssr1, which is also involved in iron homeostasis (Srivastava et al., 2014) 
the phospholipase Plb1 (not identified in CBS-138 and PEU52), and Plb2, which was not 
present in the LBF PEU52 and the two reference strains. 
Interestingly, the absence of Plb1 and Plb2 in the LBF and the highly flocculent PEU52 is 
associated with a low killing rate (70%) in the G. mellonella in vivo infection model (Figure 
22A). The function of Plb1 and Plb2 is still not well investigated in C. glabrata. However, it 
is known that differential expression of phospholipase B genes are important in C. albicans 
oral and vaginal infections (Naglik et al., 2003) as well as invasive candidiasis in C. glabrata 
(reviewed by Ghannoum, 2000). 
As proposed by the Groot et al. (2008), the Cwp1.1, Cwp1.2 and tir1, identified in the 
C. glabrata core proteome, were described as possible β-1, 3-glucan- β-1, 6-glucan 
crosslinkers via GPI-anchors. The protein CAGL0M01826g, previously detected in 
C. glabrata reference strains and all C. parapsilosis clinical isolates belongs to the Ecm33 
family proteins which function is not still identified but seems to be involved in cell wall 
integrity and biogenesis (Pardo et al., 2004; Martínez-López et al., 2006).  
In addition to the core proteome, we observed a variable proteome whose constitution 





variable proteomes of C. glabrata and C. parapsilosis are detectable and can be related to 
their phylogenetic differences. Thus, our data suggests that the capacity of C. glabrata and 
C. parapsilosis clinical isolates to colonize host surfaces is mainly conferred by this variable 
proteome. 
We observe that strong biofilm formation capacity, cell aggregation, cell sedimentation 
and agar invasion will usually reflect crepe or concentric (PEU486, PEU496 and PEU586) 
morphotypes with a high number or adhesins in the wall (Table 21). Klotz and 
collaborators (Klotz et al., 2007) already suggested this assumption describing that 
aggregation capacity affects the establishment of biofilms in C. albicans with a 
modification in the expression of adhesin-encoding genes. There, the expression of Als 
family proteins, like Als3, is involved in cell aggregation as the first step of the colonization 
process in single and mixed biofilms, and the ALS7 adhesin-encoding gene (ortholog: 
CPAR2_404800) has been proved to be part in epithelial adhesion in C. albicans (Neale et 
al., 2018, Richardson et al., 2018; Bertini et al., 2016). Our proteomic studies showed that 
isolates with rough morphologies and HBF, usually present Als6 or Als7 in the cell wall 
(isolates PEU486, PEU495, and PEU496). Surprisingly, the strong biofilm-forming isolate 
with crepe morphotype (PEU586) was lacking of the CPAR2_404790 (ortholog of Als6 in 
C. albicans); this absence correspond with a reduction in G. mellonella killing rate (80%). 
Therefore, we propose that the Als6 would be involved, together with the extracellular 
lipases (Toth et al., 2014), in C. parapsilosis virulence. Interestingly, all hyper biofilm-
forming clinical isolates analyzed in this study, presented, both, Hwp1 and Iff/hyr family 
proteins in their cell wall, determining their relevance in the colonization process. 
Our proteomic analyses for nine selected C glabrata clinical isolates identified eighteen 
GPI-CWPs proteins differentially expressed under biofilm conditions (Table 12). Ten out of 
these were previously undetected adhesin-wall proteins (de Groot, unpublished data). 
The largest group of adhesins of C. glabrata in the variable proteome is the Epa family, 
known to be involved in epithelia cell adhesion. For example, Epa3 takes part in osmotic 





isolates analyzed excluding the Epa7 in the reference strain CBS-138. Epa6 and Epa7 are 
highly homologous and the N-binding site adhere to β-glucans (Epa7) and α- and β-glucans 
(Epa6) (Castaño et al., 2005). The proteomic identification of Epa adhesins in our clinical 
isolates’ cell walls correlates well with gene transcriptional regulation data under biofilm 
conditions and subtelomeric silencing (Iraqui et al., 2005). Contrary, the main adhesin-
encoding genes did not show a general increase in the transcription profile in the two HBF 
isolates PEU427 and PEU382 (Gómez-Molero et al., 2015). It has previously been claimed 
that that Epa22 (Kraneveld et al., 2011) is highly expressed in biofilms, however here it 
was only identified in the LBF and highly flocculent strain PEU52, suggesting a possible 
function in flocculation and thereby cell sedimentation. 
Six C. glabrata proteins identified in HBF isolates belonging to clusters III (Awp13), V 
(Awp8, Awp9, Awp10 and Awp11) and VII (Awp12) (Gómez-Molero et al., 2015) and four 
remaining to be categorized (de Groot, unpublished data) were previously undetected. 
Solely, the newly described: Awp8, Awp9, Awp10, Awp11, CAGL0L00227g and 
CAGL0F09273g are included in the cluster V as the Awp2-4 (de Groot et al., 2008 and 
2013) sharing a remarkable number of peptides with Epa family proteins. We observed 
that these novel adhesins were frequently present in HBF isolates and less in IBF or LBF 
groups. Although the molecular function of these proteins are still undetermined, they 
seem to have a role in cell adhesion. Awp12 is similar to the S. cerevisiae flocculins 
homologs to the Epa family (Gómez-Molero et al., 2015, Weig et al., 2004; de Groot et al., 
2008, Thierry et al., 2010, Desai et al., 2011; de las Peñas et al., 2003) and it is only 
presented in the CBS-138 and IBF isolates. In contrast, Awp13 (cluster III) and Aed1 were 
only identified in the HBF PEU427 (Gómez-Molero et al., 2015). Molecular studies on Aed1 
confirmed its function in adherence to epithelia (Desai et al, 2011). While the molecular 
role of Awp13 is unknown, genome sequence analyses corroborated by phenotypical 
analyses in this study (Carreté et al, 2018), remarked independent deletions of AWP13 in 
three IBF-HBF blood isolates CST35, F15021 and F03013. A possible outcome of the 
AWP13 deletion is a reduction of the adherence capacity inside the host to facilitate the 





frequently identified in the IBF and HBF clinical isolates with large variations between 
them. In contrast, Epa family proteins are quite constantly detectable in all the isolates 
studied. Therefore, we suggest that the Awp family is the one that will confer remarkable 
proteome variability. 
Along our proteome subset, we identified several remarkable exceptions. Isolate PEU30 is 
hyper-adherent to silicone elastomers, but not able to form biofilms on polystyrol 
material. It only presents three adhesins in the cell wall, two of them belonging to the Epa 
family (Epa3 and Epa6). In addition, it is, together with the LBF reference strain 
ATCC90876, one of the only isolates presenting Awp1 in the cell wall. PEU30 was isolated 
from tissue of a catheterized patient; this allows hypothesizing that, while the capacity to 
adhere to catheters may be mediated by Epa3 and Epa6 (Kuchariková et al., 2015), once 
the pathogen has colonized the host surface, a low number of adhesins in the cell wall 
could facilitate the invasion and dissemination inside the host. 
Surprisingly, isolates with high capacity to form aggregates PEU45 (HBF) and PEU52 (LBF) 
present a unique adhesin not identified before in the reference strain CBS-138. The 
CAGL0L00227g is still understudied but we propose a possible function related to 
aggregation and flocculation in pre-existing biofilms or cell-cell interactions. Further 
studies based on adhesins mutation and overexpression should be performed to firmly 
confirm these observations.  
The HBF isolates PEU427 and PEU45 showed the highest number of different adhesins and 
the strongest capacity to form biofilms on polystyrol. PEU45 also had an intermediate-high 
capacity to adhere to silicone, potentially conferred by the Epa family proteins (reviewed 
by Timmermans et al., 2018). The highly hydrophobic isolate PEU427 (Gómez-Molero et 
al., 2015) was isolated from tracheal secrete which is rich in mucin and hydrophobic 
constituents with serine and threonine residues which are thought to mimick the residues 
present in the tandem repeat regions of the CWPs (Bustamante-Marín et al., 2017). In 
summary, we observed a clear increase in the number of different adhesins in the cell wall 





Next to the functional N-terminal lectin domain, another structural feature of cell wall 
adhesins is the more C-terminal repeat region (reviewed by Hoyer et al., 2008). Looking in 
genome sequences obtained for the five C. parapsilosis isolates of the single patient, we 
observed that a large C. parapsilosis genome plasticity is mainly observed in the high 
amplification of the repeat-encoding NH2-terminal domain of HWP1 (Figure 36), a gene 
involved in biofilm formation and epithelia adherence (Nobile et al., 2006). This cell wall 
protein is not frequently identified in LBF clinical isolates (Table 21) and the homolog in 
C. albicans presents high similarities to small mammalians proteins used as substrate for 
mammalian transglutaminases (Staab et al., 1999). 
For C. glabrata it has been shown that, despite its highly clonal population structure, a 
remarkable amount of recombination along the evolutionary process is still ongoing 
(Dodgson et al., 2003 and 2005; Lin et al., 2007). Studies of Carreté et al. (2018) show that 
isolates from different clades seems to be more diverse than isolates that belonging to the 
same clade; this in line with the observation that C. glabrata presents a higher genomic 
plasticity compared with C. albicans populations (Hirakawa et al., 2015). Approximately, 
nearly half of the deleted or the duplicated genes from the collection of 33 genome-
sequenced C. glabrata clinical isolates investigated here code for CW-adhesin proteins. 
This suggests that variations on the adhesin repertoire together with differences in cell-
adherence capacity are a main selection mechanism within the C. glabrata population 
(Carreté et al., 2018). 
Since both species belong to two different subclades in the Candida spp. phylogenetic 
tree, also the cell wall proteome organization varies. Our data supports the idea that 
C. glabrata and C. parapsilosis have developed different adaptive strategies for survival in 
a human host: 
Looking at C. glabrata, the second most frequent fungal species isolated from blood 
cultures, and which is generally incapable to form hyphae, it is interesting to evaluate how 
it can cross from a colonized surface into the blood stream. One theory is that C. glabrata 





al., 2014; Tati et al., 2016). Using our isolates, we could confirm that clinical isolates with 
high capacity to form biofilms and aggregates (Table 14) are also the ones that easily 
adhere to C. albicans hyphae. This correlates with the increased presence of adhesins 
identified in the cell wall (Figure 26). However, C. glabrata and C. albicans co-isolation 
from blood cultures was not frequently observed (Figure 28). A reduced presence of 
C. albicans cells in C. glabrata blood cultures were found could, however be explained if 
C. albicans will be only used by C. glabrata to invade the tissue and does not reach the 
bloodstream for subsequent dissemination (Table 16 and Figure 28). 
Tati et al. (2016) identified the EPA8, EPA19, AWP2, AWP7 and CAGL0F00181 adhesins to 
be important in the interaction between C. glabrata and C. albicans hyphae. In addition, 
we could identify novel adhesins that were expressed in the strains able to bind hyphae 
(Figure 26) and may facilitate this interaction. 
In contrast, cell aggregation capacity (Figure 20A), cell sedimentation (Figure 20 B), or 
biofilm formation capacity do not imperatively correlate with virulence in G. mellonella 
animal model for either species (Figure 20 D, 22, 47). Strikingly, for most isolates with high 
numbers of adhesins in the wall, a reduction in virulence, at least in the G. mellonella 
model, and not an increase is observed here. 
No variations between murine infection model and G. mellonella animal model have been 
described previously for C. glabrata clinical isolates. It usually presents an only low killing 
rate across infection models (Rossoni et al., 2013) and a high C. glabrata inoculum is 
needed to increase the virulence (Ames et al., 2017). Nevertheless, we were able to 
observe differences among both C. glabrata and C. parapsilosis clinical isolates in the 
G. mellonella infection model, but there was no distinctiveness with respect to LBF or HBF 
isolates (Figure 22 and Figure 47). In case of C. glabrata clinical isolates, approximately 
24% of the isolates had a killing rate lower than 100% and those were mainly isolated 
from urine catheters and oral cavity independently of the capacity to form biofilms. We 
propose as a possible port of entry into the host that strains from catheters or oral cavity 





to those of C. albicans, and the enzymatic activity in C. glabrata invasive candidiasis 
(Ghannoum et al., 2000) is higher compared to oral cavity (Ibrahim et al., 1995), wounds 
or urine (Price et al., 1982), only a reduced expression of phospholipase B in the oral 
cavity or urine tract could explain the reduced killing rate. Interestingly, the postulated 
absences could be observed in the avirulent C. glabrata LBF clinical isolate PEU52 which 
cell wall proteome is absent of Plb1 and Plb2 (Figure 22, table 13). 
C. parapsilosis strain PEU586 was the exception to these findings: it had a high capacity to 
form biofilms and seven adhesins were identified in the wall, but the killing rate in 
G. mellonella was less than 100%. This seems to indicate that this isolate was a better 
colonizer than tissue invader. Within our C. parapsilosis subset, isolates with crepe 
morphotypes and a large number of adhesins in the cell wall generally displayed higher 
killing rates in G. mellonella animal model as compared to isolates with a reduced number 
of adhesins (Table 21 and Figure 47B). Strikingly, we found that two non-adherent smooth 
clinical isolates (CDC-317 and PEU501) each only containing three adhesins 
(CPAR2_404780/CPAR2_404800, CPAR2_806670 and CPAR2_603340) in their cell wall had 
a high killing rate (100% and 95%, respectively). Consequently, this suggests that isolates 
with smooth colony types and LBF capacity are more virulent while presenting fewer 
adhesins in the cell wall. This may represent a potential adaptive mechanism contributing 
towards the invasion process. 
In contrast to C. glabrata, C. parapsilosis is able to switch between cellular forms and thus 
different colony morphotypes (Laffey et al., 2005). In line with this, the capacity of 
C. parapsilosis to form strong biofilms on abiotic surfaces again suggests this as a possible 
entry route into the host (Reviewed by Trofa et al., 2008; Ruan et al., 2008), with a 
subsequent dissemination within the patient described above (Figure 32). Retrospectively 
looking at the treatment course, the patient received echinocandins (Caspofungin) once 
samples were positively identified as C. parapsilosis. Afterwards, fluconazole was 
administered in addition, and the treatment continued only with fluconazole after an 
improvement of the patient. C. parapsilosis biofilms are known to resist azole antifungal 





collaboration with Dr. Guillermo Quindós for several isolates of our collection. A reduction 
in biofilms´ growth was only observed after echinocandin and amphotericin B treatment. 
Therefore, these observations would explain the patient´s improvement. The recurrent 
exchanges in the catheter happened once the BAL positive culture was isolated. The first 
time blood culture was positive corresponded with another catheter exchange (Gómez-
Molero et al., unpublished data). 
The different morphologies of the C. parapsilosis isolates isolated from this patient were 
however not caused by morphotypic switch, but rather represented three independent 
linages. The fact that the blood culture isolate bsc-1700 was genetically closest to a throat 
isolate (tsc-1702) let us speculate the possible route of dissemination: 
From our data, we propose that the blood stream infection was initiated during surgery, 
by the smooth morphotype strains spreading more easily to different tissues due to the 
inability to adhere to biotic and abiotic surfaces (Uppuluri et al., 2010). This is in contrast 
to the crepe strains present in the same locations, which have strong ability to adhere and 
likely stay in a fixed location resulting in less likelihood to reach the bloodstream. 
Unfortunately, the sample isolated from central venous catheter (CVC) was not retained in 
the diagnostic laboratory; this would have let us known the phenotypic and genotypic 
properties to better analyze the whole pathogenic process. 
These observations are in similarity with the report that a C. albicans strain isolated from a 
blood stream infection was incapable to form biofilms due to the lack of EFG1 (Hirakawa 
et al., 2015). During disseminated candidiasis with C. albicans, hyphae, pseudohyphae, 
and yeast are presented (Noble et al., 2017). This is in accordance with our observations in 
C. parapsilosis that the yeast form, which is at least, partially characterized by the absence 
of adhesins in the C. parapsilosis cell wall, may facilitate the dissemination into and in the 
blood stream. The remaining C. parapsilosis smooth isolates with their low number of 
adhesins in the wall with high killing rates in G. mellonella, let us speculate about their 





Consequently, this suggests that isolates with smooth colony types and LBF capacity may 
be more virulent while presenting fewer adhesins in the cell wall. This may represent a 
potential adaptive mechanism contributing towards the invasion process. In line with this, 
we propose that the adaptive strategy to adhere to host surfaces is mediated by the 
number of different adhesins present in the cell wall, along with their abundance as 
suggested previously for C. glabrata (reviewed by Timmermans et al., 2018). In addition, 
we emphasize that the main pathogenic and immunogenic differences within clinical 
isolates would be represented by the variable proteome. We suggest that both species 
use their specific phenotypes and cell surface properties with subsequent variation of the 
cell wall proteome as selective pathogenic strategy. 
A large genetic variability is presented in C. glabrata clinical isolates (reviewed by López-
Fuentes et al., 2018; Bader et al., 2012) compare with C. parapsilosis (Tavanti et al., 2010). 
However Pryszcz et al. (2013), revealed, as well, unexpected variations between distant 
C. parapsilosis clinical isolates. 
In this work, we have observed several instances of genomic variation. Within these 
analyses (Carreté et al., 2018), C. glabrata isolates with duplications of adherence wall 
proteins PWP4 (Desai et al., 2011) and deletions of AWP13 (Gómez-Molero et al., 2015) 
corresponded with three hyper biofilm-forming isolates (CST35, F15021 and F03013) 
(Figure 16) from blood cultures. We suggest that deletions of AWP13 could be a possible 
adaptive mechanism carried by the clinical isolates to easily reach the bloodstream.  
The majority of the adhesin encoding genes identified in C. glabrata are located in 
subtelomeric regions (de Groot et al., 2008) which are known to be controlled by 
subtelomeric silencing. This may be another indicator that the presence of adhesins on 
the cell surface may counter dissemination and therefore virulence during infections. A 
possible biological explanation may be that genetic modification of the adhesin-encoding 
genes facilitates the colonization and subsequent dissemination in the bloodstream. In 
different analyses (Biswas et al., 2017; Vale-Silva et al., 2017; Carreté et al., 2018), pairs of 





SNPs as compared to other strains indicating a high degree of similarity within pairs. 
Despite their clonality, the number of variations between isolates from the same patient is 
still remarkable. In case of the trio of isolates analyzed here, the number of mutations 
shared between the first (SAT01) and the third isolate (SAT03) indicated that the 
mutations did not occur during the isolation process and they were pre-existing variations 
in the population. One hypothesis was that independent isolates from different infections 
must be taken into consideration but non-synonymous variations seem to accumulate 
during the course of the infection (Carreté et al., 2019). We observed a reduced biofilm 
formation capacity in the strain isolated from blood (Figure 17A) which correlates with a 
point mutation in SIR4, part of biofilm formation regulation and subtelomeric silencing 
pathways (Leiva-Peláez et al., 2018). 
The genetic variations observed in C. glabrata (Carreté et al., 2018) complement our 
phenotypic analyses indicating large variability between C. glabrata clades, which likely 
reflects geographical differences and dispersion mediated by humans. The degree of 
phenotypic intensities correlates with a large diversity towards CWP-encoding genes 
(López-Fuentes et al., 2018). A high genomic plasticity leads enrichment in non-
synonymous mutations of cell wall encoding genes (Gabaldón et al., 2013). Here, a 
recurrent infection from a unique external source and the low adherence capacity of 
SAT03 with a mutation in SIR4 may have facilitated the dissemination in the bloodstream 
as we also proposed for C. parapsilosis. 
 




5. Conclusion and summary 
Analyzing phenotypic variations of large Candida glabrata and Candida parapsilosis strain 
collections, showed several differences in genome and proteome organization. The overall 
observation was as a very high variability between the isolate’s capacities to form biofilms 
on abiotic surfaces for both species. 
In C. glabrata, biofilm formation capacity positively correlates with cell aggregation and 
cell sedimentation. By MS/MS spectrometric analyses of selected high biofilm-forming 
clinical isolates, we were able to differentiate a core and a unique variable proteome. An 
increased number of adhesins in C. glabrata cell wall, including ten new adhesins for the 
first time detected in this study correlated with a strong capacity to colonize host surfaces 
as well and co-interact with C. albicans hyphae facilitating epithelia invasion. The inability 
of C. glabrata to form hyphae may therefore be balanced by a high number of adhesins 
and adhesin-encoding genes in the cell wall. Alternatively, differences in the variable 
proteome may also indicate a high immunogenic heterogeneity to facilitate host evasion. 
A positive correlation between intermediate or high capacities to form biofilms on abiotic 
surfaces and an increased incorporation of adhesins in the cell wall was found also for 
C. parapsilosis. Increased biofilm formation phenotypes became visible morphologically by 
the appearance of “rough” colony morphotypes. While such isolates’ biofilms are 
notoriously insusceptible to azoles, EUCAST-based antifungal susceptibility testing was not 
able to predict this. Therefore, non-smooth morphologies identified in patient cultures 
might serve as an interesting novel diagnostic indicator to initiate echinocandin-based 
treatment to eradicate the biofilms of C. parapsilosis. 
We also found a wide spectrum of C. parapsilosis killing rates in a G. mellonella animal 
model. The lack of Als6 in the cell wall was directly related with a reduced virulence and, 
surprisingly, C. parapsilosis isolates with low biofilm-formation capacity and therefore 
smooth morphotype presented a notably higher virulence. 




Taken together, our phenotypical data point towards the unique role of non-adhesin 
presenting cells during dissemination in the patient, i.e. that “smooth” C. parapsilosis 
morphotypes will disseminate easier than “rough” morphologies, and therefore be more 
virulent in infection models. 
Genome sequence analyses of matched isolates in C. glabrata point to mechanisms other 
than the previously described subtelomeric silencing, namely deletions and duplications of 
cell wall adhesin-encoding genes, as an important adaptive mechanism moving on from 
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Sets of strains used in this study 
 
Five C. parapsilosis isolates from the same patients used in this study case report 
clinical isolate source of isolation clinical isolate source of isolation 
bsc-1700 blood culture-smooth tsc-1702 throat swab-smooth 
nsc-1701 nose swab-smooth tcc-1702 throat swab-crepe 
ncc-1701 nose swab-crepe  
*Isolates used in this study were provided by University Medical Centre (UMG), Göttingen, Germany 
One hundred seventeen C. parapsilosis clinical isolates used in biofilm formation capacity to polystyrol, agar 
invasion and antifungal susceptibility analyses 
 
 
clinical isolate source of isolation clinical isolate source of isolation 
PEU307 nose swab 9 PEU876 oral 6 
PEU308 skin 4 PEU881 nose swab 9 
PEU317 respiratory 5 PEU882 invasive 1 
PEU320 nose swab 9 PEU883 invasive 1 
PEU336 nose swab 9 PEU884 respiratory 5 
PEU356 nose swab 9 PEU885 device 3 
PEU357 skin 4 PEU886 invasive 1 
PEU358 urine 8 PEU887 urine 8 
PEU385 nose swab 9 PEU890 invasive 1 
PEU391 invasive 1 PEU891 respiratory 5 
PEU506 device 3 PEU893 GI 2 
PEU525 respiratory 5 PEU894 invasive 1 





Continued from previous page 
PEU583 nose swab 9 PEU811 nose swab 9 
PEU584 invasive 1 PEU899 nose swab 9 
PEU589 nose swab 9 PEU913 nose swab 9 
PEU596 respiratory 5 PEU915 urine catheter 7 
PEU617 urine catheter 7 PEU916 invasive 1 
PEU623 respiratory 5 PEU918 urine catheter 7 
PEU628 device 3 PEU924 device 3 
PEU630 invasive 1 PEU935 urine catheter 7 
PEU647 nose swab 9 PEU937 nose swab 9 
PEU648 nose swab 9 PEU940 nose swab 9 
PEU649 nose swab 9 PEU941 invasive 1 
PEU650 urine catheter 7 PEU944 urine catheter 7 
PEU660 device 3 PEU950 nose swab 9 
PEU663 device 3 PEU960 respiratory 5 
PEU674 nose swab 9 PEU961 urine catheter 7 
PEU681 nose swab 9 PEU-963 device 3 
PEU682 nose swab 9 PEU965 urine 8 
PEU688 nose swab 9 PEU968 nose swab 9 
PEU689 nose swab 9 PEU969 nose swab 9 
PEU707 respiratory 5 PEU971 urine catheter 7 
PEU709 nose swab 9 PEU972 nose swab 9 
PEU720 nose swab 9 PEU974 device 3 
PEU724 device 3 PEU975 device 3 
PEU732 urine catheter 7 PEU976 invasive 1 
PEU738 device 3 PEU981 nose swab 9 
PEU750 respiratory 5 PEU984 skin 4 
PEU751 device 3 PEU990 respiratory 5 





Continued from previous page 
*Isolates used in this study were provided by University Medical Centre (UMG), Göttingen, Germany 
Seven C. parapsilosis isolates used in biofilm formation capacity assay to polystyrol, In vivo virulence test and 
biofilm formation analyses in presence of antifungal drugs 
 
clinical isolate source of isolation  clinical isolate source of isolation 
PEU486 skin 4 PEU582 urine 8 
PEU495 skin 4 PEU586 nose swab 9 
PEU496 nose swab 9 PEU651 device 3 
PEU501 nose swab 9  
*Isolates used in this study were provided by University Medical Centre (UMG), Göttingen, Germany 
PEU760 nose swab 9 PEU997 skin 4 
PEU761 invasive 1 PEU1001 urine catheter 7 
PEU762 invasive 1 PEU1010 urine catheter 7 
PEU763 respiratory 5 PEU1013 nose swab 9 
PEU768 nose swab 9 PEU1019 device 3 
PEU769 skin 4 PEU1020 device 3 
PEU772 device 3 PEU1021 device 3 
PEU776 nose swab 9 PEU1023 device 3 
PEU781 nose swab 9 PEU1024 nose swab 9 
PEU783 nose swab 9 PEU1026 urine 8 
PEU784 nose swab 9 PEU1028 nose swab 9 
PEU808 nose swab 9 PEU1031 nose swab 9 
PEU815 device 3 PEU1032 urine catheter 7 
PEU850 urine 8 PEU1072 nose swab 9 
PEU856 respiratory 5 PEU1077 nose swab 9 
PEU-859 nose swab 9 PEU1079 respiratory 5 
PEU860 nose swab 9 PEU1085 nose swab 9 
 
 






Thirty-two C. glabrata clinical isolates genetically sequenced + 2 positive controls 
clinical isolate * ID synonymous cluster source of isolation country 
M17 US02Bal017 3 blood USA 
F1019 EF1019Blo1 3 blood France 
F1822 EF1822Blo1 3 blood France 
M12 US01BG2Blo 3 blood USA 
CST78 US003NY078 3 blood USA 
F2229 EF2229Blo1 3 blood France 
I1718 EF1718Blo1 3 blood Italy 
EB0911Sto EB0911Sto 2 stool (GI) Belgium 
CST35 US003NY035 2 blood USA 
CST34 US000NY034 1 blood USA 
CST109 US003NY109 1 blood USA 
CST80 US003NY080 1 blood USA 
M7 US02Bal007 1 blood USA 
EB101M EB0101MouC 1 oral cavity Belgium 
BO101S EB0101StoC 1 stool (GI) Belgium 
B1012S EB01012StoC 1 stool (GI) Belgium 
B1012M EB01012MouC 1 oral cavity Belgium 
EF1237Blo1 EF1237Blo1 4 blood France 
EI1815Blo1 EI1815Blo1 4 blood Italy 
EF1620Sto EF1620Sto 4 stool (GI) France 
EF0616Blo1 EF0616Blo1 4 blood France 
F15 F15035, EF1535Blo1 5 blood France 
F11 F11017, EF1117Blo1 5 blood France 
E1114 EB1114Mou (O) 7 oral cavity Belgium 
M6 US02Bal006 7 blood USA 
CST110 US003NY110 7 blood USA 
EG01004Sto EG01004Sto 7 stool (GI) Germany 
F15021 EF1521Blo1 7 blood France 
F03013 EF0313Blo1 7 blood France 
BG2 US01BG2Blo 7 blood USA 
P35_2 P35_2 6 oral cavity Taiwan 
P35_3 P35_3 6 oral cavity Taiwan 
PEU382 positive control - urine Germany 
PEU427 positive control - respiratory Germany 
*Isolates used in this study were provided by Toni Gabaldón Estevan, Centre for Genomic Regulation (CRG) 





Three C. glabrata isolates used for biofilm formation capacity to polystyrol and azoles susceptibility 
clinical isolate source of isolation 
SAT01BAL-EF54001Bal bronchiolo-alveolar lavage 
SAT02PL-EF54001Per peritoneal fluid 
SAT03BC-EF54001Blo blood culture 
*Isolates used in this study were genetically sequenced provided by Toni Gabaldón Estevan, Centre for Genomic  
Regulation (CRG) Barcelona, Spain. Genome data published by (Carreté et al., 2019). 
 
Thirty-two C. glabrata isolates phenotypically classified used for genome sequencing 
clinical isolate source of isolation clinical isolate source of isolation 
PEU30 invasive 1 PEU542 oral 6 
PEU45 device 3 PEU563 GI 2 
PEU52 oral 6 PEU597 oral 6 
PEU123 urine catheter 7 PEU598 skin 4 
PEU135 respiratory 5 PEU607 skin 4 
PEU235 urine catheter 7 PEU608 oral 6 
PEU259 respiratory 5 PEU611 urine catheter 7 
PEU329 respiratory 5 PEU619 GI 2 
PEU382 urine 8 PEU622 invasive 1 
PEU427 respiratory 5 PEU644 respiratory 5 
PEU471 skin 4 PEU652 device 3 
PEU474 skin 4 PEU656 urine 8 
PEU483 urine catheter 7 PEU670 respiratory 7 
PEU522 device 3 PEU671   
PEU531 urine catheter 7 PEU675 skin 4 
PEU537 device 3 PEU693 urine 8 





List of daily screening C. glabrata clinical isolates used in biofilm formation analyses to polystyrol and silicone 
isolate source of isolation isolate source of isolation 
PEU69 respiratory 5 PEU532 GI 2 
PEU96 urine 8 PEU537 device 3 
PEU113 urine catheter 7 PEU542 urine catheter 7 
PEU117 urine 8 PEU546 skin 4 
PEU119 skin 4 PEU552 GI 2 
PEU122 skin 4 PEU553 urine catheter 7 
PEU123 urine catheter 7 PEU554 oral 6 
PEU124 Invasive 1 PEU558 urine catheter 7 
PEU134 respiratory 5 PEU563 GI 2 
PEU135 respiratory 5 PEU587 GI 2 
PEU159 oral 6 PEU597 oral 6 
PEU162 urine 8 PEU598 skin 4 
PEU193 respiratory 5 PEU601 GI 2 
PEU209 invasive 1 PEU612 urine catheter 7 
PEU210 skin 4 PEU622 invasive 1 
PEU214 oral 6 PEU635 oral 6 
PEU297 urine 8 PEU636 GI 2 
PEU299 GI 2 PEU653 oral 6 
PEU302 urine 8 PEU656 urine 8 
PEU311 invasive 1 PEU668 skin 4 
PEU314 invasive 1 PEU671 urine catheter 7 
PEU324 respiratory 5 PEU675 skin 4 
PEU326 urine 8 PEU676 skin 4 
PEU328 respiratory 5 PEU686 GI 2 
PEU329 respiratory 5 PEU692 urine 8 
PEU330 GI 2 PEU698 device 3 
PEU342 device 3 PEU706 oral 6 
PEU349 urine catheter 7 PEU731 blood culture 9 
PEU352 skin 4 PEU746 device 3 
PEU353 respiratory 5 PEU749 device 3 
PEU368 skin 4 PEU764 device 3 
PEU373 urine 8 PEU777 device 3 
PEU379 GI 2 PEU782 urine catheter 7 





Continued from previous page 
PEU398 oral 6 PEU795 respiratory 5 
PEU400 urine 8 PEU802 device 3 
PEU401 urine 8 PEU814 urine catheter 7 
PEU471 skin 4 PEU953 skin 4 
PEU474 skin 4 PEU954 device 3 
PEU478 device 3 PEU956 invasive 1 
PEU483 urine catheter 7 PEU957 oral 6 
PEU508 device 3 PEU1011 skin 4 
PEU509 device 3 PEU1044 blood culture 9 
PEU511 skin 4 PEU1048 blood culture 9 
PEU513 GI 2 PEU1049 blood culture 9 
PEU522 device 3 PEU1050 blood culture 9 
PEU531 urine catheter 7 PEU1055 blood culture 9 
 PEU1056 blood culture 9 
*Isolates used in this study were provided by University Medical Centre (UMG), Göttingen, Germany. 
 
Seventy-seven C. glabrata clinical isolates used in Galleria mellonella infection animal model 
isolates BF isolates BF isolates BF isolates BF isolates BF 
PEU531 LBF PEU328 LBF PEU520 LBF PEU386 HBF PEU326 HBF 
PEU523 LBF PEU331 LBF PEU521 LBF PEU1360 HBF PEU329 HBF 
PEU294 LBF PEU317 LBF PEU529 LBF PEU1270 HBF PEU342 HBF 
PEU364 LBF PEU337 LBF PEU533 LBF PEU542 HBF PEU352 HBF 
PEU494 LBF PEU389 LBF PEU534 LBF PEU400 HBF PEU353 HBF 
PEU322 LBF PEU397 LBF PEU535 LBF PEU427 HBF PEU373 HBF 
PEU527 LBF PEU404 LBF PEU536 LBF PEU1330 HBF PEU382 HBF 
PEU541 LBF PEU458 LBF PEU538 LBF PEU123 HBF PEU401 HBF 
PEU29 LBF PEU464 LBF PEU543 LBF PEU183 HBF PEU403 HBF 
PEU1274 LBF PEU469 LBF PEU544 LBF PEU293 HBF PEU513 HBF 
PEU519 LBF PEU478 LBF PEU545 LBF PEU297 HBF PEU522 HBF 
PEU52 LBF PEU498 LBF PEU546 LBF PEU299 HBF PEU532 HBF 
PEU16 LBF PEU502 LBF PEU547 LBF PEU302 HBF PEU537 HBF 
PEU30 LBF PEU510 LBF PEU548 LBF PEU311 HBF PEU540 HBF 
PEU295 LBF PEU514 LBF PEU1273 LBF PEU324 HBF PEU1359 HBF 
PEU314 LBF PEU1332 LBF 
*Red boldfaced, isolates with killing rate lower than 100%. 
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